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1.1  In Vitro Fertilization 
  
1.1.1 Historical aspects of in vitro fertilization 
 
In vitro fertilization (IVF), literally meaning ‘fertilization in glass’, is 
characterized by co-culture of aspired oocytes with spermatozoa and 
subsequent transfer of the embryo(s) into the uterine cavity. The 
original indication for this treatment was subfertility resulting from 
impaired function of the fallopian tubes (Steptoe 1975). Since then, 
indications for the usage of IVF have increased considerably (Diedrich 
et al. 1992; Macklon et al. 1991).  
The first efforts in the field of IVF in human were made in the 
1940’s. By incubating surgically harvested oocytes with spermatozoa in 
vitro, two-cell pre-embryos were observed (Rock & Menkin 1944). 
These embryos were not transferred into the uterus. A major 
breakthrough was achieved in 1959 by the fertilization of rabbit eggs in 
vitro and subsequently transferring the four-cell embryos into the 
fallopian tubes of recipient rabbits, followed by the delivery of healthy 
rabbits (Chang 1959).  This was the first proof that the concept of 
fertilizing mammalian eggs in vitro could produce normal offspring. 
The first attemps in IVF were characterized by the use of 
polyovulating agents and aspiration of human oocytes by laparoscopy 
resulting in an ectopic pregnancy (Steptoe & Edwards 1976). This 
technique failed to result in a life-born baby and was temporary 
abandoned. Edwards and Steptoe resorted to retrieving the single egg 
characteristics of the normal menstrual cycle. As a consequence, the 
best result was the recovery of solely one oocyte. On the 25th of July 
1978 the first baby arising from IVF, Louise Brown, was born in the 
U.K. (Steptoe & Edwards 1978). Unfortunately, by aspirating the oocyte 
in the natural cycle only a few pregnancies were reported. 
Subsequently, the use of human menopausal gonadotropin (HMG) to 
stimulate multiple follicular development was re-introduced with more 
success (Garcia et al. 1983a; Garcia et al. 1983b). 
 
 
1.1.2 Ovarian stimulation for IVF  
 
Gonadotropins have been used in the treatment of anovulatory patients 
for many years. The first preparations were extracted from the serum of 
pregnant mares, the so-called pregnant mare serum gonadotropin 
(PMSG) (Cole & Hart 1930). The addition of human chorionic 
gonadotropin (hCG) increased the chance of success in terms of the 
occurrence of ovulation (Hamblen & Davies 1945).  Due to the 
formation of antibodies against PMSG (Leathum & Rakoff 1948) their 
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clinical use in humans was abandoned. An alternative was found in 
extracted human pituitary gonadotropin (HPG). By using this 
preparation, treated patients were able to conceive while the formation 
of antibodies was avoided (Gemzell 1966). The application of HPG was 
abandoned after concerns were expressed that HPG may lead to 
transmission of prion diseases such as Jacob-Kreutzfeld disease 
(Frasier & Foley 1994). From the urine of menopausal women it 
became possible to extract HMG (Albrecht 1956). The estimated risk of 
Kreuzfeld Jacob disease after clinical application of HMG was 
considered to be minimal. The application of purified follicle stimulating  
hormone (FSH), lacking the luteinizing hormone (LH) activity of HMG, 
in ovarian hyperstimulation for IVF was introduced (Acosta et al. 1985). 
FSH alone, in the absence of LH, was capable in maintaining estradiol 
(E2) synthesis and allowed the oocytes to mature up to the final stages 
(Jones et al. 1985).  
When HMG became commercially available, gonadotropins 
were also applied for initiation of multiple follicular development for IVF 
(Mettler et al. 1982; Garcia et al. 1983a; Garcia et al. 1983b). Timing of 
induction final stages of oocyte maturation by human chorionic 
gonadotropin (hCG) was crucial for obtaining good quality oocytes 
(Laufer et al. 1984), requiring intensive ultrasound and hormonal 
monitoring (DeCherney & Laufer 1984; Trounson & Calabrese 1984). 
Despite intensive and frequent monitoring by both ultrasound and 
hormonal measurements, many IVF cycles had to be cancelled due to 
premature luteinization or ovulation (Hamori et al. 1987). In order to 
improve the efficacy of IVF treatment, the avoidance of a premature LH 
rise to occur was needed.  
Indications that ovarian stimulation by clomiphene citrate lead 
less frequently to a premature ovulation compared to gonadotropins 
(Wu 1977; Wu 1978; Testart & Frydman 1982) encouraged the use of 
clomiphene citrate in IVF to aim for the recovery of more oocytes, 
resulting in a higher success rate (Trounson et al. 1981). Clomiphene 
citrate (Greenblatt et al. 1961) is an anti-estrogen interfering with the 
negative feedback mechanism at hypothalamic and pituitary level 
(Odell & Swerdloff 1975). After interruption of the negative feedback 
loop, an endogenous rise in FSH occurs (Adashi 1984). This 
endogenous rise in FSH may initiate the development of multiple 
dominant follicles and subsequent multiple pregnancies (Goldfarb & 
Crawford 1969). For induction of final oocyte maturation and timing of 
oocyte aspiration (Hoult et al. 1981) hCG was administered. In an effort 
to enhance the number of oocytes obtained after oocyte aspiration, 
some centres introduced clomiphene citrate in combination with human 
menopausal gonadotropin (HMG) (Quigley et al. 1984). However, no 
considerable improvement in number and quality of recovered oocytes 
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was obtained by means of this strategy (Testart et al. 1985; Plachot et 
al. 1985) and the risk of a premature ovulation remained. 
 It became clear early in the development of IVF that ovarian 
stimulation to initiate multiple dominant follicular development has 
improved the clinical outcome of assisted reproductive techniques, 
especially the results of IVF (Quigley et al. 1982; MacDougall et al. 
1994). Although in the early days of IVF both gonadotropins and anti-
estrogens were used, gonadotropins gained popularity in the following 
years (Dor et al. 1992). The rapid increase in serum estradiol levels (as 
a result of multiple dominant follicular development) frequently induces 
a premature rise in endogenous LH (Yen 1977; Liu & Yen 1983; 
Vargyas & Marrs 1987). Despite monitoring the cycle by the use of 
ultrasound and hormonal assessments, the risk of premature 
luteinization remained (Buttery et al. 1983). When a premature LH rise 
occurs, between 7% - 24% of the IVF cycles are cancelled prior to 
oocyte retrieval (Jansen & Tucker 1999; Cummins et al. 1989; Smitz et 
al. 1988a; Hamori et al. 1987). However, the development of 
gonadotropin releasing-hormone (GnRH) analogs contributed to the 
prevention of a premature LH surge (Fraser & Baird 1987; Frydman et 
al. 1988a; Frydman et al. 1988b). 
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1.2 Prevention of a premature LH surge  
 
1.2.1 Native GnRH 
 
Andrew Schally (figure 1.1) began working at the Allan Memorial 
Institute of Psychiatry’s laboratory of experimental therapeutics with 
adrenocorticotropic hormone (ACTH) and adrenal cortical steroids in 
1954. His choice of the hypothalamic endocrine field was most 
profoundly influenced by the work of one of his mentors, Geoffrey 
Harris, who first formulated the basic theories pertaining to 
hypothalamic control of secretion of the anterior pituitary gland. 
Schally’s decades of research in this field were structured upon these 
theories.  In 1955, Schally demonstrated the existence of corticotropin 
releasing factor (CRF) in hypothalamic and neurohypophysial tissue; 
this was the first experimental evidence of pituitary function being 
regulated by hypothalamic hormones (Schally 1978). 
 
                                              
Figure 1.1 Figure 1.2 
Andrew Schally Roger Guillemin 
 
Andrew Schally and Roger Guillemin (figure 1.2) began 
working with great enthusiasm at Baylor on the elucidation of the 
structure of CRF. However, their early findings were discouraging and 
frustrating because of problems with the isolation of CRF. Their failure 
to obtain enough CRF to determine its structure tended to cast doubt 
on the initial findings. Eventually, Schally and Guillemin ended their 
collaboration and started working separately on thyroid stimulating 
hormone releasing factor (TRF) and GnRH. They both succeeded 
simultaneously in isolation and identification of first TSH (Guillemin et 
al. 1965; Schally et al. 1966) followed by GnRH (Amoss et al. 1971; 
Schally et al. 1971) for which they shared a Nobel prize for physiology 
and medicine in 1977 with Rosalyn Yalow (for her work in 
radioimmunoassay). 
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GnRH is a small 10 amino acid large peptide (Table 1.1) which 
is intermittently secreted by the hypothalamus, inducing pulsatile 
secretion of FSH and LH from the anterior pituitary gland (Figure 1.3). 
The amino-acids at position number 6 are involved in enzymatic 
splicing, those at position number 2 and 3 are involved in gonadotropin 
release, while residues 1, 6, and 10 are important for the three-
dimensional structure and receptor binding (Clayton & Catt 1980) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 
Scheme of pituitary-gonadal axis. In response to hypothalamic pulsatile gonadotropin 
releasing-hormone (GnRH) secretion, the pituitary releases follicle stimulating hormone 
(FSH) which stimulates growth of dominant follicles in the ovary (1). Growing follicles 
produce estrogens, which inhibit FSH release from the pituitary (2). By means of an as 
yet unclarified mechanism, when a Graafian follicle is present, the pituitary responds to 
further rising estrogen levels by releasing an luteinizing hormone (LH) surge (3) causing 
ovulation (4).  
 
 
Ovary 
Pituitary 
1 
2 
3 
Estrogens 
LH surge 
Ovulation 
4 
GnRH 
FSH (+LH) 
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Position   1 2 3 4 5 6 7 8 9 10 
Native  
GnRH  pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2 
GnRH 
agonists buserelin pGlu His Trp Ser Tyr D-Ser Leu Arg Pro Ethylamid 
 
 goserelin pGlu His Trp Ser Tyr D-Ser Leu Arg Pro AzGly 
 
 leuprolin pGlu His Trp Ser Tyr D-Leu Leu Arg Pro Ethylamid 
 
 triptorelin pGlu His Trp Ser Tyr D-Trp Leu Arg Pro Gly-NH2 
 
 nafarelin pGlu His Trp Ser Tyr D-Nal Leu Arg Pro Gly-NH2 
GnRH 
antagonists Nal-Glu D-Nal D-Phe D-Pal Ser Arg D-Glu Leu Arg Pro D-Ala 
 cetrorelix D-Nal D-Phe(4CI) D-Pal Ser Tyr D-Cit Leu Arg Pro D-Ala 
 ganirelix D-Nal DpCIPhe D-Pal Ser Tyr D-hArg(Et2) Leu L-hArg(Et2) Pro D-Ala 
 antide D-Nal D-Phe(4CI) D-Pal Ser Nic-Arg D-Nic-Lys Leu Ip(Lys) Pro D-Ala 
 antarelix D-Nal D-Cpa D-Pal Ser Tyr D-Hci Leu Ip(Lys) Pro D-Ala 
 azaline-B D-Nal D-Cpa D-Pal Ser Tyr D-Aph(atz) Leu Ip(Lys) Pro D-Ala 
 
Table 1.1  
Amino-acid sequence of human gonadotropin-releasing hormone (GnRH) elucidated in 
1971 by Schally and Guillemin. GnRH agonists and GnRH antagonists have 
replacements of the amino-acid sequence on various positions. 
 
 
1.2.2 GnRH agonists 
 
Soon after identification of the GnRH sequence, GnRH agonists were 
developed. An important feature leading to this development was the 
observation that a continuous administration of GnRH caused a 
decreased pituitary secretion of LH and FSH. By substituting amino 
acids on residue 6 and 10 of the GnRH sequence potent GnRH 
agonists were created (Coy et al. 1975) (Table 1.1). Administration of 
these compounds leads to a constant stimulation of the pituitary GnRH 
receptor system due to an extended half-life and an enhanced binding 
affinity for the GnRH receptor compared to native GnRH.  
The mechanism of action of GnRH agonists is paradoxical. 
After administration of GnRH agonists an initial bolus release of 
gonadotropins is observed, the so-called ‘flare-up’ phase. Within 12 
hours a 10, 5, and 4 times higher plasma concentration is observed for 
LH, FSH, and E2, respectively (Lemay et al. 1984). Subsequently, 
pituitary secretion of LH and is suppressed by the formation of pituitary 
receptor/GnRH agonist complexes and internalization (Hazum et al. 
1985; Suarez-Quian et al. 1986), the so called phase of ‘down-
regulation'. Approximately 90 days after cessation of GnRH agonist 
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treatment full pituitary recovery and physiological pituitary gonadotropin 
secretion is observed (de Ziegler et al. 1989). 
 
 
1.2.3 GnRH agonists in IVF 
 
After reports of births following ovarian stimulation and pituitary ‘down-
regulation’ for IVF (Shaw et al. 1985), various IVF protocols were 
developed (Figure 1.4). The 'short protocol' is characterized by 
administration of gonadotropins immediately after initiation of GnRH 
agonist treatment in the early follicular phase, utilizing the initial ‘flare-
up’ of endogenous gonadotropins (Howles et al. 1987).  
 
 
Figure 1.4 
Scheme of ovarian stimulation for IVF and prevention of a premature LH rise with a 
gonadotropin-releasing hormone (GnRH) agonist, 'long protocol' (top panel) and ‘short 
protocol’ (bottom panel). In the 'long protocol', pituitary ‘down-regulation’ is initiated on 
cycle day 1 or on cycle day 21 of the previous cycle for at least 2 weeks (initial ‘flare-up’ 
phase is detectable), followed by co-treatment with human menopausal gonadotropin 
(HMG), follicle stimulating hormone (FSH), or recombinant FSH for ovarian 
hyperstimulation.  In the ‘short protocol’ ovarian hyperstimulation is initiated on cycle day 
2 or 3 with HMG, FSH, or recombinant FSH, together with daily co-treatment with a 
GnRH agonist to avoid a premature LH rise. Duration of the treatment period is at least 
two weeks longer in the 'long protocol' in comparison to the ‘short protocol’. 
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The 'long protocol' is characterized by pituitary down regulation 
prior to ovarian stimulation by gonadotropins (de Ziegler et al. 1987; 
Schmutzler et al. 1988). The 'short protocol' may be favored in terms of 
patient convenience and costs (Frydman et al. 1988a). However, in 
terms of obtaining large quantities of both oocytes and embryos, 
pregnancy rate, and less cancellations the 'long protocol' may be 
superior compared to the 'short protocol' (Hughes et al. 1992). 
 
 
1.2.4 Drawbacks arising from the use of GnRH 
agonists for VF 
 
At present, the most commonly practised ovarian stimulation regimen 
in IVF includes pituitary down regulation with a GnRH agonist for at 
least two weeks followed by the co-administration of high dose 
exogenous gonadotropins. This so called 'long protocol' aims to 
stimulate ongoing growth of several follicles in normo-ovulatory 
women. The presence of many pre-ovulatory follicles allows for lower 
efficacy at oocyte pick-up, fertilization in-vitro, embryo culture and 
implantation. This approach to ovarian hyperstimulation involves 
prolonged, complex, expensive treatment protocols and intensive 
monitoring, while the risk of complications remains. Short-term risks 
include OHSS (Friedman et al. 1984; Golan et al. 1988) and higher 
order multiple pregnancies arising from the transfer of multiple embryos 
(Feldberg et al. 1986; Simpson et al. 1986; Chetkowski et al. 1989). In 
an effort to reduce the risks on complications the need for frequent and 
intensive monitoring increased further (Mendelson et al. 1985). With 
regards to long term complications, epidemiological studies have yet to 
clarify a possible association between ovarian hyperstimulation and 
ovarian cancer (Shoham 1994; Bristow & Karlan 1996).  
In ovarian stimulation cycles without the application of GnRH 
agonists the possible need for luteal phase support was abandoned 
after the observation that although the luteal phase may be shorter 
following oocyte aspiration after ovarian stimulation by HMG (Gronow 
et al. 1985), it was shown not to be clinically important in terms of 
pregnancy rates (Leeton et al. 1985). In cycles characterized by 
ovarian stimulation by gonadotropins and pituitary down regulation by 
GnRH agonists, luteal phase support seems mandatory (Smitz et al. 
1988b; Balasch et al. 1991; Smitz et al. 1992; Beckers et al. 2000).  
In general, large quantities of oocytes are obtained after 
profound ovarian stimulation for IVF. Cryopreservation of 
supranumerical embryos and transfer in subsequent (unstimulated) 
cycles is often considered to justify the stimulation of a large number of 
follicles. Certainly, repeated ovarian stimulation and painful oocyte 
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pick-up procedures may be prevented using cryopreserved embryos. 
The added value of cryopreservation programs remains debatable 
however (Jones et al. 1995; Jones et al. 1997a) and the resulting 
increase in specific pregnancy rates  (i.e.: increased chance of an 
ongoing pregnancy from a transfer of cryopreserved embryos after a 
failed fresh transfer) may be substantially less than generally 
perceived. Additionally, cryopreservation of excess embryos gives rise 
to complex ethical, religious and legal considerations.  
Concerns over the complications arising from current strategies 
for ovarian hyperstimulation for IVF have been increasingly expressed 
(Edwards et al. 1996; Fauser et al. 1999) and novel approaches to 
ovarian stimulation for IVF are now needed. The application of GnRH 
antagonist may contribute to safer, less expensive, and milder 
protocols for ovarian stimulation for IVF (Bouchard & Fauser 2000). 
 
 
1.2.5 GnRH antagonists 
 
The clinical development of GnRH antagonists after identification in 
1971 of the human GnRH sequence was more complex compared to 
the development of GnRH agonists. The main reasons for this were 
problems with solubility and histamine release. GnRH antagonists bind 
specifically and competitively to receptors on the gonadotrophic cells. 
When amino-acid on position number 2 of the sequence is replaced or 
removed, this compound is able to bind on the GnRH receptor without 
activating the receptor. Soon after administration of GnRH antagonists,  
gonadotropin release is suppressed and this lasts as long as the GnRH 
antagonist treatment is continued. GnRH antagonist action is 
characterized by an immediate suppression of pituitary gonadotropin 
release and a rapid recovery of normal secretion of endogenous LH 
and FSH (Ditkoff et al. 1991). 
The first generation of these compounds are characterized by 
modifications on position number 1, 2 and 6 of the sequence of human 
GnRH. The potency in suppressing gonadotropin release however, 
remained relatively poor. By enhancing its potency the histamine 
release was also increased due to the existence of GnRH receptors on 
mast-cells (Kiesel & Runnebaum 1992). The other problem, the 
hydrophobic character of the N-terminus which leads to gel-formation 
after injection, had to be resolved. 
The third generation of GnRH anatagonists are characterized 
by modifications on position number 1, 2, 3, 6, and 10 of the sequence 
of human GnRH (Table 1.1). The histamine releasing properties and 
solubility of these compounds are within acceptable limits. Two of 
these compounds, cetrorelix and ganirelix, are recently introduced and 
could be valuable tools in reproductive medicine. Antide is currently are 
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in phase II trial research, while antarelix and azaline-B are in pre-
clinical stage research. 
 
 
1.2.6 GnRH antagonists for IVF 
 
After 2 decades of preclinical development of GnRH antagonists (Loy 
1994; Reissmann et al. 1994; Reissmann et al. 1995) these 
compounds are now in clinical use.  Although the purpose for which 
this drug was developed was originally a non-steroid contraceptive 
drug (Kenigsberg & Hodgen 1986) GnRH antagonists have potential 
benefit in assisted reproduction. The main objective of using GnRH 
antagonists in IVF is the avoidance of a premature LH rise.  GnRH 
antagonist action is characterized by an immediate suppression of 
pituitary gonadotropin release and a rapid recovery of normal secretion 
of endogenous LH and FSH (Ditkoff et al. 1991). Preliminary clinical 
trials in the field of assisted reproduction have already been initiated 
with the second generation GnRH antagonist Nal-Glu (Frydman et al. 
1991). A small comparative study of Nal-Glu with leuprolide acetate for 
IVF in seven patients resulted in equal oocyte and embryo 
assessments for both treatment groups and pregnancies were reported 
in the Nal-Glu group (Cassidenti et al. 1991). The effectiveness of Nal-
Glu for avoiding the premature LH surge was compared with leuprolide 
acetate for IVF in thirty patients. In this study the serum luteinizing 
hormone and estradiol levels in the late follicular phase were lower and 
more mature oocytes and embryos of better quality were obtained in 
the Nal-Glu group compared with the leuprolide acetate group 
(Minaretzis et al. 1995a). Due to the acute suppression of LH release 
by Nal-Glu timing of oocyte aspiration in natural cycle IVF seems to be 
possible and pregnancies were reported (Paulson et al. 1994).  
While the main objective of using GnRH antagonists in IVF is 
the avoidance of a premature LH rise, they could have potential 
additional advantages over GnRH agonists since it lacks the 
undesirable ‘flare-up’ effect and the relatively long period necessary for 
the pituitary to obtain a status of  ‘down-regulation' of GnRH agonists. 
The use of a smaller total amount of gonadotropins for IVF appears to 
be possible with GnRH antagonists in comparison to GnRH agonists 
(de Jong et al. 1999a). The mechanism of action of GnRH antagonists 
is characterized by rapid suppression of pituitary LH release. 
Therefore, administration could be restricted to the time when to expect 
a premature LH rise, i.e. the late follicular phase. Up to the mid-
follicular phase the endogenous gonadotropin secretion is could be left 
undisturbed by using GnRH antagonists. 
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 Cetrorelix [N-Ac-D-Nal(2)1, D-Phe(4CI)2, D-Pal(3)3, D-Cit6, D-
Ala10]-GnRH is a stable solvable third generation GnRH antagonist with 
minimal histamine-releasing properties. Within several hours after 
administration of this drug a rapid reversible suppression of the 
pituitary-gonadal axis is obtained. Recent studies have shown that the 
GnRH antagonist cetrorelix, either at single or multiple doses, is 
effective in preventing a premature LH rise during ovarian stimulation 
for IVF (Diedrich et al. 1994; Olivennes et al. 1994; Olivennes et al. 
1995). Pregnancies were reported in all trials. The minimal effective 
dose of cetrorelix was 0.25 mg (Albano et al. 1997) and 3 mg 
(Olivennes et al. 1998a) for the multiple and single dose respectively. 
Cetrorelix has no negative influence on the luteal phase (Albano et al. 
1996; Lin et al. 1999). Without the provision of subsequent luteal 
support the luteal phase is comparable with the normal menstrual cycle 
(de Jong et al. 1999a), although a shortening of the luteal phase and 
an impairment of corpus luteum function have been reported (Albano et 
al. 1998).  
 Ganirelix [N-Ac-D-Nal(2)1, DpCIPhe2, D-Pal(3)3, D-hArg(Et2)6, 
L-hArg(Et2)8, D-Ala10]-GnRH is a stable solvable potent third generation 
GnRH antagonist with minimal histamine-releasing properties (Nestor 
et al. 1992; Nelson et al. 1995). This compound is characterized by an 
immediate reversible suppression of pituitary gonadotropin release 
within several hours after administration (Nelson et al. 1995). A large 
randomized controlled trial has shown that the GnRH antagonist 
ganirelix is effective in preventing a premature LH rise during ovarian 
stimulation with recombinant FSH for IVF (The ganirelix dose-finding 
study group 1998). Pregnancies were reported (Itskovitz-Eldor et al. 
1998; The ganirelix dose-finding study group 1998). A possible 
beneficial effect of a high dose ganirelix in the treatment of imminent 
ovarian hyperstimulation syndrome has been suggested (de Jong et al. 
1998). 
 Antide [Ac-D-Nal1, D-Phe(4CI)2, D-Pal3, Nic-Lys5, D-Nic-Lys6, 
Ip-Lys8, D-Ala10]-GnRH is a very potent long-acting stable third 
generation GnRH antagonist. Treatment with antide produced profound 
long-term inhibition of tonic gonadotropin levels, yet hyper-
responsiveness to exogenous GnRH administration was maintained 
(Leal et al. 1989). Anti-reproductive effects and induction of luteolysis 
have been reported in animal studies (Habenicht et al. 1990; Gordon et 
al. 1991; Srivastava & Sridaran 1991; Srivastava et al. 1994). The 
development of this drug is in phase II trial research. 
 Antarelix [Ac-D-Nal1, D-Cpa2, D-Pal3, D-Hci6, Ip-Lys8, D-Ala10]-
GnRH is a potent soluble third generation GnRH antagonist 
(Deghenghi et al. 1993; Sorensen et al. 1996). This drug is in pre-
clinical phase. 
Azaline-B [Ac-D-Nal1, D-Cpa2, D-Pal3, Aph5(atz), D- Aph6(atz), 
Ip-Lys8, D-Ala10]-GnRH is a potent soluble third generation GnRH 
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antagonist (Campen et al. 1995; Rivier et al. 1995). This drug is in pre-
clinical stage. 
 
 
1.2.7 A comparison of GnRH agonists and GnRH 
antagonists 
 
Both GnRH agonists and GnRH antagonists are used to avoid a 
premature LH rise. Their mechanism of action and timing of application 
is totally different. The main differences are summarized in Table 1.2. 
 GnRH antagonists have a direct dose dependent action 
whereas GnRH agonists have an initial ‘flare-up’ phase after which the 
pituitary is ‘down-regulated'. This affects the timing of ovarian 
hyperstimulation for IVF (Figure 1.5). An IVF regimen with a GnRH 
antagonist reduces the duration of treatment by two to three weeks, 
leading to an increase in patients convenience. Besides that, GnRH 
antagonist could have potential advantages over GnRH agonists since 
it lacks the undesirable ‘flare-up’ effect and the relatively long period 
necessary for the pituitary to obtain a status of  ‘down-regulation' of 
GnRH agonists.  
 
GnRH agonists GnRH antagonists 
Avoidance of premature LH rise Avoidance of premature LH rise 
Increasing doctor’s convenience Increasing patient’s convenience 
IVF regimen is time consuming, 
complicated, and expensive 
IVF regimen is less time consuming, less 
complicated, and likely less expensive 
Large amounts of exogenous 
gonadotropins needed 
Less exogenous gonadotropins needed 
 
Slow recovery of pituitary function after 
cessation 
Rapid recovery of pituitary function after 
cessation  
Induction of an endogenous LH surge 
impossible 
Induction of an endogenous LH surge 
possible 
 
Table 1.2 
Main differences between the mechanisms of action of GnRH agonists and GnRH 
antagonists when used to prevent a premature LH rise during ovarian hyperstimulation 
for IVF.  
 
Since timing of treatment largely depends on the normal menstrual 
cycle of patients, there are implications for the doctor’s convenience.  
An IVF treatment cycle with the GnRH antagonist can commence with 
an undisturbed menstrual cycle and recruitment of a normal cohort of 
follicles, allowing normal pituitary function in the early to mid-follicular 
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phase. On top of endogenous FSH release, exogenous FSH is 
administered. This could lead to a reduction in gonadotropin 
consumption of patients in comparison to the ‘long protocol’. Following 
GnRH agonist co-treatment during the follicular phase, luteolysis is 
initiated earlier due to slow recovery of endogenous pituitary secretion 
of gonadotropins (Smitz et al. 1988b). Therefore, provision of luteal 
support is common practice following ovarian stimulation for IVF 
(Soliman et al. 1994).The pituitary has been shown to recover rapidly 
after cessation of GnRH antagonist treatment (Ditkoff et al. 1991), 
which may permit abandoning additional luteal support. 
 
 
Figure 1.5 
Scheme of ovarian stimulation for IVF and prevention of a premature LH rise with a 
gonadotropin-releasing hormone (GnRH) agonist ('long protocol') or a GnRH antagonist 
(‘Lübeck protocol’). In the 'long protocol', pituitary ‘down-regulation’ is initiated on cycle 
day 1 or on cycle day 21 of the previous cycle for at least 2 weeks, followed by co-
treatment with human menopausal gonadotropin (HMG), follicle stimulating hormone 
(FSH), or recombinant FSH for ovarian hyperstimulation.  In the GnRH antagonist 
protocol, ovarian hyperstimulation is initiated on cycle day 2 or 3 with HMG, FSH, or 
recombinant FSH, followed by daily co-treatment with a GnRH antagonist to avoid a 
premature LH rise. Duration of the treatment period is at least two weeks longer in the 
'long protocol' in comparison to the GnRH antagonist protocol.  
 
 
1.2.8 New drugs and new paradigms for IVF treatment 
 
Over the last decades the clinical outcome of IVF, in terms of achieving 
an ongoing pregnancy, has improved considerably by applying the 
profound ovarian stimulation by polyovulating agents and pituitary 
down regulation by a GnRH agonist. However, the dramatically 
increasing number of achieved (multiple) pregnancies as a result of 
applying this regimen should be considered as a drawback. A recent 
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study by the National Center for Health Statistics in the United States 
shows that in the year 1997, the number of triplets and higher order of 
multiple births has risen by more than 400% since 1980, mainly 
attributed to the use of those polyovulating agents (National center for 
heath statistics 2000). In recent years outcomes of IVF using the 
natural menstrual cycle have improved. Data from several series 
indicate cancellation rates of 10-30%, egg recovery rates of 75-90%, 
fertilization rates of 60-80%, implantation rates of between 20-30% and 
ongoing pregnancy rates per started cycle of 5-15% (Garcia 1989; 
Lenton et al. 1992; Lenton & Woodward 1993; Seibel 1994; Society for 
assited reproductive technology (SART) 1996). Analysis of the cost-
effectiveness of natural cycle IVF shows that natural cycle IVF offers a 
low-cost alternative that may be more accessible to patients (Daya et 
al. 1995). However, intense monitoring still is required and this regimen 
could only be applied under specific conditions. 
 Minimal ovarian stimulation for IVF by extending the 'FSH 
window' (Baird 1987; Fauser & Van Heusden 1997; Schipper et al. 
1998) may offer an alternative approach which deals with further 
simplification of IVF treatment and allows a reduction in complication 
rates and costs. Exogenous FSH may therefore be used during the 
mid- to late-follicular phase to ensure growth of follicles up to the 
preovulatory stage and a GnRH antagonist may be used to avoid a 
premature LH rise. By making optimal use of endogenous FSH, the 
amount of exogenous FSH required should be substantially reduced.  
 In addition, with the use of GnRH antagonists during 
the late follicular phase, final stages of oocyte meiotic maturation can 
be induced by cessation of the GnRH antagonist, recombinant LH (The 
european recombinant human LH study group 1998), native GnRH 
(Gordon et al. 1990), or GnRH agonist instead of hCG (Olivennes et al. 
1996). Since these approaches may reduce the risk on OHSS, and 
therefore deserve attention.  
In conclusion, the expectation of the introduction of GnRH 
antagonists for avoiding the premature LH rise in IVF may offer the 
already mentioned less expensive, less time-consuming, and more 
user-friendly treatments with possibly lower complication rates. But 
also, perhaps most importantly, the possibility of ‘softer’ IVF treatment 
strategies, high singleton pregnancy rates while avoiding multiple 
gestations and their concomitant problems. Studies are needed to 
establish the optimal starting day and dose of FSH administered, the 
options for induction of final stages of oocyte meiotic maturation, and 
the role of luteal support following GnRH antagonist administration. 
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1.3 Aim and outline of the thesis 
 
This thesis compromises eight studies dealing with the application of 
GnRH antagonists in IVF. It is clear that GnRH antagonists in IVF may 
offer new opportunities for improving various regimens for ovarian 
stimulation for IVF. Questions with regard to complications of profound 
ovarian stimulation for IVF received special attention in this thesis.  
 The first objective was to establish the minimal effective dose 
of the GnRH antagonist ganirelix for the prevention of a premature LH 
surge during ovarian stimulation with recombinant FSH for IVF. A 
double blind randomized study (phase II trial) was carried out to 
address this issue. Secondly, the possible influence of different doses 
of the GnRH antagonist ganirelix on follicular development and 
endocrine parameters was determined. 
 After establishing the minimal effective dose of the GnRH 
antagonist ganirelix (0.25 mg/d) for the prevention of a premature LH 
surge during ovarian stimulation for IVF, a non-inferiority trial was 
conducted (phase III trial). The suggested GnRH antagonist IVF 
protocol, derived from the already mentioned phase II trial, was 
compared with the ‘long protocol’ as gold standard. 
By means of a observational longitudinal study the additional 
benefit of the cryopreservation program in addition to the ‘long protocol’ 
is investigated. The results of this study added legitimacy to the design 
of a strategy of ovarian stimulation for IVF aiming at less follicle, 
oocytes, and embryos. To test this concept, a pilot study was 
conducted in which the ‘FSH window’ is extended by minimal 
intervention in the mid-follicular phase of the normal menstrual cycle. In 
addition, a GnRH antagonist is used for the prevention of a premature 
LH surge in the late follicular phase. 
   Minimal ovarian stimulation for IVF may reduce the chance 
for complications such as OHSS. Inducing an endogenous LH surge 
for final oocyte maturation by using a GnRH agonist is possible in case 
a GnRH antagonist for the prevention of a premature LH surge during 
ovarian stimulation for IVF is applied, in contrast to the the case with 
‘long protocol’. In addition, this approach may further reduce the 
chance on OHSS. The possibilty of conceiving after induction of final 
oocyte maturation is illustrated by a case report. Finally, by a 
randomized multi-center study, the endocrine physiology of the luteal 
phase after ovarian hyperstimulation for IVF and prevention of a 
premature LH surge by a GnRH antagonist, is explored comparing 
induction of the final stages of oocyte maturation with a GnRH agonist 
to hCG as gold standard.  
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2.1 Dose-finding study of the GnRH 
antagonist ganirelix 
 
2.1.1 Introduction 
 
Gonadotropin-releasing hormone (GnRH) analogues are used for a 
variety of disorders in which reversible suppression of the 
pituitary-gonadal axis is desired (Conn & Crowley, Jr. 1994). This can 
be achieved with GnRH agonists as well as with GnRH antagonists. 
GnRH agonists are currently applied for the treatment of 
endometriosis, uterine fibroids, precocious puberty, prostatic 
hyperplasia and prevention of endogenous luteinizing hormone (LH) 
surges during ovarian stimulation. With respect to the latter indication, 
various dosages and regimens are applied, but the minimal effective 
dose of GnRH agonists remains to be established. 
Disadvantages of GnRH agonists during ovarian stimulation 
are the initial release of gonadotropins (‘flare-up’), the rather long 
period until pituitary suppression becomes effective, and possibly the 
higher therapeutic dose of follicle stimulating hormone (FSH) required 
due to suppression of endogenous FSH release. In contrast to GnRH 
agonists, GnRH antagonists immediately suppress pituitary 
gonadotropins by GnRH receptor competition and permit flexibility in 
the degree of pituitary-gonadal suppression. Moreover, 
discontinuation of GnRH antagonist treatment leads to a rapid and 
predictable recovery of the pituitary-gonadal axis (Gordon et al. 1990; 
Felberbaum et al. 1995). In women undergoing ovarian stimulation, 
GnRH antagonist treatment is required for only a few days when a 
premature LH surge is imminent. For this purpose the applied dose of 
GnRH antagonist should prevent the occurrence of LH surges but 
also retain sufficient endogenous LH to support FSH-induced 
steroidogenesis. Since the inhibitory effect of GnRH antagonists on 
LH is more pronounced than on FSH, a low therapeutic dose also 
minimizes the suppression of endogenous FSH, if any. 
The successful application of GnRH antagonists to prevent 
premature LH surges during ovarian stimulation for in-vitro fertilization 
(IVF) was first published by Cassidenti et al. (1991) and Frydman et 
al. (1991) using the GnRH antagonist Nal-Glu. Thereafter, studies on 
single, dual or daily administration of different doses of the GnRH 
antagonist cetrorelix in women undergoing ovarian stimulation with 
human menopausal gonadotropins (HMG) were reported (Diedrich et 
al. 1994; Olivennes et al. 1994; Felberbaum et al. 1996; Albano et al. 
1997). 
The current study was designed to select the minimal 
effective dose of the third-generation GnRH antagonist Org 37462 
(ganirelix) to prevent premature LH surges during ovarian stimulation 
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when administered once daily by s.c. injection. Org 37462 was 
selected for this purpose since it induces rapid, profound and 
reversible suppression of the pituitary-gonadal axis, has a high 
aqueous solubility, and minimal histamine-releasing properties 
(Rabinovici et al. 1992; Nelson et al. 1995). In particular, the latter is 
an advantage over previous generations of GnRH antagonists which 
caused local cutaneous anaphylactoid-like reactions. The final dose 
selection was based on the incidence of LH surges >10 IU/L during 
Org 37462 treatment, the clinical outcome and the overall tolerance. 
 
 
2.1.2 Materials and Methods 
 
Patients 
A total of 333 patients, for whom ovarian stimulation and IVF with or 
without intracytoplasmic sperm injection (ICSI) were indicated, were 
screened, randomized to one of the six treatment groups and started 
ovarian stimulation with recombinant FSH (recFSH). One patient who 
started recFSH discontinued after one injection; thus, 332 patients 
underwent Org 37462 treatment. In total, 13 IVF centres in nine 
different countries participated, the number of patients per centre 
ranging from 10 to 60. Main inclusion criteria were an age of at least 
18 but not more than 39 years, a bodyweight of 50-75 kg and body 
mass index (BMI) of 18-29 kg/m2, and regular menstrual cycle ranging 
from 24 to 35 days. Patients with either a history of or current type I 
hypersensitivity (urticaria, eczema, hay fever, asthma) or endocrine 
abnormality were excluded. 
 
Study design 
This study was a Phase II, multicentre, double-blind, randomized 
dose-finding study to assess the efficacy of the GnRH antagonist Org 
37462 to prevent premature LH surges in women undergoing ovarian 
stimulation with recFSH. Org 37462 (NV Organon, Oss, The 
Netherlands) was tested as a solution for injection (0.5 ml) in six 
doses, i.e. 0.0625, 0.125, 0.25, 0.5, 1.0 and 2 mg, and was 
administered subcutaneously once daily. Ovarian stimulation was 
carried out with recFSH (Puregon®, NV Organon).  
A schematic description of the applied treatment regimen is 
given in Figure 2.1. RecFSH treatment was started in patients on day 
2 of the menstrual cycle by a once-daily s.c. injection. Just before the 
first injection of recFSH, spontaneous pregnancy was excluded. 
During the first five treatment days, the daily dose of recFSH was 
fixed at 150 IU. After 5 days of recFSH treatment, Org 7462 treatment 
was begun with daily s.c. administration, the recFSH dose being 
adjusted depending on the individual ovarian response as assessed 
Dose-finding study of the GnRH antagonist ganirelix 
 
- 35 -   
by daily ultrasound. Org 37462 treatment was continued up to and 
including the day of human chorionic gonadotropin (hCG) 
administration. hCG (10 000 IU; Pregnyl®, NV Organon) was 
administered when at least three follicles >17 mm diameter were 
observed, and 30-36 h thereafter oocyte retrieval was performed and 
follicle fluid of one of the three largest follicles punctured was stored. 
Oocyte retrieval was followed by IVF with or without ICSI, and no 
more than three embryos were to be replaced 2-4 days thereafter. 
Luteal phase support was given as per the clinics' routine practice 
and standard care and was started at latest on the day of embryo 
transfer. 
 
Figure 2.1 
Schematic description of the treatment regimen using recombinant follicle stimulating 
hormone (recFSH) for ovarian stimulation and Org 37462 for the prevention of  
premature luteinizing hormone (LH) surges. hCG = human chorionic gonadotropin 
 
Assessments 
During the first 5 days of only recFSH treatment, blood samples for 
hormone analysis were collected once daily in the morning just before 
recFSH administration. During Org 37462 treatment, blood samples 
were withdrawn twice daily, viz. just before Org 37462 administration 
and about 8 h thereafter. Serum FSH, LH, estradiol and progesterone 
concentrations were measured by a central laboratory, using a 
fluoroimmunoassay (Delfia®, Wallac OY, Finland) and 
androstenedione by a coat-a-count direct radioimmunoassay 
(Diagnostics Products Corporation, Los Angeles, CA, USA). 
Org 37462 was measured in all blood samples collected from 
the first day of Org 37462 treatment onwards, and in the follicle fluid 
of one large punctured follicle. The method of analysis was previously 
described (Nerenberg et al. 1993); the detection limit was 0.02 ng/mL. 
During Org 37462 treatment, transvaginal ultrasonography 
was performed every day to measure the growth of individual follicles 
(>11 mm). 
Local tolerance after s.c. administration of Org 37462 was 
assessed at 1 and 24 h after administration. Local reactions were 
scored as either none, mild, moderate or severe for redness, swelling, 
bruising, pain and itching, respectively. 
 
Org 37462      Å Å Å Å Å 
Rec FSH y y y y y { { { { { 
Cycle day 2 3 4 5 6 7 8 9 10 3 follicles > 17 mm diameter 10000 IU hCG 
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External independent advisory committee 
An external independent advisory committee, consisting of one 
gynaecologist (IVF expert) and one statistician, was appointed at the 
start of the study in order to advise on stopping a treatment arm if LH 
surges >10 IU/L occurred during Org 37462 treatment. 
During the study, several subjects had an LH surge, while a 
few with an initially normal ovarian response to recFSH were reported 
to have follicular growth arrest and falling serum estradiol 
concentrations after starting Org 37462 treatment. Based on these 
observations and a review of all other data available, the advisory 
committee indicated that the lowest and highest dose groups were to 
be stopped during the study. 
 
Analysis and dose selection 
Three patients were excluded from the efficacy analysis because of 
protocol violations related to drug compliance or inclusion/exclusion 
criteria. In addition, the efficacy data of seven patients were excluded 
from the moment that a protocol deviation occurred: five patients 
began recFSH treatment but were switched during Org 37462 
treatment to HMG, one patient stopped Org 37462 treatment 1 day 
before stopping recFSH treatment, and one patient donated her 
oocytes.  
Dose groups (0.0625 and 2 mg) which were stopped 
prematurely were considered non-eligible. Possibly eligible dose 
groups were evaluated for the incidence of LH surges, and a 
statistical subset selection procedure for the ranking and selection of 
these dose groups was applied to the number of follicles >11 and >15 
mm on the day of the hCG injection, the number of cumulus-oocyte 
complexes retrieved, the number of good-quality embryos obtained, 
and the intrauterine vital pregnancy rate 5-6 weeks after embryo 
transfer. 
For the response variables mentioned above, the dose 
groups were ordered in terms of the calculated treatment effect 
estimates. Subsequently, a statistical subset selection procedure was 
performed which selected the dose group with the best effect 
estimate as well as the doses which were within a certain 'distance' 
from this best dose group in terms of effect estimates based on an 
analysis of variance (ANOVA) model for continuous variables and a 
logistic regression model for binary variables (Driessen 1991; Chang 
& Hsu 1992). The procedure was defined such that with 95% 
confidence the selected subset of dose groups contained the true 
best dose group. This meant that a dose that was not selected was 
unlikely to be the 'truly best' dose for that specific variable. 
Efficacy parameters were summarized using descriptive summary 
statistics (mean, SD, median minimum and maximum), unadjusted for 
centre. For the statistical subset selection procedure, efficacy 
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parameters were adjusted for centre, but only unadjusted means are 
presented. Summary statistics of the outcome of the efficacy 
parameters are presented for all patients who started Org 37462 
treatment ('per attempt' basis), unless otherwise indicated. 
 
 
2.1.3 Results 
 
Patient characteristics 
The six treatment groups were comparable in demographic and 
subfertility characteristics (data not shown). The overall (n = 329) 
mean age was 31.6 years and body mass index 22.7 kg/m2. Causes 
of subfertility were 45.9% male factor, 26.4% tubal factor, 7.9% both 
male and tubal factor, and 19.8% other factors. Overall, the 
percentages of women with primary and secondary infertility were 
58.4% and 41.6%, respectively. 
 
Serum hormone concentrations before Org 37462 treatment 
Median serum hormone concentrations measured just before the first 
recFSH administration (cycle day 2) and at treatment day 6 (cycle day 
7) just before the start of Org 37462 are presented in Table 2.2. 
A fixed daily dose of 150 IU recFSH for 5 days increased 
median serum FSH concentrations by 1.2 IU/L. Serum estradiol 
concentrations increased on average 10-fold, while median serum LH 
concentrations fell from 4.6 IU/L on the first day of stimulation to 1.8 
IU/L on day 6 of stimulation. Circulating concentrations of 
androstenedione and progesterone remained unchanged during the 
first 5 days of ovarian stimulation. 
 
Disposition and cancellations 
The final number of patients per treatment group who were treated 
with Org 37462 and included in the efficacy analysis is presented in 
Table 2.1. Thirty-nine of the 329 patients who began Org 37462 
treatment did not undergo embryo transfer because of either 
fertilization failure (n = 16), insufficient ovarian response (n = 11) or 
other reasons. In total, 12 women experienced an LH surge during 
Org 37462 treatment, but only one of these led to cancellation. In 
addition, four patients in the 2 mg group and one patient in the 1 mg 
group were switched from recFSH to HMG because of insufficient 
ovarian response. All five women finally had embryo transfer, and one 
became pregnant. The lowest and highest Org 37462 dose groups, 
were stopped during the study as advised by an External Independent 
Advisory Committee and therefore considered non-eligible. 
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Table 2.1 
Numbers of subjects per Org 37462 treatment group included in the efficacy analysis. 
Human menopausal gonadotropin (HMG), luteinizing hormone (LH), and recombinant 
follicle stimulating hormone (recFSH). 
 
Serum hormone concentrations before Org 37462 treatment 
Median serum hormone concentrations measured just before the first 
recFSH administration (cycle day 2) and at treatment day 6 (cycle day 
7) just before the start of Org 37462 are presented in Table 2.2. 
 
 
Table 2.2 
Median and 5th and 95th percentiles (in parenthesis) of serum hormone concentrations 
at the start of recombinant follicle stimulating hormone (recFSH) treatment (stimulation 
day 1) and before the first Org 37462 injection (stimulation day 6). FSH = follicle 
stimulating hormone, LH = luteinizing hormone.  
 
A fixed daily dose of 150 IU recFSH for 5 days increased 
median serum FSH concentrations by 1.2 IU/L. Serum estradiol 
concentrations increased on average 10-fold, while median serum LH 
concentrations fell from 4.6 IU/L on the first day of stimulation to 1.8 
IU/L on day 6 of stimulation. Circulating concentrations of 
androstenedione and progesterone remained unchanged during the 
first 5 days of ovarian stimulation. 
 Daily dose of Org 37462 (mg) Total 
 0.0625 0.125 0.25 0.5 1.0 2.0  
recFSH + Org 
37462 31 65 69 69 65 30 329 
Embryo transfer 27 60 62 54 60 27 290 
LH rise > 10 IU/L 5 6 1 - - - 12 
Switched to HMG - - - - 1 4 5 
 FSH (IU/L) 
LH 
(IU/L) 
Androstenedione 
(ng/L) 
Estradiol 
(pg/L) 
Progesterone 
(ng/L) 
Day 1 of recFSH 6.5 (4.0-10.0) 
4.6 
(2.2-7.7) 
1.8 
(1.0-3.2) 
30.7 
(15.1-57.6) 
0.5 
(0.29-1.3) 
Day 6 of recFSH 7.7 (5.8-11.1) 
1.8 
(0.66-6.4) 
2.0 
(1.1-3.5) 
301 
(84.2-777) 
0.4 
(<0.25-0.85) 
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Serum Org 37462 concentrations 
Figure 2.2 (upper panel) shows serum concentrations of Org 37462 
measured in each dose group twice daily for all patients who received 
at least 5 days of Org 37462 treatment. Circulating Org 37462 
increased in a linear, dose-proportional manner and steady state was 
reached within 2 days in all dose groups. At steady state (day 3), 
mean concentrations were 0.2, 0.3, 0.6, 1.1, 2.7 and 5.5 ng/mL in the 
morning (a.m.) prior to Org 37462 administration, and 0.7, 1.5, 3.0, 
6.1, 11.4 and 23.0 ng/mL about 8 It after injection (p.m.) in the 
0.0625, 0.125, 0.25, 0.5, 1.0 and 2.0 mg dose groups, respectively. In 
follicular fluid collected at oocyte retrieval, Org 37462 concentrations 
were similar to those in the circulation (data not shown). On the day of 
embryo transfer, mean serum Org 37462 concentrations were 
undetectable (<0.02 ng/mL) in the three lowest dose groups, and very 
low in the 0.5, 1.0 and 2.0 mg dose groups (0.04, 0.07 and 0.17 
ng/mL respectively). 
 
LH rises before and during Org 37462 treatment 
In total, six (1.8%) patients showed an LH rise (>10 IU/L) before the 
first Org 37462 administration. Two of these six women were 
non-responders, as their serum estradiol concentration after 5 days of 
once-daily 150 IU recFSH remained unchanged from baseline. The 
other four were high-responders in whom an LH rise was seen on 
stimulation day 6, just before the first Org 37462 administration. In 
these four patients, the increases in serum estradiol during the first 
five stimulation days were relatively high, ranging from 700 to 1860 
pg/mL on the first day of Org 37462 treatment. 
 
     
 
 
 
 
Figure 2.2 
Serum Org 37462 concentrations (upper 
panel) and immunoreactive luteinizing 
hormone (LH) concentrations (lower 
panel) measured just before each Org 
37462 injection in the morning (a.m.) 
and measured approximately 8 h later in 
the afternoon (p.m.) for patients with at 
least 5 days of Org 37462 treatment. 
 
 
All subjects with an LH rise during Org 37462 treatment were 
evaluated for daily compliance of Org 37462 by monitoring their 
serum concentrations of the drug. Among these subjects (n = 15), 
three had a rise while serum Org 37462 concentrations had fallen 
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temporarily to baseline, showing that the Org 37462 had either been 
wrongly injected or not administered. A typical example of an LH 
surge occurring in the 0.25 mg group is shown in Figure 2.3. The 
remaining 12 patients with an LH rise showed daily drug compliance 
during Org 37462 treatment (Figure 2.4), the incidence of rises being 
16. 1 % (n = 5), 9.2% (n = 6) and 1.4% (n = 1) in the 0.0625, 0. 125 
and 0.25 mg groups respectively. In the 0.25 mg group, only one 
patient had an LH value >10 IU/L (10.6 IU/L) during Org 37462 
treatment, indicating that a circulating concentration of 1-4 ng/mL Org 
37462 is sufficient to prevent LH surges from occurring (see Figure 
2.2). 
 
  
Figure 2.3 
Typical example of a patient with an 
immediate luteinizing hormone (LH) 
rise due to non-compliance toward 
daily treatment with Org 37462. 
 
  
  
 
Figure 2.4 
Scatter plot of individual luteinizing 
hormone (LH) values > 10 IU/L measured 
during Org 37462 treatment.
 
Of the 12 patients with LH values >10 IU/L, seven also had 
rises of serum progesterone (>1 ng/mL). One patient (0.0625 mg 
group) out of 12 patients with an LH rise was cancelled: this patient 
had serum LH values >10 IU/L prior and during treatment with 0.0625 
mg Org 37462. The other 11 patients underwent embryo transfer, with 
four becoming pregnant, though three of these women showed a rise 
in serum progesterone (at least one value >1.0 ng/mL) before hCG 
administration. 
 
Total dose of recFSH and duration of Org 37462 treatment 
Little difference was noted between the dose groups with respect to 
the total amount of recFSH administered, the mean daily dose 
ranging from 181 IU (0.25 mg group) to 204 IU (1.0 mg group) and the 
median daily dose from 150 IU (0.0625 mg group) to 183 IU (1 mg 
group). The duration of Org 37462 treatment ranged between 2 days 
(minimum, all groups) and 12 days (maximum, 1 mg group) and 4. or 
5 days (median values) in the six dose groups. Overall, the duration of 
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Org 37462 treatment was 5 days, while that of ovarian stimulation 
was 10 days. 
 
Hormone values during Org 37462 treatment and on the day of 
hCG 
Serum LH concentrations decreased with increasing Org 37462 
concentrations in a dose-related manner (Figure 2.2, lower panel). 
Serum LH concentrations tended to increase during Org 37462 
treatment, especially in the two lowest dose groups. In the two highest 
dose groups, serum LH concentrations were mostly <1 IU/L (for the 1 
and 2 mg groups, 75% and 95% of all subjects, respectively), 
indicating profound pituitary suppression. 
During ovarian stimulation from day 6 of recFSH treatment 
onwards, increases in serum estradiol concentrations fell in relation to 
the increasing doses of Org 37462. In addition, in the 2 mg dose 
group, a slight decline in serum estradiol was seen after the first Org 
37462 administration (Figure 2.5). 
 
 
 
 
 
Figure 2.5 
Serum estradiol concentrations 
measured once daily just before each 
Org 37462 injection for patients with at 
least 5 days of Org 37462 treatment. 
See Figure 2.2 for key.
 
Median values of hormone concentrations measured on the 
day of hCG administration are shown in Table 2.3. Serum FSH 
concentrations were similar among dose groups, and ranged from 8.8 
to 10.2 IU/L Median serum LH concentrations fell with increasing 
doses of Org 37462, from 3.6 IU/L in the lowest dose group to 0.4 
IU/L in the highest. In the 0.25 mg treatment group, the amounts of 
endogenous LH at the start of Org 37462 treatment (1.8 IU/L) and on 
the day of hCG administration (1.7 IU/L) were similar (Table 2.2). In 
parallel to endogenous LH, rises in serum estradiol also decreased 
largely with increasing Org 37462 doses. Serum estradiol 
concentrations were lower before the second Org 37462 
administration than before the first in 23%, 47% and in 96% of women 
treated with 0.5, 1 and 2 mg Org 37462, respectively. Only in the 
three lowest dose groups did all patients have serum estradiol values 
>200 pg/mL on the day of hCG administration (data not shown). In 
addition, serum androstenedione concentrations also tended to 
decrease in a dose-related manner, whereas serum progesterone 
concentrations were similar among the different dose groups. 
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Number of follicles on the first day of Org 3 7462 treatment and 
on the day of hCG 
On day 6 of recFSH stimulation, before the first Org 37462 
administration, the overall number of follicles >11 and >15 mm was 
4.1 and 0.5, respectively. On the day of hCG administration, the mean 
number of follicles >11 and >15 mm was similar between the 
treatment groups, and ranged from 9.4 to 11.4 and from 6.2 to 7.5, 
respectively. The statistical selection procedure selected the 0.125, 
0.25 and 1 mg dose groups as eligible for both parameters. The mean 
number of follicles of > 17 mm diameter before hCG administration 
was also similar between the dose groups, and ranged from 3.7 to 
4.7. The 0.25 mg dose group had the largest number of follicles of 
>11 and >15 mm diameter. 
 
 Daily dose of Org 37642 (mg) 
 0.0625 0.125 0.25 0.5 1.0 2.0 
FSH (IU/L) 9.1 (6.9-25.8) 
9.0 
(6.2-20.8) 
9.1 
(6.4-19.2) 
10.2 
(6.0-20.6) 
9.8 
(6.2-25.4) 
8.8 
(6.8-26.3) 
LH (IU/L) 3.6 (0.6-19.9) 
2.5 
(0.6-11.4) 
1.7 
(<0.25-6.4)
1.0 
(0.4-4.7) 
0.6 
(<0.25-2.2)
0.4 
(<0.25-0.8) 
AD (ng/mL) 2.6 (1.3-5.4) 
2.6 
(1.1-4.4) 
2.4 
(1.3-4.4) 
2.2 
(1.3-3.5) 
2.0 
(1.1-3.6) 
1.5 
(1.1-2.5) 
E2 (pg/mL) 
1475 
(645-3720) 
1130 
(462-3780)
1160 
(384-3910)
823 
(279-2720)
703 
(284-2340)
430 
(166-884) 
P (ng/mL) 0.8 (0.4-2.8) 
0.6 
(0.3-1.9) 
0.7 
(0.3-1.8) 
0.6 
(0.3-1.4) 
0.6 
(0.3-2.0) 
0.5 
(0.3-1.6) 
 
Table 2.3 
Median and 5th and 95th percentiles (in parentheses) of serum hormone 
concentrations on the day of human chorionic gonadotrpohin (hCG) just before the last 
Org 37462 administration. FSH = follicle stimulating hormone, LH = luteinizing 
hormone, AD = androstenedione, E2 = estradiol, P = progesterone. 
 
 
Treatment outcome 
The clinical outcome for the main parameters is given in Table 2.4. 
The mean numbers of cumulus-oocyte complexes, embryos obtained 
and embryos transferred were similar between the different treatment 
groups, and the statistical subset procedure selected all four 
completed treatment groups as eligible. 
The mean number of embryos transferred in the various dose 
groups ranged from 2.3 to 2.7. Although comparable numbers of 
embryos were replaced, the implantation rate (number of gestational 
sacs divided by the number of replaced embryos) was relatively low in 
the three highest dose groups, especially in the 2.0 mg group. In 
addition, the number of pregnancy losses during the first 6 weeks 
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after embryo transfer was relatively higher in the 1.0 and 2.0 mg 
treatment groups. 
Overall, a total of 67 intrauterine pregnancies with heart 
activity (52 single and 15 multiple gestations) was established by 
ultrasound at 5-6 weeks after embryo transfer. The pregnancy rate 
was highest in the 0.25 mg group (36.8% per attempt and 40.3% per 
transfer, n = 25; see Table 2.4), but the dose selection procedure 
indicated both 0. 125 and 0.25 mg as eligible doses. In total, 13 
miscarriages were reported, but in four of these only a positive hCG 
test was available to document the early pregnancy. Because of the 
lower implantation rates and higher miscarriage rates, the vital 
pregnancy rates were lowest in the three highest dose groups, 
especially the 2.0 mg treatment group. Serum estradiol 
concentrations on the day of hCG, or at the day of oocyte retrieval, of 
women who became pregnant were within the same range as those 
from women who did not become pregnant or who had an early 
miscarriage (Figure 2.6). 
 
 
Table 2.4 
Clinical outcome in the six different dose groups for all patients who started Org 37462 
treatment (per attempt) unless otherwise indicated. Values are mean 6 SD, unless 
otherwise indicated. aIncluding one subject who was lost to follow-up after assessment 
of a vital pregnancy. 
 
 Daily dose of Org 37462 (mg) 
 0.0625 0.125 0.25 0.5 1.0 2.0 
Recovered cumulus-
oocyte complexes 9.0 + 5.7 9.5 + 5.5 10.0 + 5.4 8.8 + 6.6 9.3 + 6.0 8.6 + 4.4 
Embryos:       
Total 5.4 + 3.6 5.9 + 4.3 5.4 + 4.4 4.6 + 4.2 5.3 + 3.9 4.9 + 3.7 
Good quality 3.8 + 2.8 3.3 + 2.6 3.3 + 3.0 2.5 + 2.7 3.3 + 2.7 3.5 + 3.7 
Implantation rate (%) 14.2 16.6 21.9 9.0 8.8 1.5 
Early miscarriage rate per 
embryo transfer (%) 
0 
(0/27) 
3.3 
(2/60) 
1.6 
(1/62) 
3.7 
(3/54) 
8.5 
(5/59) 
13.0 
(3/23) 
Vital pregnancy rate:       
Per attempt (%) 23.3 (7/30) 
26.2 
(17/65) 
36.8 
(25/68) 
11.6 
(8/69) 
14.1 
(9/64) 
3.8 
(1/26) 
Per embryo transfer (%) 25.9 (7/27) 
28.3 
(17/60) 
40.3 
(25/62) 
14.8 
(8/54) 
15.3 
(9/59) 
4.3 
(1/23) 
Ongoing pregnancy rate:       
Per attempt (%) 23.3 (7/30)a 
23.1 
(15/65) 
33.8 
(23/68) 
10.1 
(7/69) 
14.1 
(9/64) 
0 
(0/26) 
Per embryo transfer (%) 25.9 (7/27)a 
25.0 
(15/60) 
37.1 
(23/62) 
13.0 
(7/54) 
15.3 
(9/59) 
0 
(0/23) 
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Follow-up of the 67 women with a vital pregnancy revealed an 
additional six miscarriages up to 16 weeks after embryo transfer. In 
the 0.25 mg group, the ongoing pregnancy rate 12-16 weeks after 
embryo transfer was 33.8% per attempt and 37.1% per transfer. 
Interestingly, the group of patients with an ongoing pregnancy 
included one patient (0.5 mg dose group) with only 84 pg/mL estradiol 
on the day of hCG. 
In total, three ectopic pregnancies occurred in the three 
lowest dose groups (one in each group) and in total, seven patients 
treated with 0. 125, 0.25, 0.5 or 1.0 mg Org 37462 per day were 
reported to have grade II (n = 5, including three pregnancies) or III (n 
= 2) ovarian hyperstimulation syndrome (OHSS). 
 
 
 
 
 
 
 
 
 
Figure 2.6 
Scatter plot of individual serum 
estradiol concentrations on the day of 
human chorionic gonadotropin (hCG) 
of women who became pregnant and 
those who had a miscarriage or 
menses. 
 
Safety and tolerance 
In total, eight patients (2.4%) were hospitalized because of an ectopic 
pregnancy (n = 3), OHSS (n = 2), miscarriage (n = 1), fever (n = 1) or 
pelvic inflammation (n = 1). Adverse experiences indicated as 
possibly or probably drug-related were reported for 11 patients and 
included asthenia, nausea and malaise. 
The local tolerance outcome indicated that daily, s.c. 
administered Org 37462 was well tolerated. The percentage of 
patients with at least one moderate or severe local tolerance reaction 
(skin redness, swelling, bruising, pain or itching) occurring I h after 
Org 37462 injection was 20.5% and 1.2%, respectively. At this time 
point, skin redness was most frequently observed and increased in a 
dose-dependent manner, from 3.2% in the 0.0625 mg group to 33% 
in the 2 mg group (overall 19.6%; 0.25 mg treatment group 17.1%). At 
24 h after injection, bruising was the most commonly observed 
reaction (overall 2.4%). None of the patients had to discontinue Org 
37462 treatment because of a hypersensitivity reaction or because of 
any drug-related adverse experience. 
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2.1.4 Discussion 
 
This is the first randomized, dose-finding study establishing the 
minimal effective dose of a GnRH analogue in patients undergoing 
ovarian stimulation (Itskovitz-Eldor et al. 1998). In total, six doses of 
the GnRH antagonist Org 37462 were tested during ovarian 
stimulation with recFSH, lacking LH activity. The outcome of this 
study indicates that 0.25 mg Org 37462 per day was the minimal 
effective dose with regard to preventing LH surges, and resulted in a 
good clinical outcome. 
Whereas the 0.25 mg Org 37462 per day was effective with 
respect to the prevention of LH surges, lower daily doses (viz. 0.0625 
or 0.125 mg) resulted in LH rises (>10 IU/L) during Org 37462 
treatment. In total, four of 11 women with LH rises after starting Org 
37462 treatment became pregnant, indicating that the rises did not 
reduce the clinical pregnancy rates in the two lowest dose groups. 
After daily administration of Org 37462, a steady-state level 
was reached within 2 days and, on the day of embryo transfer, 
circulating Org 37462 was virtually absent. Daily Org 37462 
compliance appeared to be essential to prevent LH surges, as one 
forgotten or failed Org 37462 injection resulted in an immediate LH 
rise, supporting a rapid recovery of pituitary blockade and an 
unaffected synthesis and storage of endogenous LH (Felberbaum et 
al. 1995). 
The median duration of Org 37462 treatment was 4-5 days, 
up to and including the day of hCG. During this treatment period, 
serum LH curves showed a transient increase, especially in the lower 
dose groups. This observation might indicate that, due to increases in 
serum estradiol concentrations in the late follicular phase, an 
increased endogenous GnRH secretion occurs (Filicori et al. 1986), 
causing displacement of Org 37462 at the level of the GnRH receptor. 
This hypothesis supports a deterministic role for endogenous GnRH 
in eliciting the spontaneous LH surge during ovarian stimulation 
cycles (Dubourdieu et al. 1994; Karsch et al. 1997). 
In the present study, serum Org 37462 concentrations 
increased in a linear, dose-proportional manner, while serum LH and 
estradiol concentrations decreased in a dose-dependent manner. 
Accordingly, the amount of circulating androstenedione tended to 
decrease with increasing Org 37462 doses. The present study clearly 
demonstrates that the remaining endogenous LH concentrations 
during GnRH antagonist treatment may become critical when pituitary 
suppression is too profound. In patients treated with 1 or 2 mg Org 
37462 per day, serum LH concentrations were mostly <1 IU/L, which 
is much lower than in patients undergoing controlled ovarian 
stimulation with recFSH in combination with a ‘long protocol’ of a 
GnRH agonist. The latter treatment usually results in serum LH 
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concentrations between 1 and 2 IU/L depending on the compound 
and regimen applied (Devroey et al. 1994). In five patients with no or 
minimal follicular growth after starting treatment with 1 or 2 mg Org 
37462, treatment cycles were successfully rescued after switching 
from recFSH to HMG. Whether this reversal was related to the 
exogenous LH activity and/or increasing estrogen concentrations 
remains unclear, but if so, this finding would be in contrast to those of 
previous studies in gonadotropin-deficient women, demonstrating that 
despite minimal estrogen increases, recFSH may induce normal 
follicle growth up to pre-ovulatory stages (Couzinet et al. 1988; 
Schoot et al. 1992; Schoot et al. 1994). In addition, in the present 
study the number of antral follicles, number of oocytes, fertilization 
rate, number of (good quality) embryos and the number of transferred 
embryos were similar in the six dose groups (data not shown). This 
indicates that an impaired estradiol synthesis does not interfere with 
normal folliculogenesis, oocyte maturation and fertilization processes. 
In previous studies with comparable doses of the GnRH antagonist 
cetrorelix, dose effects on estradiol rises were less apparent, as 
patients were treated daily with HMG containing LH activity (Albano et 
al. 1996; Albano et al. 1997). In contrast, a small comparative study 
applying 5 mg of the GnRH antagonist Nal-Glu for only 2-3 days, 
revealed serum LH and peak estradiol concentrations in the GnRH 
antagonist group which were clearly lower than in the GnRH agonist 
group (Minaretzis et al. 1995a). In view of the current findings, it 
needs to be assessed whether in women undergoing ovarian 
stimulation with recFSH (instead of HMG), a single-dose protocol with 
a relatively high dose of GnRH antagonist to prevent LH surges for 
several days would be feasible. The lower vital pregnancy rates in the 
highest dose groups could not be explained by the lower rises of 
serum estradiol on the day of hCG or oocyte retrieval, but the total 
numbers of patients per treatment group were small and hamper a 
final explanation of the outcome among the higher dose groups. 
Additional research will be required to examine whether Org 37462 
has any direct effects on the ovary or endometrium, although recent 
research seems to indicate that the GnRH-receptor is not expressed 
in human preovulatory follicles, endometrium or decidua (Latouche et 
al. 1989; Minaretzis et al. 1995b; Brus et al. 1997; Ikeda et al. 1997). 
The further development of Org 37462 (0.25 mg/day) for 
patients undergoing ovarian stimulation may have several advantages 
over the current practice, namely a ‘long protocol’ of a GnRH agonist. 
The main advantage will concern patient convenience since the 
overall duration of treatment with GnRH analogue will be reduced 
from several weeks to several days. In the present study the amount 
of recFSH per ovarian stimulation cycle in the 0.25 mg dose group 
was 22 ampoules (75 IU/ ampoule), which on average was 300-400 
IU less than the amount of recFSH used in a ‘long protocol’ of the 
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GnRH agonist buserelin (Out et al. 1995). Using daily 0.25 mg 
cetrorelix, and the same criteria for giving hCG, Albano et al. (1997) 
reported that 33 ampoules of HMG were needed when starting 
ovarian stimulation, with a daily dose of 225 IU HMG. With this higher 
starting and total dose of gonadotropins, the duration of treatment 
was similar, but the number of small antral follicles seemed to be 
larger. 
A daily dose of 0.25 mg Org 37462 during ovarian stimulation 
with recFSH resulted in lower peak serum estradiol concentrations 
than previously reported for recFSH in a ‘long protocol’ of intranasal 
buserelin (median values 1160 pg/mL versus 1602 pg/mL, 
respectively) (Out et al. 1995). In the current regimen, monitoring of 
estradiol concentrations during ovarian stimulation is only required in 
case of increased risk for developing OHSS, which reduces the 
monitoring costs and patient discomfort. It has been suggested 
previously that GnRH antagonist treatment may play a role in 
preventing severe OHSS (de Jong et al. 1998). Moreover, the 
immediate reversibility of the hypogonadotrophic state allows the 
administration of native GnRH or GnRH agonist to induce ovulation 
for subjects at risk of developing OHSS (Olivennes et al. 1996). 
However, to establish the improved safety and patient convenience of 
this short Org 37462 regimen, additional clinical studies will be 
required. 
 
 
2.1.5 Appendix 
 
In the current study, a statistical subset selection procedure was 
performed to select the dose group with the best effect estimate, but 
no statistical tests were carried out to compare the results of the 
various dose groups. A rationale for this approach is summarized 
below. 
P-values do not depend only on the outcome of a study but 
also on the sample size. An example may illustrate this. An observed 
difference in pregnancy rates of 20% versus 25% in two groups of 
500 subjects each would yield P = 0.06. In the present study, with 
dose groups of approximately 60, such a difference would yield P = 
0.51, while a much larger difference, e.g. 15% versus 29%, would be 
required to obtain a (non-significant) P-value of 0.06. The P-value is 
not a measure of clinical significance, but is an indication for the 
robustness of the outcome; a large trial tends to produce more 
reliable results (Freeman 1993).  
Differences of 15% were not expected in the present study, 
so the outcome of each individual test of significance was a priori 
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expected to be negative and therefore non-informative (Altman & 
Bland 1995).  
On the other hand, many tests of significance could have 
been carried out as there are six dose groups and many outcome 
parameters (multiplicity). Also, in such a complicated study, some 
unexpected and remarkable results are likely to appear for which a 
test may be carried out (post-hoe testing). Such an approach will 
inevitably lead to significant results, the validity of which may be low 
(data dredging). Statistical correction for multiplicity or using 
confidence intervals would not solve these problems, it would only 
modify them (Pocock 1997). 
The methods used in the trial circumvent those problems by 
looking at the whole pattern, the aggregate outcome for all doses. 
Conclusions are neither based on nor made about the differences 
between individual dose groups. The aim of the analysis is modest; it 
describes the results and suggests a dose for further investigation in 
Phase III confirmatory trials. 
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2.2 Follicular development during ovarian 
stimulation for IVF and various doses of 
a GnRH antagonist 
 
2.2.1 Introduction 
 
The recent clinical introduction of gonadotropin releasing-hormone 
(GnRH) antagonists provides the opportunity to develop novel 
strategies for assisted reproduction. GnRH antagonist action is 
characterized by an immediate suppression of pituitary gonadotropin 
release and a rapid recovery of normal pituitary secretion of 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
(Ditkoff et al. 1991). Recent studies have shown GnRH antagonists, 
either at single or multiple doses, to be effective in preventing a 
premature LH rise during ovarian stimulation for in vitro fertilization 
(IVF) (Frydman et al. 1991; Diedrich et al. 1994; Olivennes et al. 
1994; Albano et al. 1996; The ganirelix dose-finding study group 
1998). The administration of GnRH antagonists in such a regimen can 
be limited to the period vulnerable to a premature LH surge (de Jong 
et al. 2000). Under these conditions, ovarian stimulation with FSH can 
start in the early follicular phase of the undisturbed normal menstrual 
cycle, without the need for prior pituitary ‘down-regulation’.  
Estrogens have several important functional roles in the 
human female reproductive system including induction of the mid-
cycle gonadotropin surge, stimulation of cervical mucus production 
and endometrial proliferation. Under LH stimulation, theca cells 
convert cholesterol into androstenedione (AD) and testosterone (T) by 
means of cytochrome p450 side chain cleavage oxidases and 3β-
hydroxy-steroid dehydrogenase (Erickson et al. 1985). Only when the 
follicles are at a more advanced stage of development, reaching the 
dominant stage at a diameter beyond 10 mm (Pache et al. 1990; van 
Dessel et al. 1996), does FSH dependent granulosa cell aromatase 
activity convert the theca derived AD and T to estrone and E2 (Hillier 
et al. 1981; van Santbrink et al. 1995). This so-called 'two-
gonadotropin, two-cell' concept emphasizes that sufficient stimulation 
of both theca cells and granulosa cells by LH and FSH is required for 
adequate E2 biosynthesis (Short 1962; Schoot et al. 1992).  
Changes over time in FSH levels during the follicular phase 
are crucial for determining the growth of either single or multiple 
dominant follicles (Fauser et al. 1999). When follicles are at a more 
advanced stage of maturation, their requirement for FSH is reduced 
(van Santbrink et al. 1995). Recent in vivo evidence demonstrates 
that dominant follicle development and E2 production is also 
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dependent on late follicular phase LH concentrations (Zeleznik et al. 
1974; Sullivan et al. 1999).  
In contrast to GnRH agonists, the suppression of LH secretion by 
GnRH antagonists is more pronounced than that of FSH (Hall et al. 
1988). However, the effects of GnRH antagonist induced suppression 
of gonadotropin secretion on follicle dynamics and ovarian E2 
production have not been described. The aims of the present study 
were to investigate the influence of different dosages of GnRH 
antagonist on follicular development and to assess the relationship 
between the follicle diameter, total follicular surface area, number of 
follicles and serum steroid and gonadotropin levels in patients 
undergoing ovarian stimulation for IVF. The influence of GnRH 
antagonist on the 'two-gonadotropin, two-cell' mechanism could thus 
be explored. 
 
 
2.2.2 Materials and methods 
 
Patients characteristics 
A total of 329 women between 18 and 39 years of age, for whom 
ovarian stimulation and IVF with or without intracytoplasmic sperm 
injection (ICSI) was indicated, were included in the present 
prospective, double-blind, randomized, multi-centre trial. The study 
protocol was approved by the Local Ethics Review Committees. All 
women had a normal menstrual cycle history (cycle length 24-35 
days), a body weight of 50-75 kg, a body mass index (BMI) of 18-29 
kg/m2, were in good health and had refrained from any hormonal 
therapy for at least 30 days prior to entering the study. On 
transvaginal ultrasound, two normal ovaries were observed in all 
subjects, and a normal follicular hormone status was determined. The 
subjects were studied during a single IVF treatment cycle. All patients 
(n = 311) who proceeded to human chorionic gonadotropin (hCG) 
administration for final oocyte maturation were included in the 
analysis. Patients (n = 18) with an insufficient response (defined as < 
3 follicles of  > 17 mm) to ovarian stimulation, drug non-compliance, 
protocol violations related to in- or exclusion criteria, or other reasons 
for which hCG for final oocyte maturation was not given, were 
excluded from analysis.  
 
Stimulation regimen and IVF procedure 
Prior to ovarian stimulation, subjects were randomly assigned to one 
of the six treatment groups. Stratified randomization was performed 
by code numbers. Patients received a fixed dose of 150 IU 
recombinant FSH (recFSH, Puregon®, NV Organon, Oss, The 
Netherlands) as a daily s.c. injection, from cycle day (CD) 2 until CD 
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7. From CD 7 until the day hCG was administered, the recFSH dose 
could be adjusted according to the individual ovarian response as 
assessed by daily ultrasound. Participants were co-treated with a 
GnRH antagonist (ganirelix, Orgalutran®/Antagon™, NV Organon) in a 
dose of either 0.0625, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/day from CD 7 
onwards. When at least 3 follicles > 17 mm were observed on 
transvaginal ultrasound, 10.000 IU hCG (Pregnyl®, NV Organon) was 
administered by i.m. injection. Oocyte collection took place 36 h after 
hCG administration. A maximum of 3 embryos were transferred on 
day 2 to 5 after oocyte retrieval. Luteal phase support (hCG or 
progestins) was initiated on or before the day of embryo transfer, 
according to the clinics' routine practice.  
 
Monitoring 
Bloodsampling for hormone analysis took place daily, immediately 
prior to recFSH administration, on the morning of CD 2 until and 
including CD 6. Thereafter (from CD 7 until and including the day of 
hCG) daily bloodsamples were withdrawn just before GnRH 
antagonist administration. During the follicular phase, transvaginal 
ultrasound (TVS) was applied, according to the clinics' standards, to 
monitor the number and size of the follicles. Follicle size was 
categorized into 3 subclasses of follicles: 11-15 mm, 15-17 mm, and > 
17 mm, respectively (The ganirelix dose-finding study group 1998). 
Follicular surface areas were calculated using the formula: surface 
area = 4πr2, where r (the radius of the follicle) was derived from the 
mean diameter of each subclass. Total follicular surface area per 
patient was obtained from the sum of the surface area of each follicle. 
When no pregnancy occurred, the time of onset of the next 
menstruation was documented. Biochemical pregnancy was defined 
as a positive urinary hCG test 2 weeks after embryo transfer. Viable 
pregnancy was defined as a positive intrauterine fetal heart activity 
observed by TVS 5-6 weeks after embryo transfer. 
 
Hormone assays 
Blood samples were centrifuged within 1 h after withdrawal and 
stored at – 20°C until assayed. Serum LH, FSH, E2, and P levels were 
measured by a central laboratory, using a fluoroimmunoassy 
(Delphia, Wallac OY, Finland) and AD by a coat-a-count direct 
radioimmunoassay. Interassay coefficients of variation were less than 
4.7, 7.0, 9.9, 9.1 and 9.3 % for FSH, LH, E2, P and AD respectively. 
All samples from one subject were run in the same assay. 
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Statistical analysis 
Potential differences between the groups in age, duration of 
subfertility, total amount of FSH administered, number of follicles, and 
total follicular surface area were analyzed using the Kruskal-Wallis 
and Mann-Whitney tests, as were potential differences in LH, FSH, 
E2, AD, and P. Potential differences within the same group on 
different time intervals were analyzed using the Friedman and 
Wilcoxon matched pair test. Potential differences in cancellation rate 
and pregnancy rate were analyzed using Fisher’s exact test. 
Univariate regression was used to test the effect of the dose of GnRH 
antagonist on logarithmic transformed levels of E2 on the day of hCG. 
With multiple regression the effect of dose of GnRH antagonist on 
logarithmic transformed E2 levels was tested, controlling for 
logarithmic transformed AD, FSH, LH, and total follicular surface area. 
In principle, this analysis assesses statistically the effect of dose 
GnRH antagonist on E2 levels when corrected for the other variables. 
Differences were considered to be statistically significant if P < 0.05. 
 
 
2.2.3 Resuls 
 
No significant differences were found between the treatment groups 
in duration of subfertility or indication for IVF (data not shown). The 
mean age was 31.6 years and the mean body mass index was 22.7 
kg/m2. Eighteen of the 329 women who began ovarian 
hyperstimulation for IVF were excluded from analysis. Five were 
excluded due to premature luteinization, drug non-compliance or 
imminent ovarian hyperstimulation and thirteen due to insufficient 
ovarian response. The latter was observed in 2, 1, 4, 2, and 4 patients 
in the 0.0625, 0.25, 0.5, 1.0, and 2.0 mg GnRH antagonist treatment 
group, respectively. A total of 311 patients proceeded to hCG 
administration for final oocyte maturation and were included in the 
analysis. The total duration of ovarian stimulation, total amount of 
gonadotropins used, total number of oocytes retrieved, and number of 
embryos developed after fertilization were not significantly different 
between the six treatment groups (Table 2.5). Pregnancy and 
implantation rates were higher in the treatment groups receiving low 
doses of GnRH antagonist treatment, as shown previously (The 
ganirelix dose-finding study group 1998). 
No significant differences in the number of follicles, arbitrarily 
categorized into 3 size classes, were found on the day of initiation of 
ovarian stimulation, starting day of GnRH antagonist treatment, one 
day before hCG, or on the day of hCG (Figure 2.7). The total follicular 
surface area per patient on the day of hCG was not significantly 
different between the six treatment groups (data not shown).  
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Table 2.5 
Patient characteristics and late follicular phase ultrasound and endocrine assessments 
(mean + SD) in 311 women undergoing ovarian hyperstimulation for in vitro fertilization 
(IVF) using recombinant follicle stimulation hormone (recFSH) and various doses of the 
gonadotropin releasing hormone (GnRH) antagonist ganirelix.  
* Kruskal-Wallis test: P < 0.0005, hCH = human chorionic gonadotropin, LH = luteinizing 
hormone, FSH = follicle stimulating hormone, E2 = estradiol, AD = androstenedione, P 
= progesterone. 
 
FSH levels increased throughout the follicular phase in all six 
treatment groups (P < 0.005) but serum FSH concentrations did not 
differ between the groups at any stage during the follicular phase 
(Table 2.5). With respect to the serum LH concentrations, no 
significant differences were observed between the six groups prior to 
 Daily dose of ganirelix (mg) 
 
0.0625 0.125 0.25 0.5 1.0 2.0 
 
No. of patients reaching 
hCG (n) 
 
29 
 
65 
 
66 
 
63 
 
62 
 
26 
Age (yrs) 31.6 + 4.3 31.9 + 3.8 31.4 + 2.9 31.2 + 4.0 31.7 + 3.8 32.2 + 4.2 
Total dose of recFSH (IU) 1810 + 1104 1840 + 826 1831 + 688 2068 + 1011 2243 + 1219 1997 + 1228 
Follicular phase length (days) 9.6 + 1.7 9.9 + 1.8 10.0 + 1.7 10.1 + 1.9 10.6 + 2.4 9.3 + 1.9 
Ultrasound (day of hCG)       
No. of follicles ø 11-15 mm 10.6 + 5.2 10.7 + 4.8 11.7 + 4.6 10.2 + 4.6 10.6 + 4.4 9.4 + 3.6 
No. of follicles ø 15-17 mm 7.0 + 2.9 7.3 + 3.2 7.6 + 3.1 6.7 + 2.7 7.0 + 2.8 6.3 + 2.4 
No. of follicles ø > 17 mm 4.2 + 1.7 4.6 + 2.1 4.5 + 2.0 4.4 + 2.2 4.3 + 1.9 3.7 + 1.2 
No. of follicles ø > 11  21.8 + 8.3 22.6 + 9.0 23.8 + 8.5 21.2 + 8.2 21.9 + 7.5 19.4 + 6.2 
Total Follicular Surface  
Area (mm2) 14770 + 5244 15446 + 6052 16048 + 5760 14489 + 5553 14857 + 5009 13115 + 4082 
Endocrinology (day of hCG)       
LH (IU/L) 5.3 + 5.4* 3.5 + 3.1* 2.4 + 2.2* 1.6 + 1.3* 0.8 + 0.6* 0.4 + 0.2* 
FSH (IU/L) 11.6 + 6.1 10.6 + 5.7 10.4 + 4.2 11.7 + 4.9 11.7 + 5.7 12.0 + 6.4 
E2 (pg/mL) 1714 + 905* 1625 + 1259* 1468 + 1157* 1099 + 787* 913 + 720* 480 + 225* 
AD (ng/mL) 2.9 + 1.3* 2.8 + 1.4* 2.8 + 2.6* 2.2 + 0.7* 2.1 + 0.8* 1.6 + 0.5* 
P (ng/mL) 1.1 + 0.9 0.8 + 0.5 0.8 + 0.7 0.7 + 0.4 0.9 + 1.3 0.7 + 0.4 
Embryology       
No. of oocytes retrieved 9.6 + 5.3 9.6 + 5.4 10.3 + 5.2 9.8 + 6.2 9.5 + 6.0 8.6 + 4.4 
No. of embryos obtained 5.8 + 3.4 5.9 + 4.3 5.6 + 4.4 5.1 + 4.1 5.4 + 3.9 4.9 + 3.7 
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starting GnRH antagonist treatment. However, a significantly lower LH 
serum level was found on the day prior to and on the day of hCG 
administration in the 0.25, 0.5, 1.0, and 2.0 mg GnRH antagonist 
treatment groups as compared to the 0.0625 and 0.125 mg GnRH 
antagonist treatment groups, P < 0.005 (Figure 2.8). 
 
 
  
 
Figure 2.7 
Number of follicles (categorized into three different size classes) for the lowest dose 
(0.0625 mg/d; left panel) and the highest dose (2.0 mg/d; right panel) of the 
gonadotropin releasing hormone (GnRH) antagonist ganirelix during ovarian stimulation 
for IVF. Gray area, 11-14 mm; white area, 15-17 mm; black area, > 17 mm. 
 
 
 
Figure 2.8 
Box and whisker plot of serum 
luteinizing hormone (LH) levels 
on the day of human chorionic 
gonadotropin (hCG) in women 
undergoing ovarian stimulation 
for in vitro fertilization (IVF) using 
recombinant follicle stumulating 
hormone (recFSH) and 2.0 mg 
per day of the gonadotropin 
relaesing hormone (GnRH) 
antagonist ganirelix. 
 
AD levels were significantly lower on the day prior to and on 
the day of hCG administration in the 1.0 and 2.0 mg treatment groups 
compared to those receiving the smaller doses, P < 0.05 (Table 2.5). 
The effect of increasing doses of GnRH antagonist on serum E2 levels 
was similar to that on LH levels. A significantly lower E2 level was 
detected on the day prior to and on the day of hCG in those receiving 
0.5, 1.0, and 2.0 mg of GnRH antagonist compared to those receiving 
0.0625, 0.125, and 0.25 mg P < 0.05 (Table 2.5). Follicular phase 
progesterone (P) levels did not differ across the 6 treatment groups. 
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Univariate regression analysis showed the serum level of E2 
on the day of hCG to be related to the dose of GnRH antagonist, LH, 
FSH, AD and total follicular surface area (all P < 0.001). E2 levels on 
the day of hCG for the different doses GnRH antagonist, adjusted for 
AD, FSH, LH, and total follicular surface area, are depicted in Figure 
2.9. Multiple regression of E2 levels with daily dose of GnRH 
antagonist controlling for AD, FSH, LH, and total follicular surface 
area on the day of hCG, demonstrated a regression coefficient of -
1.61 and a standard error of 0.035 (P < 0.001). 
 
 
 
 
Figure 2.9 
Logarithmic transformed E2 levels 
on the day of hCG (adjusted for 
AD, FSH, LH, and total follicular 
surface area) under different 
doses of the GnRH antagonist 
ganirelix during ovarian 
stimulation for IVF. 
 
 
2.2.4 Discussion 
 
This study demonstrates that follicle growth dynamics were similar in 
all treatment groups receiving various daily doses of the GnRH 
antagonist ganirelix (0.0625 - 2.0 mg/d). Although the multicentre 
design of the study, the use of different ultrasound machines and 
measurement criteria may have masked subtle differences in follicle 
size, clear equivalence in follicle size and total follicular surface area 
were observed in all groups. In addition, in terms of follicles observed, 
oocytes retrieved, and embryos obtained, data from the different 
treatment groups were also camparable. The duration of stimulation 
and the total amount of gonadotropins administered were 
independent from the GnRH antagonist dose in women undergoing 
ovarian stimulation for IVF.  
In the present study, serum FSH levels rose during the 
follicular phase resulting in similar late follicular phase levels in all six 
treatment groups. FSH serum concentrations reflect the sum of 
exogenous FSH and endogenous FSH, possibly suppressed by 
GnRH antagonist (de Jong et al. 2000). Minor differences in pituitary 
FSH release due to the suppressive action of increasing doses of 
GnRH antagonist were not reflected in changes in serum FSH. Thus, 
prevention of the physiological decrease in FSH was effected, 
enabling ongoing growth of multiple dominant follicles. Under FSH 
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stimulation, low levels of LH are sufficient to induce growth of healthy 
preovulatory follicles (Schoot et al. 1992; The european recombinant 
human LH study group 1998). It may therefore be speculated that the 
low LH concentrations occuring during high dose GnRH antagonist 
treatment were sufficient to allow normal follicular growth in the 
presence of exogenous FSH stimulation.  
A clear dose related fall in LH levels on day of hCG was 
observed, with levels in the highest dose group only 12% of those 
observed in the lowest dose group (Figure 2.8). LH levels in all 
treatment groups were significantly lower than observed in the normal 
menstrual cycle (Macklon & Fauser 2000). Caution is required when 
interpreting these LH data since the sampling frequency may not 
have fully represented the pulsatile nature of endogenous LH 
stimulation of follicles. Further, samples for LH analysis were 
withdrawn prior to GnRH antagonist administration, almost 24 hours 
following the previous injection, whereas maximum of suppress of LH 
by GnRH antagonists is normally established after 4 hours (Oberye et 
al. 1999b). Data concerning the recovery of pulsatile LH secretion 
under different dosages of GnRH antagonist treatment is lacking. In 
contrast to the case with studies of GnRH agonists, LH levels 
assessed in the present study do not represent 24 hour exposure of 
the ovaries to LH. In addition, the magnitude of overestimation of LH 
may be GnRH antagonist dose related. 
 Despite similar patterns of follicular growth, E2 levels showed 
a dose related response to GnRH antagonist. On the day of hCG, E2 
levels in the 2.0 mg GnRH antagonist group reaching only 33 % of the 
E2 levels observed in the 0.25 mg GnRH antagonist group. However, 
even in these highly suppressed conditions, absolute E2 
concentrations were still elevated compared to late follicular phase 
levels in the menstrual cycle (Macklon & Fauser 2000). The 
production capacity for E2 derived from the number of granulosa cells 
can be quantified by measuring the total follicular surface area per 
patient (van Wezel & Rodgers 1996). In both spontaneous and 
stimulated cycles, E2 production per unit total follicular surface area 
remains relatively constant throughout the late follicular phase (Eissa 
et al. 1986). In the present study, E2 serum levels per unit total 
follicular surface area decreased with increasing daily doses of GnRH 
antagonist. Low E2 levels in the high dose GnRH antagonist treatment 
groups despite comparable number of follicles on day of hCG may 
indicate a decrease in E2 production by granulosa cells (McNatty et al. 
1979) which may simply reflect a reduced availability of AD, the 
substrate for aromatization to E2. Indeed, a significant regression 
coefficient was calculated between E2 and AD serum levels on day of 
hCG. 
Lower serum AD levels on the day of hCG were observed in 
the two high GnRH antagonist dose groups. This may in turn have 
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been due to suppressed LH activity. Alternatively, AD levels in serum 
may not represent the availability in the follicular compartment since a 
substantial part of circulating AD is produced by the adrenals 
(Abraham et al. 1969). 
Consistent with the 'two-gonadotropin, two-cell' concept 
(Short 1962; Makris & Ryan 1977; Sullivan et al. 1999), FSH, LH, and 
AD levels were all found to affect E2 biosynthesis. However, when E2 
levels were adjusted for FSH, LH, and AD levels and total follicular 
surface area, the daily dose of GnRH antagonist still appeared to 
exhibit an additional suppressive action on E2 levels (regression 
coefficient = -1.61, SD = 0.035, P < 0.001). This analysis suggested 
that GnRH antagonist may be impacting on E2 levels by means of an 
additional mechanism not directly related to these other variables. 
Evidence for the differential effects that GnRH analogs have on 
granulosa-lutein cell steroidogenesis (Minaretzis et al. 1995a) and for 
the presence of GnRH receptors on human granulosa cells (Latouche 
et al. 1989) would be consistent with an additional agonist/antagonist 
mediated affect on E2 production, possibly acting on intra-ovarian 
modifiers of response to FSH and LH such as vascular endothelial 
growth factor (VEGF) and insuline-like growth factor (IGF) (Fauser & 
Van Heusden 1997). 
Pregnancy and implantation rates were lower in the treatment 
groups of patients receiving higher doses (1.0 - 2.0 mg/d) of GnRH 
antagonist compared to those receiving a lower dose (0.0625 - 0.5 
mg/d), as reported previously (The ganirelix dose-finding study group 
1998). It remains doubtful if this observation is of any clinical 
relevance, since the minimal effective dose of the GnRH antagonist 
ganirelix was established at 0.25 mg/d (The ganirelix dose-finding 
study group 1998). A proper analysis of pregnancy and implantation 
rates implies accurate evaluation of the luteal phase, the analysis of 
follicular phase characteristics is unsuitable for that purpose. 
However, a large randomized multicentre trial showed similar 
pregnancy and implantation rates of a GnRH antagonist protocol, 
utilizing a daily dose of 0.25 mg ganirelix, in comparison to a 'long 
protocol' (The european orgalutran study group et al. 2000).  
In conclusion, follicular growth was not influenced by the daily 
dose of GnRH antagonist in ovarian hyperstimulation protocols for 
IVF. Despite similar follicular growth patterns, a marked dose related 
suppression of late follicular phase E2 levels was observed, 
secondary to a dose related suppression of LH, and to some extent 
AD levels. Multivariate analysis showed E2 levels to be additionally 
affected by the dose GnRH antagonist itself. These data suggest that 
lack of circulating androgens and LH may not be the only factors 
causing low E2 levels in the high dose GnRH antagonist treatment 
groups and that high doses of GnRH antagonists may influence 
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follicular steroidogenesis by an additional, as yet unelucidated 
mechanism. 
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2.3 Non-inferiority study of a GnRH 
antagonist protocol for IVF 
 
2.3.1 Introduction 
 
Ganirelix is the active ingredient of Orgalutran® and Antagon™,a 
gonadotropin-releasing hormone (GnRH) antagonist preparation 
developed for the prevention of premature LH surges in women 
undergoing ovarian stimulation. In comparison with native GnRH, 
ganirelix has substituted amino acids at positions 1, 2, 3, 6, 8 and 10, 
which results in a potent antagonist with only minimal histamine-
releasing properties (Rabinovici et al. 1992; Nelson et al. 1995) and 
high aqueous solubility. The latter property is reflected by the high 
absolute bioavailability (F) of ganirelix being more than 90% after s.c. 
injection (Oberye et al. 1999a). 
In current practice, GnRH agonists are used to suppress 
endogenous gonadotropins during ovarian stimulation (Loumaye 
1990). However, agonists initially stimulate the release of 
gonadotropins (‘flare-up’), and complete pituitary suppression is only 
achieved after 2–3 weeks pretreatment when pituitary desensitization 
occurs due to receptor down regulation. 
The introduction of a GnRH antagonist such as ganirelix 
allows a short and simple treatment regimen for IVF patients 
undergoing ovarian stimulation, since antagonists immediately 
suppress gonadotropins by blocking the GnRH receptor, and thus 
treatment may be restricted to those days when a premature LH 
surge is likely to occur. Studies in healthy female volunteers and IVF 
patients have shown that steady-state concentrations of ganirelix are 
reached within 2–3 days of treatment, and that maximal suppression 
of endogenous LH occurs about 4 h after each injection (Oberye et al. 
1999b). Moreover, after discontinuation, a rapid recovery of pituitary 
function (Gordon et al. 1990) was observed, also due to the relative 
short elimination half-life (about 13 h) of ganirelix. The additional 
anticipated advantages of antagonist treatment in ovarian stimulation 
programmes are a reduction of the use of gonadotropins, a lower risk 
for developing ovarian hyperstimulation syndrome (OHSS), and the 
ability to use a bolus injection of a GnRH agonist to trigger a midcycle 
LH surge for final follicular maturation (Olivennes et al. 1996). 
Moreover, in cases of multiple follicles and excessively high estradiol 
concentrations, the use of GnRH agonist instead of human chorionic 
gonadotropin (hCG) is thought to prevent the clinical manifestation of 
OHSS (Itskovitz-Eldor et al. 1991). If nevertheless, the IVF cycle is 
cancelled, ganirelix treatment may be continued to prevent 
spontaneous ovulation as well as signs and symptoms of OHSS (de 
Jong et al. 1998). 
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The third-generation GnRH antagonists cetrorelix and 
ganirelix have both been applied in a multiple-dose regimen in women 
undergoing ovarian stimulation. Clinical research of cetrorelix started 
off with relatively high daily dosages of 3 and 1 mg (Diedrich et al. 
1994; Felberbaum et al. 1995), but finally the lowest effective daily 
dose of cetrorelix appeared to be 0.25 mg (Albano et al. 1997; Albano 
et al. 1998). To select the minimal effective daily dose of ganirelix, a 
multicentre, double-blind, randomized, dose-finding study was 
performed in 333 women including six different dosages ranging 
between 0.0625 and 2 mg (Itskovitz-Eldor et al. 1998; The ganirelix 
dose-finding study group 1998). In this study, patients were treated 
with a fixed dose of 150 IU recFSH for 5 days before starting 
ganirelix. The study revealed that a daily dose of 0.25 mg ganirelix 
prevented LH from rising above 10 IU/L during stimulation, and 
resulted in a good clinical outcome, i.e. the ongoing pregnancy rate 
was 34% per attempt (23/68) and 37% per transfer (23/62). Moreover, 
as in other studies (Fujimoto et al. 1997; Oberye et al. 1999b), serum 
ganirelix concentrations increased in a linear dose-proportional 
manner, and serum LH decreased in a dose-proportional manner, 
indicating that the degree of pituitary suppression can be adjusted by 
changing the ganirelix dose. 
In the current study the efficacy and safety of a multiple dose 
regimen administering 0.25 mg ganirelix daily was assessed in a 
randomized study in women undergoing ovarian stimulation with 
recFSH for IVF or intracytoplasmic sperm injection (ICSI). 
 
 
2.3.2 Materials and methods 
 
Patients 
A total of 730 patients, for whom ovarian stimulation and IVF or ICSI 
was indicated, was screened and randomized in this study. In total, 
20 IVF centres in 10 European countries participated, and the number 
of randomized patients per centre ranged from 11 to 60. Main 
inclusion criteria were: age at least 18 years but not older than 39 
years; body mass index (BMI) between 18 and 29 kg/m2; regular 
menstrual cycle, ranging from 24 to 35 days. 
 
Study design 
This trial was a phase III, multi-centre, open-label, randomized study 
to assess the efficacy and safety of the GnRH-antagonist ganirelix in 
women undergoing ovarian stimulation. Eligible patients were 
randomized by an interactive voice response system (IVRS) to either 
treatment with ganirelix (Orgalutran®, Org 37462; NV Organon, Oss, 
The Netherlands) or buserelin (Suprecur®; Hoechst, Frankfurt Am 
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Main, Germany) in a ratio of 2:1. To improve balance, a minimization 
method was used for randomizing patients to treatment (Treasure & 
MacRae 1998), stratifying for centre age, for primary or secondary 
infertility, and for IVF or ICSI. 
A diagrammatic representation of the applied treatment 
regimens is shown in Figure 2.10. Injections of recFSH (Puregon®; 
NV Organon) and ganirelix were given in the morning. In the ganirelix 
group, treatment with recFSH was started in patients on day 2 or 3 of 
the menstrual cycle by a once-daily s.c. injection. After 5 days of 
recFSH treatment, ganirelix treatment was started by daily s.c. 
administration in the upper leg. Ganirelix treatment was continued up 
to and including the day of hCG administration.  
In the buserelin reference group, pretreatment with buserelin 
was started in the midluteal phase (cycle day 21–24) with a daily dose 
of 0.6 mg intranasally (four puffs per day). Ovarian stimulation was 
started after 2 weeks if pituitary ‘down-regulation’ was established 
(serum estradiol concentration <50 pg/mL or <200 pmol/L). In case 
‘down-regulation’ was not achieved after 2 weeks, stimulation was 
postponed and the daily dose of buserelin was doubled to 1.2 mg. 
The dose of buserelin at which ‘down-regulation’ was established (0.6 
or 1.2 mg) was continued up to the day of hCG. If ‘down-regulation’ 
with buserelin was not achieved within 4 weeks, treatment 
discontinued. 
 
 
 
 
Figure 2.10 
Schematic of the treatment 
regimen with ganirelix (upper 
part of diagram) and with a 
‘long protocol’ of intranasal 
buserelin (lower part) in patients 
undergoing ovarian stimulation 
with recombinant FSH (rFSH; 
Puregon®). 
 
 
In both treatment groups, ovarian stimulation was started with 
a fixed daily dose of 150 IU recFSH for the first five treatment days. 
From day 6 onwards, the dose of recFSH was adapted depending on 
the ovarian response as monitored via ultrasonography. On the day of 
hCG, recFSH was not administered. hCG (10 000 IU, Pregnyl®; NV 
Organon) was administered when at least three follicles of >17 mm 
diameter were observed, and 30–36 h thereafter oocyte retrieval was 
performed. Oocyte retrieval was followed by IVF or ICSI, and no more 
than three embryos were to be replaced 2–5 days thereafter. Luteal 
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phase support was given according to the clinics’ routine practice, 
and was started no later than the day of embryo transfer. 
 
Assessments 
In the ganirelix group prior to the start of recFSH, and in the buserelin 
group prior to the start of buserelin, an hCG test was to be performed 
to exclude pregnancy. When bleeding did not occur within 2 weeks 
after starting buserelin treatment, an additional hCG test was 
performed. Just before the first injection of recFSH, a blood sample 
was taken for hormone assessment and ultrasonography (USS) was 
performed. From recFSH treatment day 6 up to and including hCG 
administration, the patient returned to the clinic for USS and blood 
sampling before ganirelix administration once every 2 days. Serum 
FSH, LH, estradiol and progesterone were assessed by a central 
laboratory by means of fluoro-immunoassay (Delfia®, Wallac OY, 
Finland). 
Local tolerance was assessed by the patient at 1, 4 and 24 h 
after each ganirelix injection. The subject was asked to record on a 
diary card the score (none, mild, moderate or severe) for five different 
parameters, i.e. bruising, swelling, pain, itching and redness. 
 
Statistical methods 
The study was designed as a non-inferiority trial to test whether the 
combination of efficacy, safety and convenience of ganirelix treatment 
was clinically equivalent to the current care, i.e. GnRH agonist 
treatment in a ‘long protocol’. As a large previous study with Puregon 
and intranasal buserelin in a ‘long protocol’ had an excellent clinical 
outcome (Out et al. 1995), this regimen was selected as the reference 
treatment in the current study. Data from the intent-to-treat (ITT) 
group were used for efficacy analysis, and data from the all-subjects-
treated (AST) group were used for safety analysis. The ITT group 
and the AST group consisted of all patients randomized who started 
treatment. Patients in the ITT group were grouped according to the 
treatment they should have received by randomization, whereas 
patients in the AST group were grouped according to the actual 
treatment they received. 
 
Efficacy analysis 
A total of 701 subjects started treatment with recFSH or buserelin and 
was included in the ITT group. Of the treated subjects, 463 were 
randomized to the ganirelix group and 238 to the buserelin group. 
One subject was randomized to buserelin, but was treated with the 
ganirelix regimen, and one subject was randomized to buserelin and 
received during buserelin treatment also three injections of ganirelix. 
Since both subjects were intended to receive buserelin, they were 
included in the ITT group of buserelin. One subject with a 
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spontaneous pregnancy who started buserelin treatment was also 
included in the ITT group. Main efficacy parameters were treatment 
failure, number of cumulus–oocyte complexes, number of good 
quality embryos, and ongoing pregnancy rate. For patients treated 
with both IVF and ICSI, oocyte quality was not analysed.  
The estimated difference of ganirelix and buserelin in ongoing 
pregnancy rate was compared with the margin of –5%. For cumulus–
oocyte complexes, the lower one-sided 97.5% confidence limit of the 
treatment difference was compared with the equivalence margin of –3 
oocytes. For continuous efficacy variables, adjusted-for-centre 
treatment means and their differences were calculated, using a 
weighted average over the centres based on the Cochran–Whitehead 
method (Whitehead & Whitehead 1991). For the ongoing pregnancy 
outcome the Cochran–Mantel–Haenszel weights (Cochran 1954) 
were used. Lower one-sided 97.5% confidence limits of the adjusted-
for-centre treatment differences between ganirelix and buserelin were 
calculated for the number of oocytes, good quality embryos, and the 
ongoing pregnancy rate. For the rate of study medication treatment 
failure in each group, a one-sided 97.5% confidence limit was 
calculated based on the binomial distribution. 
 
Freeze–thaw cycles 
Embryos were frozen in 18 out of the 20 IVF centres; in two German 
centres only two-pronuclear (2PN) oocytes were frozen which were 
not included in this analysis. Data were collected for all patients (n = 
126) who did not become pregnant after replacement of fresh 
embryos, and for whom spare embryos were cryopreserved. By June 
1999, 53 of these patients had had at least one embryo transfer using 
thawed embryos. The outcome of these first freeze–thaw cycles is 
presented. 
 
Safety analysis 
Analysis was performed by means of frequency distributions of the 
incidence of adverse events, local tolerance outcome, clinically 
significant abnormal laboratory values and vital signs. For patients 
treated with the ganirelix regimen, analysed data included all days of 
stimulation, thus also the first 5 days of recFSH treatment when 
patients were not yet exposed to ganirelix. 
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2.2.3 Results 
 
The two treatment groups were similar with respect to age, body 
height, weight and BMI (see Table 2.6). The overall (n = 701) mean 
age, body height, weight and BMI were 31.9 years, 166.6 cm, 63.8 kg 
and 23 kg/m2 respectively. The majority (98%) of patients was 
Caucasian. No relevant differences were found between the 
treatment groups for the cause of subfertility which was overall 40.1% 
male factor, 29.2% tubal factor and 15.5% unknown factors. The 
overall percentage of subjects with primary infertility was 56.5%, and 
similar in both groups. 
 
 
Characteristic Ganirelix n = 463 
Buserelin 
n = 238 
Age (years)a 31.9 + 3.6 31.9 + 3.8 
Body mass index 
(kg/m2)a 23.0 + 2.9 23.0 + 2.7 
Duration of subfertility 
(years)a 4.5 + 2.7 4.4 + 2.7 
Main causes of 
subfertility (%)   
   Male (only) 41.0 38.2 
   Tubal (only) 29.8 28.2 
   Unknown 13.8 5.0 
Parity (%)   
   Primary infertility 56.6 56.3 
   Secondary infertility 43.4 43.7 
 
Table 2.6 
Demographics and subfertility characteristics. 
a Values are mean + SD. 
 
Disposition and cancellations 
In total, 730 subjects were randomized, 486 patients to the ganirelix 
group and 244 patients to the buserelin group (ratio~2:1). A total of 
701 subjects received recFSH or GnRH analogue treatment. The 
number of patients per treatment stage is presented in Table 2.7.  
In total, 16 subjects (3.5%) in the ganirelix group and 14 
subjects (5.9%, including the patient who was randomized to this 
group but was treated with ganirelix) in the buserelin group had a 
treatment failure in that they did not receive hCG, or received hCG 
because of premature luteinization. The overall cancellation rate up to 
embryo transfer was 13.8 and 12.6% for the ganirelix and buserelin 
groups respectively. Main reasons for discontinuation of treatment 
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were insufficient ovarian response (3.2 versus 2.5%) and fertilization 
failure (6.2 versus 4.1%). Overall, eight patients in the ganirelix group 
and two patients in the buserelin group had intrauterine insemination 
instead of oocyte retrieval. In the buserelin group, seven patients 
(3.0%) were discontinued before starting recFSH due to insufficient 
‘down-regulation’. In the ganirelix group, two patients (0.4%) were 
discontinued because of premature luteinization. 
 
 
 
Table 2.7 
Number of patients per treatment stage. 
a Two patients who were randomized to the buserelin group were treated with ganirelix, 
one of whom received no buserelin at all (see Materials and methods; Efficacy 
analysis). 
b Includes one patient  who received HCG because of premature luteinization. Values in 
parentheses are percentages. hCG = human chorionic gonadotropin. 
 
Duration of GnRH analogue treatment and total dose of recFSH 
The median (range) duration of GnRH analogue treatment was 5 (2–
14) days in the ganirelix group, and 26 (18–44) days in the buserelin 
group. The total amount of GnRH analogue administered was 1.25 
versus 16.2 mg. The median (range) duration of recFSH treatment 
was 9 (6–18) and 10 (6–19) days respectively. The total amount of 
recFSH administered was in total 1500 (900–6400) IU and 1800 
(900–6450) IU, and the median daily dose was 150 IU/day and 178 
IU/day in the ganirelix and buserelin groups respectively. 
 
LH rises (>10 IU/L) before and during ganirelix treatment 
Early LH rises at day 6 of stimulation, before the first ganirelix 
administration, were observed in 20 patients (4.3%). In these patients 
serum LH values ranged between 10.4 and 33.4 IU/L and 
concomitant rises of serum progesterone >1 ng/mL were observed in 
seven out of these 20 patients. On day 6 of stimulation, this subset of 
patients had on average 6.8 follicles >11 mm diameter, and their 
 Ganirelix Buserelin 
No. of subjects randomized to group 463 238 
Treated with buserelin - 237 (100) 
Treated with recFSH 463 (100) 228 (96) 
Treated with ganirelix 460 (99) 2a 
hCG for triggering ovulation 448 (97)b 224 (95) 
Oocyte retrieval 440 (95) 221 (93) 
Embryo transfer 399 (86) 208 (88) 
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median serum estradiol concentration was 856 (range 348–1900) 
pg/mL, indicating that most of these patients were high responders. 
Due to initiation of ganirelix treatment, endogenous LH rises were 
effectively cutdown in all 20 patients. Out of the 20 patients, 19 had 
embryo 
transfer, and in three patients an ongoing pregnancy was established. 
After the day of the first ganirelix injection, 13 women (2.8%) 
had an LH value >10 IU/L. Peak LH values ranged between 10.1 and 
58.1 IU/L, and concomitant rises (>1 ng/mL) of serum progesterone 
were observed in six patients (1.5%). Seven patients were 
discontinued before embryo transfer, and none of the other patients 
became pregnant. In the buserelin group, three patients (1.3%) had 
an LH rise to >10 IU/L during stimulation. Of these, one patient was 
discontinued and one patient became pregnant. Miscarriage did not 
occur in any of the patients with an early or late rise of serum LH after 
confirmation of an early clinical pregnancy. 
 
Follicle growth 
The mean (+ SD) number of follicles >11 mm diameter measured on 
days 6, 8 and 10 of stimulation for patients with at least 9 days of 
stimulation are presented in Figure 2.11. The number and size of 
follicles measured at the day of hCG administration are summarized 
in Table 2.8. 
 
 
 
 
 
 
 
 
Figure 2.11 
Number of follicles > 11 mm in 
diameter on stimulation days 1, 6, 
8, and 10 of recFSH for patients 
with at least 9 days of stimulation. 
Values are mean + SD.
 
Comparison of the number and size of growing follicles 
indicates a different follicle growth pattern in the ganirelix group than 
in the buserelin group. At day 6 of stimulation, after 5 days of 150 IU 
recFSH per day, absence of follicular growth (no follicles >11 mm 
diameter) was observed in 13.2% of patients treated with the ganirelix 
regimen, whereas this incidence was 31.5% in the buserelin 
reference group. Accordingly, initial follicular growth appeared to be 
more rapid in the ganirelix group than in the buserelin group, as 
indicated by the mean number of follicles >11 mm diameter on day 6 
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of stimulation (4.7 versus 3.0; Figure 2.11). On day 8 of stimulation, 
the difference between the treatment groups was less apparent, and 
on the day of hCG the opposite was observed in that the number of 
follicles >11 mm was smaller in the ganirelix group than in the 
buserelin group (10.7 versus 11.8). Comparison of follicle sizes 
between the two treatment groups indicates that this difference was 
mainly due to fewer small follicles in the ganirelix group (Table 2.8), 
as also reflected by the comparable mean number of follicles >17 mm 
at the day of hCG administration (4.9 versus 5.2). 
 
Table 2.8 
Number and size of follicles (mean + SD) grouped according to diameter and serum 
hormone values (median with 5% and 95% percentiles) on the day of hCG 
administration. Restricted to patients who received an hCG injection. 
a Includes one patient who received hCG because of premature luteinization. 
 
Serum hormone concentrations 
Median serum FSH, LH, estradiol and progesterone concentrations 
measured at days 1, 6, 8 and 10 of stimulation for patients with at 
least 9 days of stimulation are presented in Figure 2.12. At the start of 
recFSH stimulation (day 1), serum hormone concentrations were 
higher in the ganirelix group than in the buserelin group, and 
represented normal levels as measured at day 2 to 3 of the menstrual 
cycle and after pituitary ‘down-regulation’ respectively. On day 6 of 
stimulation, serum FSH and LH concentrations had become similar in 
both treatment groups, probably due to a negative feedback by initial 
rising estradiol concentrations in the ganirelix group. Median serum 
estradiol concentrations rose from 38 pg/mL on day 1 to 358 pg/mL 
on day 6 of stimulation in the ganirelix group, and from 19 pg/mL to 
160 pg/mL in the buserelin group. This increase was in accordance 
with the number of growing follicles in each group. From day 6 to the 
day of hCG, serum FSH increased by 0.5 IU/L in the ganirelix group 
and by 1 IU/L in the buserelin group. Predose concentrations of 
 Ganirelix n = 448 a 
Buserelin 
n = 224 
Follicles (n)   
   >11 mm 10.7 + 5.3 11.8 + 5.4 
   >15 mm 7.7 + 4.0 8.3 + 3.9 
   >17 mm 4.9 + 2.6 5.2 + 2.3 
Hormones   
   FSH (IU/L) 7.7 (5.0-14.1) 8.4 (5.4-17.6) 
   LH (IU/L) 1.6 (<0.6-6.9) 1.5 (<0.6-4.4) 
   Estradiol (pg/mL) 1190 (373-3105) 1700 (527-4070) 
   Progesterone (ng/mL) 0.7 (0.4-1.6) 0.7 (0.4-1.6) 
   Estradiol/follicle (pg/mL) 111 144 
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serum LH in patients treated with ganirelix were comparable with 
those measured in the buserelin group. After day 6 of stimulation up 
to the day of hCG, serum estradiol concentrations followed the 
pattern of follicular growth in that on day 8 the estradiol 
concentrations were only 128 pg/mL higher in the ganirelix group than 
in the buserelin group, whereas on the day of hCG (see Table 2.8) 
the opposite was observed, with serum estradiol concentration being 
about 500 pg/mL lower in the ganirelix group than in the buserelin 
group (1190 versus 1700 pg/mL). Finally, serum estradiol content per 
follicle (>11 mm) was lower in the ganirelix group than in the buserelin 
group.  
 
 
 
 
 
 
 
Figure 2.12 
Serum hormone concentrations 
on stimulation days 1, 6, 8 and 
10 of recFSH for patients with 
at least 9 days of stimulation. 
The boxes indicate the 75% 
and 25% percentiles, the 
vertical lines indicate the 95% 
and 5% percentiles, and 
median values are connected.
 
 
Individual serum LH values measured on day 6 and 
measured on the day of hCG were plotted in Figure 2.13. Comparison 
of the predose values in the ganirelix group with LH values measured 
during ‘down-regulation’ with buserelin, indicates a larger variability in 
the ganirelix group. A possible relationship between serum LH and 
pregnancy outcome (Figure 2.13) or between serum estradiol and 
pregnancy outcome (data not shown) was not revealed. 
 
Treatment outcome 
The mean number of oocytes recovered, their quality and the mean 
number of embryos obtained and their quality in each treatment group 
are given in Table 2.9. In comparison with buserelin treatment, 
ganirelix treatment resulted in one preovulatory follicle less (see 
above) and, as a consequence, one cumulus–oocyte complex less 
was recovered at oocyte retrieval. The estimated treatment difference 
was –1.0 oocyte (lower 97.5% confidence limit –1.8) which was within 
the equivalence margin of –3 oocytes. 
 
Non-inferiority study of a GnRH antagonist protocol 
 
- 69 -   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 
Concentrations of serum LH in 
individual patients on day 6 of 
stimulation versus serum LH on 
the day of hCG. Filled poits 
represent  values of patients who 
became pregnant. 
  
 
 
Table 2.9 
Number of cumulus–oocytes complexes recovered per attempt and per oocyte 
retrieval, number and quality of  embryos obtained, and number of transferred embryos. 
Values are presented as mean + SD. ICSI = intracytoplasmic sperm injection. 
 
In total, 357 patients had IVF and 291 patients had ICSI, 
whereas 10 patients had both IVF and ICSI (1.5 versus 1.3% in the 
ganirelix and buserelin groups respectively). The mean (+ SD) 
number of metaphase II oocytes recovered in ICSI patients was 83% 
 Ganirelix Buserelin 
Cumulus-oocyte complexes/attempt n = 463 8.7 + 5.6 
n = 238 
9.7 + 6.2 
Number of oocytes before IVF n = 234 9.6 + 5.7 
n = 123 
10.3 + 5.7 
Number of oocytes before ICSI n = 196 8.6 + 4.8 
n = 95 
10.3 + 5.9 
Cumulus-oocyte complexes/attempt n = 440 9.1 + 5.4 
n = 221 
10.4 + 5.8 
Embryos n = 463 n = 238 
   Total 6.0 + 4.5 7.1 + 5.2 
   Good quality 3.3 + 3.0 3.5 + 3.2 
   Frozen 1.1 + 2.3 1.3 + 2.5 
   Replaced 2.2 + 0.6 2.2 + 0.6 
Alternative approaches to ovarian stimulation for in vitro fertilization 
 
- 70 -   
in each group, i.e. 7.1 + 4.2 versus 8.5 + 5.2, and the overall 
fertilization rate was 62.1% in each group. In addition, the number of 
good quality embryos obtained was comparable between the groups, 
and the estimated treatment difference was only –0.1 embryo (lower 
97.5% confidence limit –0.4). At transfer, in each group a mean of 2.2 
embryos were replaced, including a mean of 2.0 and 1.9 good quality 
embryos in the ganirelix and buserelin groups respectively.  
The clinical outcome of all patients receiving embryo transfer, 
expressed per attempt and per embryo transfer, is shown in Table 
2.10. Although a similar number of embryos was replaced in each 
group, the implantation rate (number of gestational sacs divided by 
the number of replaced embryos) was relatively lower in the ganirelix 
group (15.7 versus 21.8%), whereas the miscarriage rate per clinical 
pregnancy was comparable (12.0 versus 13.9%). Accordingly, the 
vital and ongoing pregnancy rate tended to be lower in the ganirelix 
group than in the buserelin group. For the ITT group, the ongoing 
pregnancy rate per attempt was 20.3% in the ganirelix group and 
25.7% in the buserelin group (including one spontaneous pregnancy 
in the buserelin group). The estimated difference for the ongoing 
pregnancy rate was at the margin of –5%. When comparing the 
ongoing pregnancy rate per study site, this difference ranged from 
26.3% in favour of ganirelix to 28.6% in favour of buserelin. The 
ongoing pregnancy rate per attempt for patients (n = 337) treated at 
study sites (n = 10) that had previous experience with the ganirelix 
regimen was similar, i.e. 24.2% in the ganirelix group and 23.6% in 
the buserelin group, whereas this rate was respectively 16.5 and 
27.5% for patients (n = 363) treated in study sites (n = 10) that had 
applied the ganirelix regimen for the first time.  
Overall, 94 and 61 ongoing pregnancies respectively were 
established at 12–16 weeks after embryo transfer. The multiple 
pregnancy rate was 23.4% in the ganirelix group and 29.5% in the 
buserelin group. 
 
Outcome of subsequent freeze–thaw cycles 
The mean (+ SD) number of embryos frozen was 1.1 + 2.3 and 1.3 + 
2.5 in the ganirelix and buserelin groups respectively. The first 
frozen–thawed embryo cycles (n = 53) performed within one year 
after study completion resulted in three miscarriages, one induced 
abortion and 10 ongoing pregnancies (12–16 weeks after embryo 
transfer). Seven pregnancies (20.0%) were established in patients 
previously treated with ganirelix, and three pregnancies (16.7%) were 
established in patients treated with buserelin. The overall ongoing 
pregnancy rate was 18.9% (see Table 2.11). 
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Table 2.10 
Clinical outcome as percentage per attempt and per transfer in patients treated with the 
ganirelix regimen and with a ‘long protocol’ of buserelin 
 
 
Safety and tolerance 
The number of subjects who experienced at least one adverse 
experience was 125 (26.9%, i.e. 125/465) in the ganirelix group, and 
74 (31.4%, i.e. 74/236) in the buserelin group. The most frequently 
reported experiences were headache, abdominal pain 
(gynaecological), OHSS and miscarriages. Treatment discontinuation 
because of an adverse experience occurred for one patient in the 
ganirelix group (0.2%) due to the risk for developing OHSS, and for 
one patient (0.4%) in the buserelin group because of spontaneous 
ovulation before oocyte retrieval. The number of subjects with 
possible or probable drug-related experiences was 11 (2.4%) in the 
ganirelix group, and nine (3.8%) in the buserelin group. In the 
ganirelix group, 18 patients (3.9%) were hospitalized because of an 
adverse experience, i.e. ectopic pregnancy (n = 4), OHSS (n = 4), 
miscarriage (n = 6), threatening abortion (n = 1), hyperemesis (n = 1), 
urinary retention (n = 1) and abdominal pain (gynaecological) (n = 1). 
In the buserelin group, 11 patients (4.6%) were hospitalized because 
of ectopic pregnancy (n = 1), OHSS (n = 6 including 1 case of 
enteritis) and miscarriage (n = 4). All these adverse experiences were 
indicated as not, or unlikely to be, drug-related. 
 Ganirelix Buserelin 
No. of patients receiving embryo 
transfer 399 208 
Implantation rate (%) 15.7 21.8 
Miscarriage rate (%) 12.0 13.9 
Vital pregnancies   
   Per attempt (%) 21.8 28.2 
   Per transfer (%) 25.1 31.7 
Ongoing pregnancy rate   
   Per attempt (%) 20.3 25.7 
   Per transfer (%) 23.3 29.0 
Ongoing pregnancies   
   Singletons (%) 76.2 68.9 
   Twins (%) 20.2 26.2 
   Triplets (%) 3.2 3.3 
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The incidence of OHSS was two-fold lower in the ganirelix 
group than in the buserelin group. Eleven subjects (2.4%) in the 
ganirelix group and 14 subjects in the buserelin group (5.9%) 
experienced signs and symptoms related to OHSS. For two pregnant 
patients in the ganirelix group OHSS was graded as severe; all other 
cases were of moderate or mild intensity. 
 
 Ganirelix Buserelin Overall 
No. of first attempts 35 18 53 
Embryos (mean)    
   Good quality 1.6a 1.9 a 1.7 
   Transferred 2.1a 2.4 a 2.2 
   No. miscarriages 2 1 3 
   Induced abortions (n) 1 0 1 
   No. of ongoing pregnancies 7 3 10 
   Pregnancy rate (%) 20.0 16.7 18.9 
 
Table 2.11 
Outcome of 53 first freeze-thaw cycles. a Data are missing. 
 
The local tolerance outcome indicated that ganirelix 
administered daily by the s.c. route was well tolerated. The 
percentage of patients with at least one moderate or severe local 
tolerance reaction (skin redness, swelling, bruising, pain or itching) 
during ganirelix treatment was 16.6, 2.0 and 2.7%, at 1, 4 and 24 h 
after the injection respectively. Most frequently reported were 
moderate or severe skin redness (9.5%) or swelling (9.5%) at 1 h 
after injection, but by 4 h after injection these reactions had mostly 
disappeared. At 24 h after injection, bruising (moderate or severe) 
was most frequently reported (2.5%). None of the patients had to 
discontinue ganirelix treatment because of a hypersensitivity reaction 
or because of a drug-related adverse experience. 
 
 
2.3.3 Discussion 
 
The ganirelix regimen is a new treatment option for patients 
undergoing ovarian stimulation, which largely reduces the duration of 
GnRH analogue treatment and prevents adverse events related to 
‘flare-up’ or ‘down-regulation’ induced by GnRH agonists. In addition 
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to its convenience, the regimen appeared to be safe and well-
tolerated.  
Ganirelix is used to prevent premature LH surges occurring 
during ovarian stimulation. However, in the literature no clear 
definition on an LH surge has been provided, and therefore data 
analysis was based primarily on the incidence of LH rises >10 IU/L 
and additionally on concomitant rises of serum progesterone 1 ng/mL, 
indicating premature luteinization. During ganirelix treatment the 
overall incidence of LH rises was 2.8%, and only in 1.5% of the cases 
was a concomitant rise in progesterone concentration observed, 
demonstrating the effective suppression of endogenous LH during 
ovarian stimulation.  
In this efficacy trial, ganirelix treatment was started on day 6 
of stimulation, since the previous dose-finding study (The ganirelix 
dose-finding study group 1998) demonstrated that during the first 
days of stimulation, median serum LH concentrations decrease and 
nadir LH concentrations are reached at day 5 of stimulation. This 
initial suppression of endogenous LH is thought to be established by 
a negative feedback of rising estradiol concentrations during the first 
days of stimulation. When follicular growth is progressing and 
estradiol concentrations become as high as in the late follicular phase 
of the normal menstrual cycle, then the reverse occurs and the risk for 
a premature LH surge becomes imminent (Filicori et al. 1986). In the 
current study, early LH rises before the first ganirelix administration 
occurred in 20 patients who were high responders, i.e. stimulation 
resulted in more rapid initial follicular growth and in a more 
pronounced rise of serum estradiol as compared with the overall 
treatment group. Even though the clinical outcome of this small 
subset of patients was good, early LH rises may be prevented by 
starting ganirelix treatment on day 5 instead of day 6 of stimulation. 
On the other hand, 13.2% of all patients did not show any follicles >11 
mm diameter at day 6 of stimulation; in these lower responders 
exposure to ganirelix may be limited by delaying the start of treatment 
up to the moment of actual follicle growth. 
In the current study, duration of treatment was short, i.e. on 
average 9 days with recFSH including 5 days of ganirelix treatment. 
Since initial growth of follicles was more rapid and endogenous FSH 
concentrations were only partly suppressed (during the late follicular 
phase), the duration of recFSH treatment was one day shorter and 
the amount of recFSH required was lower in the ganirelix group. 
Since the number of subjects without any follicles >11 mm diameter 
on day 6 of stimulation was twice as high in the ‘long protocol’ of 
buserelin, the ganirelix regimen might be of special benefit for poor-
responders, who are frequently treated with a short ‘flare-up’ protocol 
of GnRH agonist (Frydman et al. 1988a).  
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Comparison of the number and size of follicles indicated that, 
in the ganirelix group, initial follicular growth was faster but the final 
cohort of growing follicles was smaller and produced on average less 
estradiol, which is explained by the different endocrine status of the 
patient at the start of stimulation. In view of this different follicular 
pattern, recFSH dose adjustments in patients treated with the 
ganirelix regimen should be based on the number and size of growing 
follicles, rather than on the amount of circulating estradiol. The 
smaller cohort of follicles and the lower estradiol concentrations are in 
good agreement with the lower incidence (less than half) 
of OHSS in the ganirelix group. The possible direct effect of GnRH 
antagonists on follicle growth, steroidogenesis, oocyte or embryo 
quality or implantation is of specific interest, since GnRH receptors 
have been identified in human granulosa-lutein cells (Latouche et al. 
1989; Brus et al. 1997), and might be present in uterine endometrial 
tissue (Raga et al. 1998), although their function and interaction with 
GnRH or GnRH analogues is not (yet) understood (Ikeda et al. 1997). 
Recent studies in vitro with human granulosa cells have 
demonstrated that neither ganirelix or cetrorelix exert any significant 
action on ovarian steroidogenesis (Verbost et al. 1999; Ortmann et al. 
2002), and in the ganirelix dose-finding study no difference was noted 
in the number or size of follicles of patients treated in the six different 
dose groups (The ganirelix dose-finding study group 1998).  
In comparison with buserelin treatment in a ‘long protocol’, 
the ganirelix regimen resulted in one preovulatory follicle less and, as 
a consequence, one cumulus–oocyte complex less was recovered at 
oocyte retrieval. This difference is within the preset equivalence 
margin of –3 oocytes, and is thought to be related to the short 
regimen rather than ganirelix per se. The recovery of fewer oocytes is 
a well-described phenomenon of the short protocol of GnRH agonists 
in comparison with the ‘long protocol’ (Tan et al. 1992; Cramer et al. 
1999). Overall, the ganirelix regimen resulted in the recovery of good 
quality oocytes as reflected by the percentage of metaphase II 
oocytes in ICSI patients (83% in each group), the high fertilization rate 
(62.1% in each group), and the number of good quality embryos, 
which was comparable with the reference group. The latter finding 
suggests a higher recovery of good quality embryos in the ganirelix 
regimen than in the buserelin group, which is in good agreement with 
the outcome of a previous small study which compared the antagonist 
Nal-Glu (5 mg/day) with the agonist leuprolide acetate (Minaretzis et 
al. 1995a). The recovery of good quality oocytes and embryos is 
further supported by the good success rates of replaced frozen 
embryos collected in the dose-finding study of ganirelix (Kol et al. 
1999), as well as in this study.  
In the current trial, on average only 2.2 embryos were 
replaced, which is in line with the current standard practice in several 
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European IVF centres not to replace more than two good quality 
embryos, in order to prevent multiple pregnancies. In comparison with 
a large previous multi-centre study of Puregon, using the same 
stimulation regimen with buserelin, the ongoing pregnancy rate per 
attempt was very similar to the outcome of the ganirelix regimen (Out 
et al. 1995). Although the clinical outcome is considered good 
(ongoing pregnancy rate per attempt was 20.3%), in the current study 
the pregnancy rate tended to be higher in the reference group. In view 
of the limited study power, it cannot be excluded that this tendency is 
related to chance. However, using the same multiple dose regimen 
and also intranasal buserelin in a ‘long protocol’ as control, others 
(Felberbaum 1999) reported a vital pregnancy rate per transfer of 
27% (compared with 25% in this study) in patients treated with human 
menopausal gonadotropin (HMG) and 0.25 mg GnRH antagonist 
cetrorelix (n = 188) and of 33% (cf. 32% in this study) in patients 
treated with the agonist (n = 85). Therefore, several other factors that 
may influence clinical outcome should be considered. For instance, 
study sites that participated in the previous ganirelix dose-finding 
study provided a favourable outcome more often for the ganirelix 
regimen compared with study sites who participated for the first time. 
This indicates that some clinical experience with the new ganirelix 
regimen might contribute positively to the success rate. In addition, 
the regimen applied has not been selected based on prospective 
research, and further optimization of the regimen might appear 
beneficial. In the current applied regimen, stimulation was started on 
day 2 or 3 of the follicular phase; thus serum gonadotropin and 
steroid concentrations were higher than after ‘down-regulation’ in the 
reference group. High concentrations of serum hormones are 
especially established in patients who receive the GnRH-agonist 
‘flare-up’ protocol, and these were reported to have a lower clinical 
pregnancy rate, which is thought to be related to a higher estradiol 
concentration before hCG administration, and a higher production of 
estradiol per oocyte recovered (Cramer et al. 1999). In the ganirelix 
group, the opposite was shown in that before hCG administration 
estradiol concentrations were lower, and also the estradiol production 
per follicle was lower in the ganirelix group than in the buserelin 
group. Although in the current study neither serum LH nor estradiol 
concentrations appeared to be predictive factors for pregnancy 
(Loumaye et al. 1997), it cannot be excluded that the hormonal milieu 
of the current ganirelix regimen is less favourable for a certain subset 
of patients. If so, patients might benefit from postponing hCG 
administration and allowing follicles to grow larger, or to pretreat 
patients with oral contraceptives which would also allow patient 
scheduling. Thus, further optimization of treatment, as well as clinical 
experience with the antagonist regimen, might further optimize clinical 
outcome in the near future. Overall, it may be concluded that ganirelix 
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introduces a new treatment option for patients undergoing ovarian 
stimulation for IVF or ICSI which is safe, short and simple. The clinical 
outcome was good, and the ongoing pregnancy rate was within the 
range of pregnancy rates of a long-protocol GnRH-agonist, the latter 
being supported by many years of clinical experience. 
Prevention of imminent OHHS – a case report 
 
- 77 -   
2.3 Prevention of imminent OHSS with high 
doses GnRH antagonist, a case report 
 
2.3.4 Introduction 
 
Ovarian hyperstimulation syndrome (OHSS) is a potentially life-
threatening complication of assisted reproduction (Schenker & 
Weinstein 1978). OHSS does not occur in the absence of either the 
endogenous luteinizing hormone (LH) surge, or surrogate human 
chorionic gonadotropin (hCG). Conditions which may indicate 
imminent OHSS include late follicular phase serum estradiol 
concentrations >12675 pmol/L (3500 pg/mL), and the occurrence of 
>25 small and intermediate sized follicles (Rizk & Aboulghar 1991). 
Under these circumstances ovarian stimulation for in-vitro fertilization 
(IVF) is usually cancelled by cessation of exogenous gonadotropins, 
withholding hCG, and continuation of pituitary down regulation by 
gonadotropin releasing hormone (GnRH) agonists in order to prevent 
unpredictable changes in release of endogenous gonadotropins. 
However, it has been reported that the continued administration of 
GnRH agonists does not affect subsequent ovarian quiescence 
(Wada et al. 1992). This may be related to prolonged suppression of 
pituitary function due to slow recovery from ‘down-regulation’ 
(Donderwinkel et al. 1993). Some residual gonadotropin release may 
remain during GnRH agonist suppression, whereas pituitary release 
of LH and follicle-stimulating hormone (FSH) may be virtually 
abolished with the sustained use of a high dose of GnRHantagonist. 
In this case report we describe an alternative method, using a high 
dose of a GnRH antagonist which may decrease the risk of a severe 
OHSS. 
 
 
2.3.5 Case report 
 
A 33 year old regularly menstruating woman (body mass index 23 
kg/m2) with an subfertility duration of 4.5 years due to tubal pathology 
underwent IVF in our unit. Before initiation of treatment, endocrine 
screening and sonographic examination appeared to be normal. As 
part of a multicentre phase II clinical trial (approved by the local ethics 
review committee), 150 IU recombinant follicle stimulating hormone 
(recFSH, Puregon®; NV Organon, Oss, The Netherlands) daily 
subcutaneous injections were administered, starting on cycle day 2. 
From cycle day 7 onwards she was co-treated daily with a GnRH 
antagonist (ganirelix, Org 37 462; NV Organon) (Nelson et al. 1995) 
0.125 mg subcutaneously. Initially normal follicular growth was 
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observed and although estradiol concentrations rose steadily, they 
remained within the limits normally associated with controlled ovarian 
hyperstimulation for IVF. The moderate starting dose of 150 IU 
recFSH was therefore continued. However, on cycle day 11 the 
patient presented with a serum estradiol level of 16 500 pmol/L, a 
level associated with an increased risk of OHSS (Rizk & Aboulghar 
1991). Transvaginal ultrasound showed four preovulatory (>16 mm) 
follicles, and nine intermediate sized (10–16 mm) follicles. It was 
decided to cancel the cycle by withholding hCG injection and 
discontinuing daily recFSH administration. On cycle day 12 
ultrasound showed an increase in the number of follicles (six 
preovulatory and 27 intermediate sized follicles). The patient 
complained of abdominal discomfort and a pocket of ascites in the 
pouch of Douglas was demonstrated on ultrasound. The estradiol 
concentration was 22 315 pmol/L and the right and left ovaries were 
enlarged, with respective mean diameters of 72 mm and 54 mm. The 
ganirelix dose was increased to 2 mg/d to prevent a possible LH 
surge (Ditkoff et al. 1991) and to further decrease endogenous LH 
and FSH secretion. Within 3 days estradiol concentrations returned to 
levels associated with a normal ovarian response for hyperstimulation 
in IVF. Moreover, symptoms and ascites disappeared over the 
following days. In the same period, the mean diameters of the right 
and left ovary decreased to 65 mm and 47 mm respectively. Daily 
serum levels of LH, FSH and estradiol are depicted in Figure 2.14. 
 
 
2.4.3 Discussion 
 
Administration of GnRH antagonists in the late follicular phase has 
recently been applied effectively in IVF programmes to prevent a 
premature rise in endogenous LH and subsequent luteinization 
instead of extended administration of GnRH agonists (Diedrich et al. 
1994; Olivennes et al. 1994; Albano et al. 1996; Felberbaum et al. 
1996; Albano et al. 1997). In contrast to GnRH agonists, GnRH 
antagonists elicit an immediate effect by competitive blockage of 
GnRH receptors (Klingmuller et al. 1993). The likelihood of preventing 
a premature LH rise and subsequent luteinization is clearly dependent 
on the dose of the GnRH antagonist (Ubaldi et al. 1996). Further 
evidence for a dose dependent pituitary response is the observation 
that gonadotropin secretion could be restored by pulsatile GnRH 
therapy during GnRH antagonist treatment (Gordon et al. 1990). 
Since in the late follicular phase growth of follicles and subsequent 
estradiol production is dependent on stimulation by both LH and FSH, 
further development of follicles may be arrested effectively in cases of 
imminent OHSS through pronounced suppression of pituitary 
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gonadotropin release by prolonged use of high dose GnRH 
antagonists. It should, however, be recognized that a spontaneous LH 
surge may still occur under these circumstances, which could induce 
OHSS without exogenous hCG. As demonstrated previously (Gordon 
et al. 1990), GnRH can override the inhibitory actions of antagonist. 
We therefore elected to increase the ganirelix dose. Simply reducing 
the dose of recFSH is unlikely to have had a significant effect since 
follicular sensitivity to FSH increases in the advanced stages of 
development. There is no clear evidence that reducing the dose of 
FSH at this late stage has a preventative effect on OHSS. 
  
 
 
 
Figure 2.14 
Estradiol (–), follicle-stimulating 
hormone (FSH) (S–S) and 
luteinizing hormone (z–z) serum 
levels during treatment with 
recombinant FSH and ganirelix for 
in-vitro fertilization in a patient with 
imminent ovarian hyperstimulation 
syndrome
 
 
GnRH receptors have been shown to be present in 
granulosa–lutein cells (Latouche et al. 1989; Minaretzis et al. 1995b) 
and some studies suggest that steroidogenic activity of cultured 
granulosa cells may be affected by GnRH (Pellicer & Miro 1990) 
suggesting that the human ovary could be a target for direct 
extrapituitary GnRH action in the human.  
For reasons of safety, we considered it mandatory to cancel 
ovarian stimulation in this IVF patient presenting with clear signs of 
imminent OHSS. Since spontaneous LH surges may occur after a 
short period of GnRH antagonist treatment (Ditkoff et al. 1991), 
sustained administration of a high dose GnRH antagonist could 
potentially reduce the risk of severe OHSS. Indeed, in-vitro studies 
demonstrate that chronic administration of GnRH antagonist virtually 
abolishes GnRH induced LH release from the pituitary (Pinski et al. 
1996). 
The present case confirms the previously reported efficacy of 
high dose GnRH antagonist in achieving rapid suppression of 
endogenous gonadotropin release even when LH levels have started 
to rise (Dubourdieu et al. 1994), and in eliciting subsequent ovarian 
quiescence. It is yet to be determined whether GnRH antagonists act 
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solely through suppression of pituitary function, or whether direct 
actions at the ovarian level may also be involved. The clinical role 
played by GnRH antagonist in this case remains uncertain since 
progression to OHSS may have been prevented by discontinuation of 
recFSH and withholding hCG. Controlled studies are required to 
assess the extent to which GnRH antagonist contributes to the early 
resolution of ovarian hyperstimulation syndrome. 
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3.1 The added value of cryopreservation of 
embryos is limited: no justification for 
maximal ovarian stimulation for IVF 
 
 
3.1.1 Introduction 
 
The first reports of a clinical pregnancy (Trounson & Mohr 1983) and 
birth (Zeilmaker et al. 1984) from frozen thawed embryos introduced 
the clinical application of cryobiology into in-vitro fertilization (IVF) 
programs. Since the recognition of cryopreservation of 
preimplantation embryos as an established clinical procedure (The 
american fertility society 1990), its application in IVF programs has 
steadily increased, becoming integral to the service provided by the 
majority of IVF centres (Fugger 1989). 
  Ovarian stimulation of multiple dominant follicle development 
has considerably improved the clinical outcome of assisted 
reproductive techniques (Quigley et al. 1982; MacDougall et al. 1994). 
At present, the most commonly practised ovarian stimulation regimen 
for IVF includes pituitary down regulation with a gonadotropin-
releasing hormone (GnRH) agonist for at least two weeks followed by 
the co-administration of high dose exogenous follicle stimulating-
hormone (FSH). This so called ‘long protocol’ aims to induce ongoing 
growth of large numbers of follicles in normo-ovulatory women, 
resulting in large quantities of oocytes (and resultant embryos) 
obtained from a single oocyte retrieval (Tan et al. 1992). The ‘long 
protocol’ for ovarian hyperstimulation has been shown to be effective 
in providing large numbers of embryos for transfer or 
cryopreservation, improved pregnancy rates, and lower cancellation 
rates compared to other stimulation protocols for IVF (Hughes et al. 
1992).   
 The transfer of all available embryos dramatically increases 
the risk of  high order multiple pregnancies and the associated 
obstetrical and perinatal complications. As a result, many IVF centres 
have adopted the policy of limiting the number of embryos transferred 
and of cryopreserving surplus embryos in an attempt to reduce the 
risk on multiple pregnancies and births (Schieve et al. 1999). Indeed, 
the availability of cryopreservation programs is frequently cited as a 
justification for maximal stimulation of large quantities of follicles in a 
single IVF cycle (Mandelbaum et al. 1998). The risks associated with 
this approach has provoked increasing concern (Edwards et al. 1996; 
Olivennes & Frydman 1998; Fauser et al. 1999). The obligatory 
intensive conventional ovarian stimulation and extended oocyte 
retrieval procedures levy a high degree of physical and emotional 
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stress on patients undergoing IVF (Fauser et al. 1999). This is 
reflected by the high drop-out rate seen in conventional IVF. If no 
pregnancy occurs in the first IVF attempt, many patients (around 
25%) fail to attend second attempt, even in countries where IVF is 
covered by health insurance (De Vries et al. 1999; Osmanagaoglu et 
al. 1999).   
Cryopreservation of supranumerical embryos and transfer of 
thawed cryopreserved embryos in a subsequent cycle is now 
generally accepted. However, this approach is not free of legal, moral 
and ethical issues (Fasouliotis & Schenker 1996; Schenker 1997). 
The added benefit of cryopreservation programs to IVF remains 
uncertain (Jones et al. 1995). A significant portion of frozen 
preimplantation embryos will not survive the thawing process (Van der 
Elst J. et al. 1995). Moreover, embryo transfer of thawed 
cryopreserved preimplantation embryos is less successful, in terms of 
pregnancy and implantation rates, when compared to transfer of fresh 
embryos (Van Steirteghem et al. 1994).  
We carried out an observational longitudinal study to 
calculate the benefit of a cryopreservation program to the overall 
cumulative ongoing clinical pregnancy rate over a maximum of three 
consecutive IVF cycles. 
 
 
3.1.2 Materials and methods 
 
Study population 
All couples with an indication for IVF (Macklon et al. 2001) who began 
their first IVF treatment, with or without intracytoplasmic sperm 
injection (ICSI), in the period between January 1995 to December 
1999 were evaluated. In the Netherlands, the obligatory health 
insurance covers three IVF cycles, independent of the indication for 
IVF. In order to reduce possible bias related to socio-economical 
status, a maximum of three IVF cycles, including subsequent 
cryopreservation of supranumerical embryos, were analyzed. Women 
who began pituitary down regulation in our routinely applied 'long 
protocol' and agreed on cryopreservation of the surplus of 
preimplantation embryos were included in the study (n = 1792). 
Couples progressed to a second or third stimulation IVF cycle only 
when all cryopreserved embryos had been thawed for intended 
transfer. Couples undergoing oocyte donation, who had undergone 
previous IVF treatments, or who had decided to cancel treatment 
were excluded from analysis. The study was performed according to 
the standards outlined in the Declaration of Helsinki. 
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IVF procedure  
All patients underwent pituitary down regulation by daily 
subcutaneous injections of 0.1 mg of the GnRH agonist triptorelin 
(Decapeptyl®, Ferring GmbH, Kiel, Germany) for at least two weeks 
prior to ovarian stimulation. Ovarian stimulation was initiated by daily 
injections (150 IU to 450 IU) of human menopausal gonadotropin 
(HMG; Humegon®, NV Organon, Oss, The Netherlands) i.m. or 
recombinant FSH (RecFSH; Puregon®, NV Organon) s.c. When at 
least 3 follicles > 18 mm were observed on transvaginal sonography, 
all medication was stopped and 10.000 IU human chorionic 
gonadotropin (hCG; Pregnyl®, NV Organon) was administered by i.m. 
injection in order to complete oocyte maturation. Oocyte retrieval took 
place 35 h after hCG administration. A maximum of 2 embryos were 
transferred on day 3 to 5 after oocyte retrieval according to our 
previously published protocol (Huisman et al. 2000; Hunault et al. 
2002). Surplus embryos of adequate quality were subsequently 
cryopreserved. Luteal phase support was initiated on the day of 
embryo transfer by daily vaginal administration of 600 mg 
progesterone (Progestan®, NV Organon), continued until 
menstruation or a positive urinary hCG test. Biochemical pregnancy 
was defined as a positive urinary hCG test 2 weeks after embryo 
transfer. Ongoing pregnancy was defined as a positive intrauterine 
fetal heart activity observed by transvaginal sonography 10 weeks 
after embryo transfer. 
 
Cryopreservation and thawing procedure 
Embryos remaining after transfer and meeting previously published 
quality criteria (Veeck 1998; Huisman et al. 2000) were frozen. The 
cryopreservation procedure was performed using a slow freezing 1.5 
M DMSO (British Drug House Ltd, Poole, UK) protocol (Van der Elst 
J. et al. 1995) in a programmed freezer (Planer Kryo 10-III; Planer 
Products, Sunbury-on-Thames, UK). The medium for 
cryopreservation consisted of Earle's balanced salt solution and 
Hams F10 medium (Life Technologies, Paisley, UK), supplemented 
with a pasteurized plasma protein solution and 1.5 M DMSO. 
Embryos were placed in medium for cryopreservation and 
subsequently transferred into cryostraws and equilibrated for 30 
minutes at room temperature. Cryostraws were then placed in the 
freezing apparatus, preset at 0 ºC and frozen as follows: The embryos 
were cooled to -4 ºC at a rate of -2 ºC/min and subsequently cooled 
further at a rate of -1 ºC/min until a temperature of -6 ºC was reached. 
Seeding was performed manually with liquid nitrogen (LN2)-cooled 
sponge forceps. Further cooling was performed at a rate of -0.3 
ºC/min to -40 ºC and then at -40 ºC/min to -120 ºC., at which 
temperature the cryostraw was immersed in LN2. Thawing was 
performed by removing the cryostraw from the LN2, followed by 
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placing in ice water. The embryos were removed from the cryostraw 
and placed in diluted freezing medium of consecutively 1.2 M, 0.9 M, 
0.6 M, 0.3 M DMSO for 5 minutes, respectively. Embryos were 
subsequently rinsed in embryo culture medium and transferred to a 
25 µL droplet in a culture dish followed by culturing before transfer. 
Post thaw survival of cryo preserved embryos was defined as < 50 % 
blastomere loss. A maximum of 2 selected thawed embryos were 
transferred in the natural cycle after ovulation timed by urinary LH 
tests or monitoring by transvaginal sonography. The same transfer 
technique was used as in fresh transfer cycles.  
 
Data analysis 
For the purpose of measuring the ongoing pregnancy rate of IVF 
treatment from both fresh and cryopreserved embryos, pregnancies 
arising from cryopreservation cycles were considered to contribute to 
the pregnancy rate of the associated stimulation cycle. The ‘patient-
specific concept’ proposed by Jones et al. (1995) is characterized by 
considering pregnancies arising from the cryopreservation cycle as 
augmentation only among patients who did not achieve an ongoing 
pregnancy from the fresh embryos transfer cycle. We applied this 
concept to evaluate the contribution of cryopreservation programs to 
the cumulative pregnancy rate of a maximum of three IVF cycles. The 
‘projected cryoaugmented pregnancy rates’, which assume that 
pregnancy rates of patients with unthawed cryopreserved embryos 
are comparable to those who had an embryo transfer of thawed 
cryopreserved embryos, were calculated (Jones et al. 1997a). 
Cumulative ongoing pregnancy rates calculated by life table analysis 
assume that patients who drop out from the study have the same 
probability of achieving an ongoing pregnancy as patients who 
continue treatment. In order to test this assumption, differences in 
patient characteristics which may affect the probability of achieving an 
ongoing pregnancy between patients who continue treatment and 
those who drop out from the study were compared using Mann-
Whitney U test and Fisher’s exact test. Clinical outcome in terms of 
ongoing pregnancy rates was analyzed by Markov chain analysis 
(Muenz & Rubinstein 1985) to estimate the added value of the 
cryopreservation program. Differences were considered significant if 
P < 0.05. 
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3.1.3 Results 
 
Patients 
In the period January 1995 to December 1999, 1251 couples met the 
inclusion criteria for analysis. The age of the women at the start of 
treatment ranged from 21 to 44 years. 77.8 % of the study population 
were treated for primary infertility. Indications for IVF were 
respectively male factor (44.4 %), tubal factor (22.5 %), idiopathic 
(21.6 %), anovulation (4.8 %), cervical hostility (4.0 %), endometriosis 
(2.4 %), and other (0.2 %). Fertilization of the oocytes by ICSI was 
performed in 12.1 % of the couples. 
 Couples who had children prior to IVF treatment and couples 
in which the IVF procedure did not result in an embryo transfer were 
more likely to stop treatment following an unsuccessful cycle 
(respective odds ratios 1.5 (95% C.I. 1.1 – 2.0) and 3.1 (95% C.I. 1.9 
– 5.1)). These couples were considered as non-informative drop-outs, 
since pregnancy rates in those patients who did continue were 
comparable to those of the rest of the study population. 
 
Treatment outcome 
In the 1251 couples analyzed, a total of 2367 IVF cycles and 392 
thawed cryopreserved embryo cycles were initiated. An embryo 
transfer of at least one embryo was performed in 71.8 % of the 
started IVF cycles. In 25.0 % of the initiated IVF cycles surplus 
embryos were available for cryopreservation. The post thaw survival 
rate of cryopreserved embryos was 24.9 % per thawed embryo. An 
embryo transfer was performed in 41.3 % of the initiated thawed 
cryopreserved embryo cycles. Pregnancy and ongoing pregnancy 
rates per initiated cycle were 21.6 % and 17.6 % for the fresh embryo 
transfer cycles and 5.9 % and 4.8 % for thawed cryopreserved 
embryo cycles, respectively. Corresponding rates per embryo transfer 
were 30.0 % and 24.5 % for the fresh embryo transfer cycles and 
14.2 % and 11.7 % for the thawed cryopreserved embryo cycles, 
respectively (Figure 3.1). 
Of the 1251 women beginning their first IVF stimulation cycle, 
864 underwent fresh embryo transfer and 227 achieved an ongoing 
pregnancy. Of the 1024 women who did not conceive, 335 had 
embryos cryopreserved. Of these, 217 women had their embryos 
thawed, resulting in embryo transfer in 94 women with 14 achieving 
an ongoing pregnancy. For 118 women unthawed embryos are still 
available for thawing and subsequent transfer. For these women a 
total of 8 projected pregnancies was calculated (25) (Table 3.1). 
A total of 741 women proceeded to a second and 375 to a 
third IVF stimulation cycle, of whom respectively 557 and 280 
underwent fresh embryo transfer, with 137 and 52 achieving an 
ongoing pregnancy, respectively. In the second cycle, embryos from 
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167 non-conceiving women were cryopreserved, of whom 112 had 
their embryos thawed, resulting in an embryo transfer for 45 women 
and subsequently 4 ongoing pregnancies. In the third cycle embryos 
of 90 non-conceiving women were cryopreserved, 63 had their 
embryos thawed, resulting in an embryo transfer for 23 women and 
subsequently 1 ongoing pregnancy. Of the non conceiving women 
who had their embryos cryopreserved in the second and third cycle, a 
total of 55 and 27 women have cryopreserved embryos available for 
thawing, respectively. For these women a total of 3 ongoing 
pregnancies could be calculated (25) (Table 3.1). 
 
 
 
 
Figure 3.1 
Treatment outcome of a total of initiated 2367 IVF cycles in 1251 patients. ET = embryo 
transfer. 
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 Cycle 1 
Cycle 
2 
Cycle 
3 
Number of patients who started IVF 1251 741 375 
Fresh embryo transfer (Fresh ET) 864 557 280 
Pregnant after Fresh ET 227 137 52 
Not pregnant after Fresh ET and no cryo 
embryos available 916 574 285 
Not pregnant after Fresh ET and cryo 
embryos available 335 167 90 
Cryopreserved embryos thawed 217 112 63 
Embryo transfer of thawed cryopreserved 
embryos (Cryo ET) 94 45 23 
Pregnant after Cryo ET 14 4 1 
Unthawed cryopreserved embryos 118 55 27 
Projected pregnancies 8 3 0 
 
Table 3.1 
Clinical outcome of 3 consecutive IVF cycles of 1251 patients starting IVF in the period 
1995-1999. Values represent number of patients 
 
The cumulative ongoing pregnancy rate per started cycle for 
3 successive fresh IVF cycles was 42.5 %. When pregnancies arising 
from transfer of thawed cryopreserved embryos were added, the 
cumulative pregnancy of consecutive 3 IVF cycles was 43.8 %. When 
projected pregnancies resulting from unthawed embryos were 
included, the cumulative ongoing pregnancy rate was 44.5 % (Figure 
3.2). 
 
 
 
 
 
 
 
 
 
Figure 3.2 
Cumulative pregnancy rate of 3 
consecutive IVF cycles, without 
embryo cryopreservation (-), 
including pregnancies resulting from 
the transfer of thawed cryopreserved 
embryos ({-{), and including 
projected pregnancies (V-V).  
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In the 227 women achieving an ongoing pregnancy arising 
from the fresh ET in their first IVF attempt, 32 had a subsequent 
transfer of thawed cryopreserved embryos. This resulted in 3 ongoing 
pregnancies (9.4%). In the women achieving an ongoing pregnancy 
arising from the fresh ET in second and third IVF attempt, in both 
attempts 9 had a subsequent transfer of thawed cryopreserved 
embryos, none of which resulted in an ongoing pregnancy. 
 
 
3.1.4 Discussion 
 
The demographic and subfertility characteristics of the study 
population were representative of those in other European centres 
(The ganirelix dose-finding study group 1998; The european 
orgalutran study group et al. 2000). The ongoing pregnancy rate per 
initiated IVF cycle excluding thawed cryopreserved embryos (16.7%), 
and the ongoing pregnancy rate per transfer of thawed cryopreserved 
embryos (11.8 %) was also comparable with that reported by other 
European centres (Mandelbaum et al. 1998; Nygren & Andersen 
2001). Comparisons of outcomes from embryo cryopreservation are 
often complicated by difficulties in controlling for differences in the 
populations of embryos being assessed (Ludwig et al. 1998; Testart 
1998). This may partially explain the relatively lower pregnancy rates 
per thawed embryo transfer we observed when compared to those 
reported in the USA IVF registries during the same period (society for 
assited reproductive technology (SART) 2000). 
By adopting the novel approach of analysing outcomes in 
terms of cumulative pregnancy rate for 3 IVF cycles, we have 
revealed the limited added value of a representative embryo 
cryopreservation program. The additional contribution of embryo 
cryopreservation to cumulative pregnancy rates over three cycles of 
IVF was just 2% (42.5% vs. 44.5%). This meant that, of the 1251 
women who started IVF treatment in the 5 year study period, only 19 
had a direct benefit from the cryopreservation program in terms of the 
‘patient specific concept’, with an additional 11 expected to benefit. 
Given the considerable day-to-day effort and commitment required to 
maintain a cryopreservation program, these results were 
disappointing. 
The low post thaw survival rate of cryopreserved embryos 
may explain these findings. Despite the application of a widely used 
and recommended cryopreservation protocol utilizing DMSO (Van der 
Elst J. et al. 1995; Van den Abbeel & Van Steirteghem 2000), and 
plastic cryostraws as the freezing container (Van den Abbeel & Van 
Steirteghem 2000), the post thaw survival rate of cryopreserved 
embryos in our study appeared to be lower (24.9 %) when compared 
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to cohorts described previously (Jones et al. 1997b; Mandelbaum et 
al. 1998). This discrepancy may be due in part to differences in the 
definition of survival. When post thaw survival of cryopreserved a 
embryo is defined as < 50 % blastomere loss, as in our center, the 
relatively low percentage survival we observed is comparable with 
other reports where similarly defined post-thaw survival rates of 27% 
have been described (Van der Elst et al. 1996). More recently, thus 
defined post-thaw survival rates of up to 78% have been reported 
(Edgar et al. 2000). However, these data were limited to early 
cleavage stage (day 2) embryos. In the present study, results from 
cryopreserved day 3,4 and 5 embryos were analyzed. The possible 
effect on outcome of the stage of development at which embryos 
were cryopreserved was not delineated. Possible differences in post 
thaw survival rate between 8-cell, morula and blastocyst stage 
embryos, and their impact on the overall outcome cannot therefore be 
ruled out. The relatively complex structure of blastocysts and their 
fluid filled cavity may render them more difficult to freeze successfully 
when compared to the morula or 8-cell embryo (Fauser et al. 2002a). 
Therefore, the blastocyst may require a different freezing procedure 
or freezing medium than those normally applied to less mature 
embryos. However, published data in this area remain contradictory 
(Troup et al. 1991; Kaufman et al. 1995).  
The severe damage which can be sustained by an embryo 
during the cryopreservation and thawing procedure is well 
documented (Fauser et al. 2002a), and the chance of implanting 
appears to be directly related to the degree of blastomere loss 
following thawing (Edgar et al. 2000). Ongoing improvements in 
cryopreservation techniques are suggested by recent data from the 
United States where a 5.9% increase in live birth rates arising from 
cryopreserved embryo cycles was observed in one year (Society for 
assited reproductive technology (SART) 2002). Moreover, it has been 
recently demonstrated that when cryopreserved embryos show no 
blastomere loss, implantation rates are similar to fresh embryos 
(Edgar et al. 2000). Further improvements in selection of embryos for 
cryo-preservation and cryo-thaw techniques which reduce the rate of 
blastomere loss will be required in order to further improve outcomes 
of cryopreservation. 
 The legal, moral and ethical issues surrounding the 
cryopreservation of supranumerical embryos (Shannon 1990; Eugster 
& Vingerhoets 1999) continue to command attention. The practice of 
holding embryos cryopreserved for many years, even when the 
couples to which the embryos belong are lost to contact is also a 
matter of concern, as illustrated by the vocal public protests aroused 
when embryo banks are destroyed. Given this background, and the 
IVF-burden imposed on patients in order to produce sufficient 
Alternative approaches to ovarian stimulation for in vitro fertilization 
 
- 92 -  
embryos for cryopreservation, the benefits of crypreservation services 
should be clear and substantial.  
Based on the current findings we conclude that profound 
ovarian stimulation aimed at producing supranumerical embryos for 
cryostorage using present techniques is poorly justified.  
The demands made on our patients by current stimulation 
protocols for IVF is illustrated by the substantial number of patients in 
our study who were unwilling to undergo a second (n = 269) or a third 
(n = 225) IVF attempt. This issue has been raised previously (Fauser 
et al. 1999) but received little attention. Apparently, a substantial 
proportion of patients refrain from subsequent IVF attempts, therefore 
reducing the overall success rate per started IVF treatment. Those 
couples who already had children were more likely to halt their 
treatment, confirming a previously described phenomenon (De Vries 
et al. 1999). The need to conceive at least one child may urge 
couples to accept the continued inconvenience, emotional and 
physical stress, and mask the effects of the ‘IVF burden’ from their 
clinicians (Shannon 1990; Eugster & Vingerhoets 1999). 
Milder ovarian stimulation protocols aimed at a producing a 
limited number of oocytes for fertilization in vitro with less burden for 
the patient and fewer risks have been proposed (de Jong et al. 2000; 
Macklon & Fauser 2001). There are indications that patients favour 
shorter, more convenient ovarian stimulation protocols even when the 
chance of conceiving in a given cycle is slightly reduced (Hojgaard et 
al. 2001). However, providing milder stimulation protocols may 
actually increase cumulative pregnancy rates, since a higher 
proportion of patients may elect to continue treatment if the first cycle 
is unsuccessful. Our findings suggest that creating supernumery 
embryos for cryopreservation is a weak justification for profound 
ovarian stimulation. We conclude that any reduction in embryos 
available for cryopreservation arising from the institution of mild 
ovarian hyperstimulation protocols will have little negative impact on 
cumulative pregnancy rates. 
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3.2 Mild ovarian stimulation for IVF – a 
concept 
 
3.2.1 Introduction 
 
At present, the most commonly practised ovarian stimulation regimen 
for in-vitro fertilization (IVF) includes pituitary down regulation with a 
gonadotropin-releasing hormone (GnRH) agonist for at least two 
weeks followed by the co-administration of high dose exogenous 
gonadotropins. This so-called 'long protocol' aims to induce ongoing 
growth of multiple dominant follicles in normo-ovulatory women. The 
presence of many pre-ovulatory follicles allows for lower efficacy at 
oocyte pick-up, fertilization in-vitro, embryo culture and implantation. 
Despite intensive monitoring, a concomitant risk of complications 
remains, introducing the need for intense ovarian response 
monitoring. Short-term risks include ovarian hyperstimulation 
syndrome (OHSS) and higher order multiple pregnancies arising from 
the transfer of multiple embryos. Potential detrimental effects of 
stimulating large numbers of follicles on oocyte quality and fertilization 
rates cannot be ruled out. Moreover, high serum estradiol (E2) 
concentrations, which occur as a result of these regimens, may 
reduce embryo implantation rates (Simon et al. 1998). With regard to 
long term complications, epidemiological studies have yet to clarify a 
possible association between ovarian hyperstimulation and ovarian 
cancer (Shoham 1994; Bristow & Karlan 1996).  
No agreement exists regarding the optimal number of oocytes 
required for IVF. Individual responses to standard treatment vary 
greatly, but in most cases between 10 and 20 oocytes are obtained.  
Cryopreservation of supranumerical embryos and transfer in 
subsequent (unstimulated) cycles is often considered to justify the 
stimulation of a large number of follicles. Certainly, repeated ovarian 
stimulation and painful oocyte pick-up procedures may be prevented 
using cryopreserved embryos. The added value of cryopreservation 
programs remains debatable however (Jones et al. 1997b) and the 
resulting increase in specific pregnancy rates  (i.e.: increased chance 
of an ongoing pregnancy from a cryo-transfer after a failed transfer) is 
less than generally perceived. Additionally, cryopreservation of 
excess embryos gives rise to complex ethical, religious and legal 
considerations. The possibility of cryopreserving supranumerical 
oocytes rather than embryos has recently been proposed (Porcu et al. 
1998) as a means of circumventing these issues. 
Given these concerns, current strategies for ovarian 
hyperstimulation for IVF have been questioned (Edwards et al. 1996; 
Olivennes & Frydman 1998; Fauser et al. 1999) and novel 
approaches to ovarian stimulation for IVF deserve consideration. 
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3.2.2 Natural cycle IVF 
 
In recent years outcomes of IVF using the natural menstrual cycle 
have improved. Data from several series indicate cancellation rates of 
10-30%, egg recovery rates of 75-90%, fertilization rates of 60-80%, 
implantation rates of between 20-30% and ongoing pregnancy rates 
per started cycle of 5-15% (Garcia 1989; Lenton et al. 1992; Lenton & 
Woodward 1993; Seibel 1994; Society for assited reproductive 
technology (SART) 1996). While less invasive and less expensive, 
cancellation rates remain high. As in standard IVF protocols, 
prevention of the luteinizing hormone (LH) surge may simplify 
treatment and reduce cancellation rates. The administration of a 
GnRH antagonist in the late follicular phase may have clinical use in 
this regard (Olivennes et al. 1995). However, intense monitoring still is 
required and this regimen could only be applied under specific 
conditions. 
 
 
3.2.3 The normal menstrual cycle as basis for mild 
ovarian stimulation for IVF 
 
Healthy, early antral follicles measuring 2-5 mm in diameter are 
present throughout the entire menstrual cycle (McNatty et al. 1983). 
These follicles will only continue to grow when sufficiently stimulated 
by rising follicle-stimulating hormone (FSH) concentrations (Baird 
1990). Due to the demise of the corpus luteum and subsequent 
decreased estrogen output (le Nestour et al. 1993) FSH levels rise at 
the end of the luteal phase (Hall et al. 1992). During the subsequent 
follicular phase, FSH levels plateau during initial days and are 
gradually suppressed thereafter by ovarian steroid and inhibin 
negative feedback. Only those follicles that happen to be at a more 
advanced stage of maturation gain gonadotropin dependence and will 
continue to grow when the 'FSH threshold' (Brown 1978) is 
surpassed. The cohort size of healthy early antral follicles recruited 
during the luteo-follicular transition is around 5 to 10 per ovary (Pache 
et al. 1990; Gougeon 1996). The duration of FSH elevation above the 
threshold, referred to as the 'FSH window', emphasizes the 
importance of duration of elevated FSH rather than the actual 
concentration (Baird 1987; Fauser & Van Heusden 1997). 
Decremental follicular phase FSH levels restrict the 'FSH window' for 
which FSH levels remain above the threshold, and appear to be 
crucial for selection of a single dominant follicle from the recruited 
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cohort (van Santbrink et al. 1995). Single dominant follicle selection 
can be disrupted by the administration of low doses of exogenous 
FSH during the mid- to late-follicular phase, effectively preventing a 
decrease in serum FSH, widening the 'FSH window' and therefore 
enabling multifollicular development (Lolis et al. 1995; Schipper et al. 
1998).  
The median day of appearance of the dominant follicle in 
normo-ovulatory women is cycle day 7 (Pache et al. 1990; van 
Santbrink et al. 1995). Interference with the process of single 
dominant follicle selection immediately prior to this point may form the 
basis for a simplified stimulation regimen for IVF. The clinical 
introduction of GnRH antagonists provides novel opportunities 
regarding this approach. GnRH antagonist action is characterized by 
an immediate suppression of pituitary gonadotropin release and a 
rapid recovery of normal secretion of endogenous LH and FSH 
(Ditkoff et al. 1991).  Recent studies have shown that GnRH 
antagonists, either at single or multiple doses, are effective in 
preventing a premature LH rise during ovarian stimulation for IVF 
(Frydman et al. 1991; Diedrich et al. 1994; Olivennes et al. 1994; 
Albano et al. 1996; The ganirelix dose-finding study group 1998). 
Thus a treatment cycle can commence with an undisturbed menstrual 
cycle and recruitment of a normal cohort of about 10 follicles. 
Exogenous FSH may therefore be used during the mid- to late-
follicular phase to prolong the growth of these follicles up to the 
preovulatory stage and a GnRH antagonist may be used to avoid a 
premature LH rise. By making optimal use of endogenous FSH, the 
amount of exogenous FSH required should be substantially reduced. 
In a recent IVF pilot study, such an intervention in the 
midfollicular phase -designed to extend the duration of the ‘FSH 
window’- resulted in multifollicular development (de Jong et al. 
1999b). As expected, the number of follicles > 15 mm observed at 
day of hCG was administered was smaller (3 1/2 follicles) compared to 
that observed in 'long protocol' regimens for maximum ovarian 
stimulation for IVF (7 1/2 follicles) (Out et al. 1996). However, the 
number of oocytes retrieved was larger (median 6-9) and sufficient 
embryos were obtained to enable embryo transfer. The total amount 
of RecFSH administered in this study (700 – 1200 IU) was 
substantially less than the amount of exogenous FSH usually 
administered in conventional ovarian stimulation regimens for IVF 
(around 2200 IU) (Out et al. 1996). With a minimal ovarian stimulation 
regimen described in this study it was possible to obtain pregnancies. 
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3.2.4 Possible benefits arising from mild stimulation 
protocols for IVF 
 
While at present still experimental, the described minimal stimulation 
protocol deserves attention for the following reasons. In addition to a 
significantly reduced duration of stimulation and amount of exogenous 
FSH used, less monitoring would be required and the chances of long 
and short-term risk should be reduced.  While fewer oocytes will be 
available for IVF than in conventional stimulation protocols, the 
smaller cohort of growing follicles may be better synchronized which 
may carry advantages in terms of better oocyte quality and capacity 
to be fertilized and form good quality embryos. In addition, the 
reduced stimulation may help to avoid adverse effects of 
hyperstimulation on corpus luteum function and endometrial 
receptivity (Simon et al. 1998).  
Following GnRH agonist co-treatment during the follicular 
phase, luteolysis is initiated earlier due to slow recovery of 
endogenous pituitary secretion of gonadotropins (Smitz et al. 1988b; 
Donderwinkel et al. 1993). Therefore, provision of luteal support is 
common practice following ovarian stimulation for IVF (Soliman et al. 
1994). A rapid recovery of pituitary LH-release after cessation of 
GnRH antagonist administration (Ditkoff et al. 1991) might permit 
abandoning additional luteal support and further simplifying IVF 
treatment.  
However, although in our recent pilot study employing a 
minimal hyperstimulation protocol pregnancies were obtained without 
provision of exogenous luteal support (de Jong et al. 1999b), the 
luteal phase differed from that of the normal menstrual cycle. The 
treated subjects showed supra-physiological progesterone and E2 
concentrations (3 to 4 times higher) and decreased FSH and LH 
levels (4 to 5 times lower) compared with the normal menstrual cycle 
controls. It appears unlikely that reduced LH and FSH concentrations 
in the luteal phase were caused by an absent pituitary recovery from 
GnRH antagonist treatment. Other non-physiological mechanisms 
could be involved. Since hCG has a longer half-life than native LH 
(Mannaerts et al. 1998) it may have prolonged effect on the early- to 
mid-luteal phase, suggesting that hCG itself or an indirect effect of 
hCG (supraphysiological steroid levels) may suppress pituitary 
secretion of gonadotropins in the luteal phase. Moreover, it has been 
demonstrated that activation of LH receptors by hCG abolished 
pulsatile GnRH release from hypothalamic cells in-vitro (Mores et al. 
1996).  
With the use of GnRH antagonists during the late follicular 
phase, final stages of oocyte meiotic maturation can be induced by 
cessation of the GnRH antagonist, recombinant LH (The european 
recombinant human LH study group 1998), native GnRH (Gordon et 
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al. 1990) or GnRH agonist instead of hCG (Gonen et al. 1990; 
Itskovitz-Eldor et al. 1991; Olivennes et al. 1996). These approaches 
are at present under investigation and may reduce the risk of OHSS. 
 Milder forms of ovarian stimulation for IVF are likely to 
generate fewer embryos. However, improvements in culture 
conditions is enabling up to 50% of embryos to reach the blastocyst 
stage, whereby implantation rates per embryo of 30-50% have been 
reported (Gardner & Lane 1998). Transfer of 1 or 2 rapidly developing 
embryos at the blastocyst stage allows the incidence of multiple 
pregnancy to be reduced without causing a fall in overall pregnancy 
rates (Scholtes & Zeilmaker 1996). Indeed, the transfer of just one 
good quality embryo may now be considered a realistic approach 
(Vilska et al. 1998). 
 In conclusion, the prospect of minimal ovarian stimulation 
protocols for IVF offers women the possibility of ‘softer’, less 
expensive and more user friendly IVF treatments, low complication 
rates, and perhaps most importantly, high singleton pregnancy rates 
while avoiding multiple gestations and presumably reduced 
complication rates. However, further studies are required to establish 
its clinical efficacy. 
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3.3 Mild ovarian stimulation for IVF, a pilot 
study 
 
3.3.1 Introduction 
 
The concept of the ‘FSH window’, emphasizes the importance of 
duration of elevated FSH rather than the actual concentration for 
follicle recruitment. The follicular phase decrease in serum FSH 
levels, which secures single dominant follicle selection in normo-
ovulatory women, can be prevented by the administration of low dose 
exogenous FSH in the mid to late follicular phase (van Santbrink et al. 
1995; Fauser & Van Heusden 1997). Such an intervention in normo-
ovulatory women results in ongoing growth of multiple dominant 
follicles (Schipper et al. 1998). The recent availability of GnRH 
antagonists for acute suppression of a premature rise in luteinizing 
hormone (LH) enables this concept to be tested clinically in IVF. The 
use of GnRH antagonists allows normal undisturbed initiation of the 
menstrual cycle for IVF. 
In this pilot-study we investigated whether it is possible to 
induce multiple dominant follicle development by instituting low doses 
of exogenous FSH from the mid-follicular phase onwards and whether 
such a regimen (including GnRH antagonist administration) might 
result in pregnancies in the absence of subsequent exogenous luteal 
support. 
 
 
3.3.2 Materials and methods 
 
Approval of the study protocol was given by the Local Ethics Review 
Committee. Informed consent was obtained from all participants. A 
total of 15 normo-ovulatory women under 38 years of age enrolled in 
our IVF program, were included in this prospective randomized pilot-
study. Subjects were studied during a single IVF treatment cycle. In 3 
patients with an insufficient response (defined as < 3 follicles > 15 
mm) to ovarian stimulation were excluded from analysis. Data 
obtained from 40 regular cycling women, as published previously 
(Fauser & Van Heusden 1997), served as controls.  
Prior to ovarian stimulation, subjects were randomly (sealed 
envelopes) assigned to one of the two stimulation regimens. Patients 
received either 100 IU (group A) or 150 IU (group B) of recombinant 
FSH (RecFSH, Puregon®, N.V. Organon, Oss, The Netherlands) as a 
daily s.c. injection, from cycle day (CD) 5 onwards until the day 
human chorionic gonadotropin (hCG) was administered. Participants 
in both groups were co-treated with a GnRH antagonist (cetrorelix, 
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Cetrotide, Asta Medica AG, Frankfurt, Germany) 0.25 mg s.c./day 
from CD 8 onwards when at least one follicle of 13 mm was present. 
Otherwise, Cetrorelix administration was postponed. When at least 
one follicle > 18 mm and 3 follicles > 15 mm were observed on 
transvaginal ultrasound (TVS), 10.000 IU hCG (Pregnyl®, N.V. 
Organon) was administered by i.m. injection to trigger final stages of 
oocyte maturation. No luteal phase support was provided.  
Oocyte collection took place 36 hours after hCG 
administration. A maximum of 2 embryos was transferred on day 3 to 
5 after oocyte retrieval. Repeated bloodwithdrawal took place during 
the entire cycle. When no pregnancy occurred, the time of onset of 
the next menstruation was documented. Viable pregnancy was 
defined as a positive intrauterine fetal heart activity observed by TVS 
5-6 weeks after embryo transfer.  
Blood samples were centrifuged within 2 h after withdrawal 
and stored at – 20°C until assayed. Luteinizing hormone (LH) and 
FSH levels were measured by IRMA.  Progesterone (P) and E2 levels 
were assessed by RIA. Intra- and interassay coefficients of variation 
were less than 3% and 8% for FSH, less than 5% and 15% for LH, 
less than 16% and 17% for P, and less than 15% and 18% for E2, 
respectively. All samples from one subject were run in the same 
assay.  
Potential differences between groups in patients age, total 
amount of FSH administered, number of follicles at day of hCG, 
number of oocytes retrieved, and number of embryos obtained were 
analyzed using the Mann-Whitney test, as were differences in LH, 
FSH, E2, and P. Potential differences in cancellation rate and 
pregnancy rate were analyzed using Fisher’s exact test. Differences 
were considered to be statistically significant if P < 0.05.  
 
 
3.3.3 Results 
 
Patient characteristics, endocrine assessments, and treatment 
outcome of patients during the intervention cycle are shown in Table 
3.2. Three patients in the 100 IU group (exhibiting less than 3 follicles 
of > 15 mm) were excluded from data analysis. Oocytes were 
retrieved from all remaining patients (n = 12). No embryos were 
obtained in 3 subjects. Three patients achieved a viable pregnancy. 
The total amount of RecFSH administered in the 100 IU group was 
significantly less as compared to the 150 IU group (700 vs. 1200, p < 
0.005).  
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Table 3.2 
Patient characteristics, steroid and gonadotropin levels, and treatment outcome of 12 
IVF patients during minimal ovarian stimulation and normo-ovulatory controls. 
Values are median (range), unless otherwise indicated. a One day before the 
spontaneous LH surge, b at day of the spontaneous LH surge, c no embryos obtained in 
1 subject, d no embryos obtained in 2 subjects, e 2 out of 4 patients who underwent 
embryo transfer conceived, f 1 out of 5 patients who underwent embryo transfer 
conceived, gduration of the luteal phase for all subjects who did not conceive, including 
one without an embryo transfer (n = 3), h  duration of the luteal phase for all subjects 
who did not conceive, including those without an embryo transfer (n = 6), and i in non-
conceiving patients. 
 
 No statistical difference was found in LH and FSH 
concentrations between the low and high dose group (data not 
shown). In both groups, LH serum concentrations fell to low levels 
during GnRH antagonist exposure compared to controls (< 2.0 IU/L), 
while FSH serum concentrations remained steady (+ 6 IU/L) during 
the follicular phase. Treated subjects of both groups combined 
showed elevated FSH and suppressed LH levels 1 day before hCG 
compared to the natural cycle (6.5 and 1.9 vs 3.8 and 4.8 IU/L, p < 
 IVF patients Controls 
 100 IU RecFSH/day 
150 IU 
RecFSH/day  
No. of subjects undergoing  
ovum pick-up 5 7 40 
Age (years) 34 (25-37) 30 (27-37) 28 (20-36) 
Follicular phase    
Duration follicular phase (days) 12 (12-14) 14 (12-16) 15 (10-20) 
Total dose of RecFSH (IU) 700 (700-900) 1200 (900-1500)  
FSH 1 day pre hCG (IU/L) 5.7 (2.7-6.6) 7.6 (5.7-11.1) 3.8 (1.8-6.3) a 
LH 1 day pre hCG (IU/L) 2.4 (0.6-3.0) 1.5 (1.2-2.6) 4.8 (1.3-10.3) a 
E2 day hCG (pmol/L) 3248 (1257-4773) 2899 (1378-8476) 820 (370-1525) b 
 
No. of follicles > 10 mm on day hCG 
administration 
 
7 (5-11) 10 (3-19)  
Clinical outcome    
No. of  oocytes retrieved per person 6 (3-10) 9 (1-19)  
No. embryos obtained per person 3 (2-8) c 3 (1-13) d  
No. of pregnancies 2 (2/4) e 1 (1/5) f  
Luteal phase    
Duration luteal phase (days) 12 (11-14) g 13 (11-21) h 12 (5-16) 
E2 5-7 days post hCG (pmol/L) 1822 (939-3094) i 1641 (898-3400) i 449 (253-940) 
P 5-7 days post hCG (nmol/L) 221.1 (96.3-409.2) i 179.0 (65.8-340.0) i 43.7 (11.7-74.9) 
FSH 5-7 days post hCG (IU/L) 0.4 (0.3-1.6) i 1.1 (0.5-2.2) i 2.5 (0.7-7.1) 
LH concentration 5-7 days post hCG (IU/L) 0.7 (0.2-0.7) i 1.0 (0.1-2.7) i 3.7 (0.2-12.1) 
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0.0001, respectively). There were no significant differences in follicle 
growth between the low and high dose group. 
 Significantly lower luteal phase LH and FSH concentrations 
were observed 5-7 days after hCG administration compared to the 
natural cycle (0.7 and 0.8 vs. 3.7 and 2.5 IU/L, p < 0.0001, 
respectively). No statistical difference was found in serum E2 and P 
concentration between the low and high dose group at any stage 
during this regimen. However, when compared to the control group, 
treated subjects of both groups combined showed elevated E2 serum 
levels on day of hCG and 5-7 days post hCG (2959, 1641 vs. 847, 
449 pmol/L, p < 0.0001, respectively), and elevated P serum levels 5-
7 days post hCG (180 vs. 44 nmol/L, p < 0.05).  
 The median duration of the luteal phase (number of days 
between day of hCG and onset of menstruation) in the patients who 
did not conceive was 12 days (10-20 days) for the treated patients 
compared to 12 days (5-16 days) for the controls. 
 
 
3.3.4 Discussion 
 
The aim of the present study was to determine if a minimal 
intervention during the mid- to late-follicular phase - designed to 
extend the duration of the ‘FSH window’- results in multiple dominant 
follicle development sufficient for IVF.  
While the mean number of follicles > 15 mm observed on the 
day of hCG administration seems smaller than that observed in the 
standard long GnRH agonist protocols for IVF, a median number of 6-
9 oocytes were retrieved and a mean of 3 embryos were generated. 
In 3 patients receiving 100 IU/d RecFSH, cycles were cancelled due 
to low response, suggesting that the FSH ‘threshold’ of remaining 
cohort follicles was not surpassed in these patients. In the remaining 
5 subjects receiving 100 IU/d, ovarian response was similar compared 
to the 150 IU/d group. The total amount of RecFSH administered in 
this study (700 – 1200 IU) was substantially less than the amount of 
exogenous FSH usually administered in conventional ovarian 
stimulation regimens for IVF (around 2200 IU).  
Late follicular phase E2 concentrations were lower compared 
to conventional ovarian stimulation regimens for IVF, but 31/2 times 
higher compared to the natural cycle consistent with multiple 
dominant follicular development. During the luteal phase E2 and P 
levels were supraphysiological while LH and FSH levels were 
extremely low. The GnRH antagonist was an unlikely causative factor 
for the observed luteal gonadotropin suppression since its cessation 
in the follicular phase leads to a rapid recovery of the pituitary-
gonadal axis (Ditkoff et al. 1991). Other possibilities include ovarian 
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hyperstimulation per sé or profound negative feedback due to high 
luteal phase steroid levels. The duration of the luteal phase in the 
treated patients was comparable with the controls despite that no 
luteal support was provided, suggesting that the use of GnRH 
antagonists during ovarian stimulation for IVF may not compromise 
subsequent corpus luteum function (Ditkoff et al. 1991).  
Using the described minimal ovarian stimulation regimen it 
was possible to obtain pregnancies despite withholding luteal support. 
However, the number of patients included in this pilot study is too 
small for meaningful conclusions regarding clinical outcome. This 
study suggests that a distinct simplification of ovarian stimulation for 
IVF is feasible. This alternative approach deserves further attention 
with the focus towards overall clinical outcome versus patient 
dyscomfort, risks, and cost. 
    
Chapter 4 
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4.1 GnRH agonist treatment for triggering 
the final stages of oocyte maturation in 
IVF, a case report 
 
4.1.1 Introduction 
 
In the normal menstrual cycle, the endogenous midcycle luteinizing 
hormone (LH) surge induces resumption of oocyte meiosis and 
dissociation of the cumulus which leads to rupture of the follicular wall 
and ovulation of the oocyte from the Graafian follicle (Hoff et al. 
1983).   
 In conventional in vitro fertilization (IVF) programs, 
gonadotropin-releasing hormone (GnRH) agonists are used for 
pituitary ‘down-regulation’ in order to prevent a premature LH surge. 
Because of its LH-like properties, human chorionic gonadotropin 
(hCG) is given to induce final oocyte maturation. However, the 
increased carbohydrate content of hCG in comparison to LH results in 
a longer circulating half-life and a longer biological effect (Moyle et al. 
1975).  
  In contrast to GnRH agonists, GnRH antagonists induce an 
immediate suppression of pituitary gonadotropin release and a rapid 
recovery of normal secretion of endogenous LH and follicle 
stimulating hormone (FSH) (Ditkoff et al. 1991).  These analogues 
have recently been developed for the prevention of premature LH 
surges during ovarian stimulation for assisted reproduction (Albano et 
al. 1997; Olivennes et al. 1998a; The ganirelix dose-finding study 
group 1998; de Jong et al. 2000). A GnRH antagonist regimen offers 
the opportunity to trigger the final maturation of the oocyte with 
pulsatile native GnRH administration (Gordon et al. 1990) or with a 
single dose of a GnRH agonist (Gonen et al. 1990). Indeed, it has 
been reported that the midcycle FSH and LH surge could thus be 
simulated in patients co-treated with a GnRH antagonist, undergoing 
ovarian hyperstimulation for intra-uterine insemination (Olivennes et 
al. 1996). Therefore, triggering of final stages of oocyte maturation 
may be induced by administration of a GnRH agonist in patients 
undergoing ovarian stimulation and co-treated with a GnRH 
antagonist to prevent a possible LH surge for IVF.  
This case report describes the characteristics of a woman who 
underwent ovarian stimulation for intracytoplasmic sperm injection 
(ICSI) co-treated with a GnRH antagonist and a single bolus of GnRH 
agonist for triggering the final stages of oocyte maturation, resulting in 
the birth of a healthy girl. 
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4.1.2 Case Report 
 
A 28-year old normo-ovulatory woman (body mass index 27.5 kg/m2) 
with an subfertility duration of 41/2 years due to male factor underwent 
ovarian stimulation for ICSI in our unit. Before initiation of treatment, 
endocrine screening and sonographic examination appeared to be 
normal. The patient participated in a multi-centre trial, approved by the 
local ethics review committee. Ovarian stimulation using 150 IU 
recFSH (Puregon, N.V. Organon, Oss, the Netherlands) daily 
subcutaneous injections was started on cycle day (CD) 2. From CD 7 
onwards, daily subcutaneous injections of 0.25 mg GnRH antagonist 
(ganirelix; Orgalutran®/Antagon™, N.V. Organon) (Nelson et al. 1995) 
were started. On CD 12 this patient showed 3 preovulatory (> 17 mm), 
and 9 intermediate sized (10 - 16 mm) follicles on transvaginal 
ultrasound sonography. According to the protocol, after randomization, 
a bolus injection of 0.5 mg GnRH agonist leuprorelin (Lupron®, Abbott 
Laboratories, Montreal, Canada) was administered subcutaneously. 
Subsequently, blood samples were taken frequently after the GnRH 
agonist was administered, on the day of oocyte pick-up, on the day of 
embryo transfer (ET), and 7 and 14 days thereafter.  
Serum concentrations of LH, FSH, estradiol (E2), and 
progesterone (P) are depicted in Figure 4.1. In the late follicular phase 
LH serum levels were 0.6 IU/L, whereas FSH serum levels remained 
steady at 5 IU/L. During the follicular phase, increasing E2 (reaching 
588 pg/mL) and steady P levels of 0.5 ng/mL were observed. After 
administration of the GnRH agonist leuprorelin an increase in 
gonadotropin levels was observed, reaching a maximum of 103 and 
12.2 IU/L for LH and FSH, respectively, at 8 hours after GnRH agonist 
administration. 
Ovum pick-up (OPU) resulted in 11 metaphase II oocytes and 1 
germinal vesicle. Subsequently, the metaphase II oocytes were 
fertilized by ICSI. As per the center’s current practice, embryo culture 
was performed to day 5 after ovum pick-up (Huisman et al. 2000). Two 
blastocyst-stage embryos were transferred and 3 were cryopreserved. 
Daily intramuscular injections of 50 mg P were provided as luteal 
phase support from the day the oocytes were transferred. Analyses of 
blood samples drawn in the luteal phase up to 14 days post-ET 
resulted in decreasing FSH and LH serum to levels which were below 
the limit of detection for their assays (< 0.6 and < 1.0 IU/L, 
respectively). From OPU up to 7 days post-ET, a decrease in E2 levels 
(from 161 pg/mL to 45.4 ng/mL) was observed, followed by an 
increase to 126 pg/mL 14 days after ET. P levels increased from 2.61 
at OPU to 36.7 ng/mL at 7 days post-ET, followed by a decrease to 16 
ng/mL at 14 days after ET.  
A viable intra-uterine twin-pregnancy was observed at 8 and 12 
weeks amenorrhoea on ultrasound, which spontaneously reduced to 
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a singleton pregnancy at 14 weeks amenorrhoea. After a non-
complicated pregnancy and spontaneous vaginal delivery, this patient 
gave birth to a healthy girl at 40 weeks amenorrhoea.  
 
 
 
 
 
 
Figure 4.1 
LH (z-z), FSH (¡-¡) (top 
panel), E2 (-), and P (S-S) 
(bottom panel) serum levels in a 
single patient undergoing ovarian 
stimulation for IVF, using the 
GnRH antagonist ganirelix to 
prevent a premature LH surge. 
Recombinant FSH (recFSH) was 
initiated on cycle day (CD) 2, 
GnRH antagonist on CD7. Final 
stages of oocyte maturation were 
induced by a single bolus of 
GnRH agonist on CD12 (t=0h). 
Monitoring during the peri-
ovulatory period was performed at 
2, 4, 8, 12, and 20-24 hours after 
the GnRH antagonist was 
administered. Luteal phase blood 
samples were withdrawn on the 
day of ovum pick-up (OPU), on 
the day of ET, 7 days after ET, 
and 14 days after ET.
 
 
4.1.3 Discussion 
 
The routinely applied ‘long protocol’ for IVF, characterized by pituitary 
‘down-regulation’ by a GnRH agonist and ovarian hyperstimulation by 
exogeneously administered gonadotropins, may lead to undesired 
complications such as the development of ovarian hyperstimulation 
syndrome (OHSS) (Itskovitz-Eldor et al. 1991). Alternative strategies 
for ovarian stimulation for IVF are needed (Edwards et al. 1996). 
These include the application of GnRH antagonists for avoiding a 
premature LH rise and the use GnRH agonists, native GnRH, and 
recombinant LH for induction of final stages of oocyte maturation 
(Fauser et al. 1999).  
 The availability of GnRH antagonists may offer alternative 
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strategies for countering imminent OHSS (de Jong et al. 1998). 
Replacing hCG with a single bolus of GnRH agonist for final oocyte 
maturation may prevent OHSS and permit continuation of the 
treatment cycle (Itskovitz-Eldor et al. 1991). This possibility arises 
because the pituitary is not ‘down-regulated’ and the GnRH receptors 
are still present. The efficacy of triggering final oocyte maturation and 
ovulation with GnRH agonists has been demonstrated in women 
undergoing ovarian stimulation with (Olivennes et al. 1996) or without 
(Romeu et al. 1997) a GnRH antagonist followed by intra uterine 
insemination. The present case describes the successful treatment of 
a woman who underwent ovarian stimulation for ICSI using a GnRH 
antagonist protocol and a single bolus of a GnRH agonist to trigger the 
final stages of oocyte maturation. A healthy baby was delivered at 40 
weeks amenorrhoea.  
  The use of GnRH agonists for triggering final stages of oocyte 
maturation instead of hCG may further reduce the incidence of OHSS, 
reduce cancellation rates, and result in a safe treatment of high 
responders. Further controlled studies are required to assess whether 
such a regimen should be applied in daily routine practice. 
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4.1 GnRH agonist treatment for triggering 
the final stages of oocyte maturation in 
IVF, a randomized controlled trial 
 
4.1.1 Introduction 
 
Human chorionic gonadotropin (hCG) represents the standard of care 
for the substitution of the endogenous luteinizing hormone (LH) surge 
to induce final stages of oocyte maturation in ovarian hyperstimulation 
protocols for in vitro fertilization (IVF). Unfortunately, hCG is also 
believed to contribute to the occurrence of the ovarian 
hyperstimulation syndrome (OHSS), a potentially life threatening 
complication (Elchalal & Schenker 1997; Fauser et al. 1999; Whelan 
& Vlahos 2000). Exogenous hCG is implicated in the development of 
multiple corpora lutea and sustained luteotropic effects due to its 
prolonged circulating half-life as compared to native LH (Damewood 
et al. 1989; Gonen et al. 1990; Beckers et al. 2000). Moreover, the 
occurrence of OHSS is associated with continued late luteal phase 
hCG production in case of pregnancy. An alternative to exogenous 
hCG could be the administration of a gonadotropin-releasing hormone 
(GnRH) agonist inducing an endogenous rise in both LH and follicle-
stimulating hormone (FSH) levels due to the initial flare effect (Gonen 
et al. 1990; Itskovitz-Eldor et al. 1991). The capacity of GnRH 
agonists to trigger ovulation following gonadotropin treatment of 
anovulatory women (Emperaire & Ruffie 1991; Kulikowski et al. 1995) 
or to induce final stages of oocyte maturation after ovarian 
hyperstimulation for IVF (Gonen et al. 1990; Itskovitz-Eldor et al. 
1991; Imoedemhe et al. 1991; Segal & Casper 1992; van der Meer S. 
et al. 1993) has been well established. The induction of an 
endogenous LH (and FSH) surge is more physiological compared to 
the administration of exogenous hCG and may reduce the risk of 
OHSS due to the much shorter half-life of LH (Imoedemhe et al. 1991; 
Shoham et al. 1995; Kol et al. 1996). Moreover, under these 
conditions luteal phase steroid levels seem closer to normo-ovulatory 
cycles (Lanzone et al. 1994) which may improve endometrial 
receptivity (Forman et al. 1988; Simon et al. 1998). Effects on oocyte 
quality and chances for subsequent fertilization remain uncertain at 
this stage. 
 For obvious reasons, GnRH agonist to induce oocyte 
maturation can only be used when GnRH agonist has not been 
applied for pituitary down regulation to prevent a premature LH rise 
during ovarian stimulation. Since the GnRH agonist ‘long protocol’ 
has been the standard of care for over a decade, alternative 
approaches to induce oocyte maturation has received little attention in 
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recent years. The mid to late follicular phase administration of a 
GnRH antagonist may also be used to prevent a premature LH rise 
during ovarian hyperstimulation. The recently introduced GnRH 
antagonist ganirelix (Orgalutran, Antagon) competes with native 
GnRH in binding to its receptor resulting in the immediate and dose-
dependent suppression of endogenous gonadotropin release (Oberye 
et al. 1999a; Oberye et al. 1999b). In previous trials, the daily 
administration of 0.25 mg ganirelix has been shown to be safe and 
effective (The ganirelix dose-finding study group 1998) requiring on 
average 5 days of treatment and a reduced total dose of recombinant 
FSH compared to a long GnRH agonist protocol (Bouchard & Fauser 
2000; The european orgalutran study group et al. 2000; The 
european and middle east orgalutran study group 2001; The north 
american ganirelix study group 2001). hCG has been used to trigger 
final oocyte maturation in these first studies applying GnRH 
antagonist. However, in contrast to GnRH agonist, the suppressive 
effect of the GnRH antagonist can be reversed immediately by 
administering native GnRH or GnRH agonist, resulting in a surge of 
endogenous LH and FSH. This new concept of triggering final oocyte 
maturation after GnRH antagonist treatment was successfully tested 
in 5 patients undergoing ovarian hyperstimulation for intra uterine 
insemination using a single dose of 0.1 mg triptorelin (Olivennes et al. 
1996). No information on the maturity of oocytes could be obtained in 
this first pilot study. In addition, a single dose of 0.2 mg triptorelin was 
effective in triggering an endogenous LH surge and final oocyte 
maturation in 8 high responder IVF patients co-treated with ganirelix 
(Itskovitz-Eldor et al. 2000). None of these patients developed OHSS.  
 The current randomized study was designed to examine 
whether, following daily late follicular phase treatment with 0.25 mg 
ganirelix, administration of a single dose of GnRH agonist is at least 
as effective compared to hCG in inducing final oocyte maturation in 
patients undergoing ovarian hyperstimulation for IVF. Here we report 
on the endocrine profile and clinical outcome of the first subset of 
patients in whom bloodsampling was performed at regular intervals 
after the administration of triptorelin, leuprolide, or hCG. 
 
 
4.1.2 Materials and methods 
 
Subjects 
The first 57 out of 200 subjects participating in this comparative 
randomized trial signed informed consent which included 
hospitalization to monitor hormonal changes after GnRH agonist was 
given to trigger final oocyte maturation. All subjects underwent 
ovarian hyperstimulation with recombinant FSH for IVF plus 
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intracytoplasmatic sperm injection (ICSI) allowing for the assessment 
of oocyte maturation (metaphase II stage). Subjects had a regular 
indication for ICSI, were between 18 and 39 years of age, had a 
regular menstrual cycle (24 – 35 days) and body weight was normal 
(body mass index 18-29 kg/m2). 
 
Study Design 
Six international centers participated in this study and the protocol 
was approved by the local ethics review committees. This study was 
an open-label randomized three-arm trial in subjects who started 
ovarian hyperstimulation with recombinant FSH (Puregon®, NV 
Organon, The Netherlands) starting at cycle day 2 or 3 and continued 
treatment  until the day of inducing final oocyte maturation (Figure 
4.2). The FSH dose was 150 or 225 IU/d s.c. for the first 5 treatment 
days. Thereafter, the daily dose could be adjusted based on the 
follicular growth as observed by ultrasound. To prevent premature LH 
surges, ganirelix (Orgalutran® / AntagonTM; NV Organon) (0.25 mg in 
0.5 mL daily) was administered s.c. starting on day 6 of FSH 
stimulation until and including the day of triggering final oocyte 
maturation. On that day, randomization was performed by means of 
an interactive telephone randomization system which stratified for 
age, primary or secondary infertility and number of follicles at least 11 
mm in diameter. Subjects were randomized in a ratio of 1:1:1 to 
treatment with either 0.2 mg triptorelin (Decapeptyl®, Ferring, 
Germany), or 0.5 mg leuprorelin (Lupron®, TAP Pharmaceuticals Inc., 
USA), or 10,000 IU hCG (Pregnyl®, NV Organon). Subjects were only 
randomized if at least 3 follicles ≥ 17 mm were observed. High 
responders (defined as having more than 25 follicles beyond 11 mm) 
were considered drop outs from the study. Approximately 30 to 36 h 
after triggering of final oocyte maturation, oocyte retrieval was 
performed followed by ICSI. No more than 3 embryos were 
transferred at 2 to 5 days after oocyte retrieval. Exogenous P was 
administered intramuscularly for luteal support (Progestine®, NV 
Organon) (50 mg in 2 mL daily) from the day of embryo transfer for at 
least two weeks or until menses.  
 
Assessments 
Prior to the start of ovarian stimulation, pregnancy was excluded by 
means of an hCG test, a  blood sample was taken for hormone 
assessments and ultrasound was performed. The subject returned to 
the clinic at least once every two days for ultrasound investigation and 
blood sampling from day 6 of stimulation until the day of triggering of 
final oocyte maturation. Blood sampling was performed prior to 
ganirelix and FSH administration. On the day of triggering final oocyte 
maturation, blood samples were taken just prior to GnRH agonist or 
hCG administration, at 2, 4, 8, 12 and 24 hours after GnRH agonist 
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injection and at 12 and 24 hours after hCG injection. Additional blood 
samples of all subjects were taken on the day of oocyte pick-up, 
embryo transfer (ET) and at 1 week and 2 weeks after ET. HCG 
concentrations were not assessed at 4 and 8 hours since previous 
pharmacokinetic studies (Mannaerts et al. 1998) demonstrated a tmax 
at 20 hours.  
 
 
  
Figure 4.2 
Schematic representation of different treatment regimens for ovarian hyperstimulation 
for IVF using recombinant FSH and ganirelix to prevent a premature rise in LH followed 
by the triggering of final oocyte maturation by a single dose of two GnRH agonists 
(triptorelin or leuprorelin) or hCG. 
 
 Serum FSH, LH, E2, hCG, and P levels were assessed by a 
central laboratory using fluoroimmunoassays (Delfia®, Wallac OY, 
Finland). Detection limits of these assays were < 1 IU/L for FSH, < 0.6 
IU/L for LH, < 14 pg/mL for E2, < 2.0 IU/L for hCG, and < 0.3 ng/mL 
for P. Intra- en interassay coefficients of variation were 1.6 and 4.1 % 
for FSH, 11.0 and 13.0 % for LH, 7.8 and 10.3 % for E2, 6.9 and 9.3% 
for hCG, and 5.0 and 6.9 % for P, respectively. 
 Embryo quality was assessed as; grade 1 (excellent  embryos 
with absent fragmentation), grade 2 (1-20% fragmentation), grade 3 
(21-50% fragmentation) or grade 4 otherwise. 
 
Statistical Methods 
The primary objective of this study was to compare endocrine 
characteristics of both GnRH agonist groups versus hCG to induce 
final oocyte maturation. Relevant data of leuprorelin, triptorelin and 
hCG have been statistically compared using analysis of covariance 
(ANCOVA) with center and treatment as factors and endocrine or 
ultrasound features as covariate. In case the overall treatment factor 
was statistically significant (i.e. the three treatment groups differ 
statistically significant) pairwise comparisons were made between 
hCG and leuprorelin or triptorelin, respectively. These pairwise 
comparisons were performed using the same analysis of covariance. 
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  Individual areas under the curve (AUC) were calculated using 
the linear trapezoidal rule. For LH and FSH the concentrations 
obtained on the day of triggering final oocyte maturation up to 24 h 
after GnRH agonist or hCG injection were included in the AUC. For E2 
and P the applied timeframe was from the day of triggering of final 
oocyte maturation until 2 weeks after ET. To correct for possible 
differences in the timeframes each AUC value was divided by the 
actual timeframe, resulting in individual estimates of the mean 
hormone concentration over time. Descriptive statistics were 
calculated for these derived concentrations per treatment (Table 4.1) 
and a one way ANCOVA was performed to compare the treatment 
effects of both leuprorelin and triptorelin versus hCG. In case the 
ANCOVA showed statistically significant differences between the 
three treatment groups, two sample t tests were performed to 
compare both leuprorelin and triptorelin versus hCG, respectively. 
  Preliminary clinical outcome parameters are described for all 
randomized patients (using descriptive statistics unadjusted for 
center) showing no major differences (Table 4.2). Definitive statistical 
evaluation will be performed separately on the extended series of 
women (as described earlier under subjects).  
  P values less then 0.05 were considered to represent 
statistically significant differences.  
 
 
4.2.3 Results 
 
Disposition and cancellations 
A total of 57 subjects started treatment with FSH of whom 47 were 
randomized. Eight subjects (14%) were not randomized due to 
insufficient ovarian response to stimulation. Two subjects were not 
randomized due to high response. One subject in the hCG group did 
not undergo ET due to a fertilization failure. 
 
Characteristics of randomized subjects 
The overall mean age was 30.4 + 4.2 years, height 1.67 + 0.07 m, 
weight 64.6 + 7.7 kg, and body mass index 23.3 + 2.5 kg/m2. The vast 
majority of subjects (98%) participating in this study were Caucasian. 
The three treatment groups were similar with respect to age, height, 
weight, and body mass index (data not shown). 
 The total amount of exogenous FSH required (1,579+395, 
1,665+455, 1,605+544 IU [mean + SD] for triptorelin, leuprorelin and 
hCG, respectively), the duration of FSH stimulation (8.6+1.1, 9.2+1.6, 
9.3+2.0 days), the duration of ganirelix treatment (4.6+1.1, 5.1+1.7, 
5.3+2.0 days) were similar (P = NS, for all these pre-randomization 
parameters) in the three treatment groups. The overall median 
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(range) duration of stimulation was 9 (6-14) days and the median total 
amount of exogenous FSH administered was 1,500 (900-2,625) IU. 
The median duration of ganirelix treatment was 5 days (range 2-10). 
The mean number of follicles ≥ 11 mm per treatment group assessed 
on day 1, 6, and 8 of stimulation, and on the day of randomization for 
induction of final oocyte maturation are presented in Figure 4.3. On 
the day of the last ultrasound investigation before triggering of final 
oocyte maturation the mean number of follicles ≥ 17 mm was 4.8 + 
2.2,  4.6 + 1.8, and 4.3 + 1.4 (P = NS) for the triptorelin, the 
leuprolide, and the hCG group, respectively.  
 
 
 
 
 
 
 
 
Figure 4.3 
Number of follicles ≥ 11 mm 
(mean + SD) assessed on 
stimulation day 1, 6, 8, and on 
the day of triggering of final 
oocyte maturation (by either 
triptorelin, leuprorelin or hCG) 
during ovarian 
hyperstimulation for IVF with 
exogenous FSH. 
 
 
 
 
 
Serum hormone levels 
Serum concentrations of LH, FSH, E2 and P measured at regular 
intervals after triggering final oocyte maturation up to 2 weeks after 
embryo transfer are presented in Figure 4.4. An endogenous LH rise 
was observed in all subjects who received either triptorelin or 
leuprorelin. In both treatment groups, serum LH levels rapidly 
increased and reached peak levels at 4 hrs after GnRH agonist 
administration. Mean (+ SD) LH levels increased from 0.9 + 0.4 IU/L 
prior to triggering oocyte maturation to peak levels of 130 + 60 IU/L 
after triptorelin administration (P < 0.001) and from 0.9 + 0.8 to 107 + 
55 IU/L after leuprorelin administration (P < 0.001). On the day of 
oocyte pick-up LH levels returned to baseline; 4.8  + 2.5 in the 
triptorelin group and 2.6 + 0.4 IU/L in the leuprorelin group. In 
subjects randomized to hCG treatment, serum hCG levels increased 
gradually and reached peak levels 240 + 101 IU/L at 24 hrs after 
administration. Thereafter, serum hCG levels declined to 5.0 + 1.6 
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IU/L one week after ET. Following hCG administration, serum LH 
remained low or undetectable during the entire luteal phase. In 
contrast to hCG treated subjects, FSH levels increased after GnRH 
agonist administration. FSH levels increased from 5.8 + 1.6 IU/L prior 
to induction of final oocyte maturation to 19.2 + 5.2 IU/L at 8 hrs after 
GnRH agonist administration in the triptorelin group. In the leuprorelin 
group these levels increased from 5.2 + 1.6 to 19.7 + 5.1 IU/L (P < 
0.001 for both groups), whereas in the hCG group serum FSH levels 
declined after hCG administration from 5.8 + 1.6 IU/L to 3.4 + 0.8 IU/L 
(P < 0.001) on the day of oocyte pick up, reflecting the clearance of 
exogenous FSH. The individual AUCs for LH and FSH within the first 
24 hours are depicted in Fig 4.4, confirming the  major difference 
comparing both GnRH agonist groups versus hCG. 
 Serum E2 and P levels were comparable from the time of 
triggering ovulation until oocyte pick-up (see Figure 4.4). Thereafter, 
serum E2 and P levels remained higher in hCG treated subjects 
compared to both GnRH agonist groups. Respective mean (+SEM) E2 
levels were 279+48, 204+30, and 609+115 pg/mL on the day of 
embryo transfer (PANCOVA = 0.0002; Ptriptorelin vs hCG = 0.0006; Pleuprorelin vs 
hCG = 0.0001), and 46+4, 45+9, and 490+145 pg/mL on week 
thereafter (PANCOVA = 0.0001; Ptriptorelin vs hCG = 0.0001; Pleuprorelin vs hCG = 
0.0001) in triptorelin, leuprorelin and hCG treated subjects, 
respectively. Mean P levels were 7.2 + 1.7, 8.0 + 1.5, and 58.6 + 9.6 
ng/mL on the day of transfer (PANCOVA = 0.0001; Ptriptorelin vs hCG = 
0.0001; Pleuprorelin vs hCG = 0.0001) and 18.0 + 3.6, 23.2 + 3.7, 45.9 + 
11.2 ng/mL one week later (PANCOVA = 0.0006; Ptriptorelin vs hCG = 0.0002; 
Pleuprorelin vs hCG = 0.0054). At the end of the luteal phase, levels of both 
hormones were comparable in the three treatment groups. The luteal 
phase AUCs (Table 4.1) confirmed elevated E2 and P levels in the 
hCG group. 
 
Clinical outcome 
The clinical outcome (number of oocytes retrieved, percentage of 
metaphase II oocytes, fertilization rates, embryo quality and 
implantation rates) is presented in Table 4.2. The number of 
miscarriages within the first 12 weeks after transfer was 3, 2 and 3 in 
the triptorelin, leuprorelin and hCG treated subjects, respectively. 
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Figure 4.4 
Serum concentrations of LH (hCG), FSH, E2 and P (mean + SEM) during triggering of 
final stages of oocyte maturation (0, 4, 8, 12, and 24h) with two GnRH agonist 
(triptorelin, leuprorelin) or hCG following ovarian hyperstimulation for IVF and during the 
subsequent luteal phase (day of ovum pick up [OPU], embryo transfer [ET], and 1 and 
2 weeks following embryo transfer). 
 
 
 
 
 Triptorelin (n=17) 
Leuprolin 
(n=15) 
hCG 
(n=15) 
LH(0-24h)  
(IU/L)a 59+14
b 53+14b 2.7+2.2 
FSH(0-24h)  
(IU/L)a 14.5+3.8
b 14.3+3.7b 5.0+1.2 
E2 (0-2 wks) 
(pg/mL)a 252+154
b 196+111c 515+286 
P(0-2 wks) 
(ng/mL)a 12.5+7.7
b 15.2+7.1b 37.8+17.1 
 
Table 4.1 
Area under the curve divided by the actual time period for serum hormone 
concentrations (mean + SD) during triggering of final oocyte maturation with the GnRH 
agonists (triptorelin and leuprorelin) or hCG following ovarian hyperstimulation for IVF 
(0-24h for LH and FSH) and during the subsequent luteal phase (0-2 weeks for E2 and 
P). 
a PANCOVA < 0.001 comparing all three groups.b P = 0.0001 vs hCG group (paired t test).c 
P = 0.0006 vs hCG group (paired t test). 
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Table 4.2 
Clinical outcome (mean + SD) of a randomized comparison between two GnRH 
agonists (triptorelin and leuprorelin) versus hCG in inducing final oocyte maturation 
after ovarian hyperstimulation with FSH and co-treatment with ganirelix in 47 IVF 
patients. a Defined as a pregnancy per IVF cycle, confirmed by detection of positive 
heart beat on ultrasound between 12 and 16 weeks of gestation. b P=NS for all features 
comparing the triptorelin or the leuprorelin group versus women receiving hCG. 
 
 
4.3.4 Discussion 
 
In the normal menstrual cycle, the midcycle LH and FSH surge 
(lasting for approximately 48 hours) is a complex and carefully 
orchestrated event elicited in the late follicular phase by persistently 
elevated estrogen concentrations in combination with a small but 
distinct rise in P (Hoff et al. 1983).  Exposure to a transient massive 
stimulation by LH elicits the resumption of meiotic maturation of the 
oocyte, rupture of the dominant follicle resulting in the release of the 
oocyte and luteinization of theca and granulosa cells resulting in the 
formation of the corpus luteum. Timing of the endogenous LH surge is 
frequently disrupted if exogenous FSH is administered either for 
ovarian hyperstimulation for IVF or for the treatment of anovulation. 
Therefore, exogenous hCG (which activates the LH receptor due to 
structural and biological similarities to LH and which is easy to extract 
from urine of pregnant women) has been used for decades to replace 
endogenous LH during FSH stimulation protocols. HCG has been 
shown to effectively induce ovulation, final oocyte maturation and 
 Triptorelin  (n=17) 
Leuprolin 
(n=15) 
hCGb  
(n=15) 
Number of 
oocytes/subject 9.8±5.4 8.7±4.5 8.3±3.3 
Proportion of metaphase 
II oocytes 72±18% 85±17% 86±17% 
Fertilization rate 61±30% 62±23% 56±18% 
Number of embryos 
obtained/subject 
Good quality (grade 1) 
Good quality (grade 2) 
Grade 1 and 2 pooled 
 
 
0.5±0.9 
1.9±1.8 
2.7±1.9 
 
 
1.6±1.8 
2.7±2.5 
3.2±2.6 
 
 
0.8±0.9 
1.7±1.9 
3.3±2.0 
Implantation rate 15±34% 18±37% 17±14% 
Ongoing pregnancy ratea 18% 20% 13% 
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corpus luteum formation. However, hCG has an extended metabolic 
clearance rate (Damewood et al. 1989; Mannaerts et al. 1998) and 
therefore hCG can still be detected in the serum 10 days after the 
preovulatory bolus injection. Consequently, continued support of the 
corpus luteum by hCG elicits supra-physiological luteal phase steroid 
concentrations. Moreover, hCG in the late follicular phase may 
stimulate growth of medium sized follicles (Sullivan et al. 1999; 
Loumaye et al. 1999; Whelan & Vlahos 2000) which may 
subsequently ovulate. A mid-cycle bolus dose of hCG induces 
elevated follicular fluid progesterone levels suggesting changes in the 
microenvironment of the oocyte just before ovulation compared to the 
endogenous LH surge (Yding Andersen C. et al. 1993).  
Next to a hyperresponse of the ovary to stimulation (i.e. large 
late follicular phase number of follicles and very high E2 levels), both 
exogenous and endogenous hCG has clearly been associated with 
OHSS (Lyons et al. 1994; Enskog et al. 1999; Mathur et al. 2000). 
The induction and stimulation of multiple corpora lutea may represent 
a key phenomenon in this regard. Although luteal phase support by 
repeated hCG injections has been clearly shown to be beneficial in 
IVF (Soliman et al. 1994), randomized comparative trials have also 
convincingly demonstrated a higher incidence of OHSS in these 
patients (Belaisch-Allart et al. 1990; Mochtar et al. 1996).  Therefore, 
luteal function in IVF cycles is currently supplemented by exogenous 
P. Moreover, it has been shown that the late and most severe form of 
OHSS occurs especially in multiple pregnancies (coinciding with 
elevated hCG production) (Lyons et al. 1994; Mathur et al. 2000).  
Indeed, withholding hCG along with discontinuation of ovarian 
stimulation effectively prevents ovulation, pregnancy and the 
development of OHSS in women presenting with an excessive 
ovarian response. Other approaches for the prevention of OHSS 
include withholding gonadotropins for some days during the late 
follicular phase (also referred to as ‘coasting’), reducing the hCG 
bolus dose, replacing hCG by GnRH agonist as addressed in the 
current study, the administration of glucocorticoids or albumen, the 
avoidance of luteal support by hCG, and cryopreservation of embryos 
and transfer in subsequent cycles.  
It has been clearly shown in several animal models that the 
mid-cycle gonadotropin surge is accompanied by a major rise in 
endogenous GnRH in the portal circulation (Caraty et al. 1995). 
Indeed, several initial studies in IVF showed that a mid-cycle 
endogenous LH rise could be induced by the late follicular phase 
administration of  exogenous GnRH or GnRH agonist. Induction of 
final oocyte maturation with GnRH agonists in patients undergoing 
ovarian hyperstimulation is believed to be more physiological and of 
special benefit to high responders with an increased risk of 
developing OHSS. In the current study, very high hCG levels (median 
GnRH agonist for the induction of final oocyte maturation – a RCT 
 
- 119 -   
> 200 IU/L) lasted for 24 hrs (from 12 hrs to 36 hrs after triggering of 
oocyte maturation) and clearance of the 10,000 IU hCG required 
around 10 days. 
Although effective, the approach to induce oocyte maturation 
by the mid-cycle GnRH agonist administration lost interest during the 
nineties since ovarian hyperstimulation protocols also included GnRH 
agonist co-administration to suppress a premature rise in LH during 
the follicular phase. This renders the pituitary in a state of 
desensitization precluding stimulation of the endogenous LH surge. 
Several recent studies have shown that short-term GnRH antagonist 
administration during the late follicular phase is also effective in 
preventing a premature LH rise. This blockage of GnRH receptors on 
the gonadotrophic cells by the antagonist can be reversed by GnRH 
stimulation, allowing reevaluation of stimulating a mid-cycle rise in 
endogenous LH. The primary purpose of the current study was to 
investigate the dynamics of the mid-cycle gonadotropin surge under 
these circumstances. The current study also demonstrates for the first 
time that final maturation of oocytes can be triggered with GnRH 
agonists rather than hCG, following ovarian hyperstimulation using 
ganirelix to prevent a premature LH rise.  An adequate pituitary 
response in terms of a rise in endogenous LH and FSH was observed 
after the administration of either 0.2 mg triptorelin or 0.5 mg 
leuprorelin and luteal phase steroid levels were found to be closer to 
the physiological range. 
Endogenous LH and FSH surges in the current study were 
comparable to those described after triggering of oocyte maturation 
using GnRH agonists in non-suppressed subjects undergoing ovarian 
stimulation for IVF (Gonen et al. 1990; Itskovitz-Eldor et al. 1991). 
Thus, in the current study the doses of GnRH agonist administered 12 
hours after the last antagonist injection were sufficient to displace 
ganirelix from the GnRH receptors. The maximum LH and FSH levels 
were comparable to circulating mid-cycle LH and FSH levels in 
natural cycles (Hoff et al. 1983). In a recent preliminary study (also 
applying 0.2 mg triptorelin for triggering of oocyte maturation in 8 high 
responder patients treated with exogenous FSH and 0.25 mg 
ganirelix) higher maximum LH concentrations compared to the current 
study were reported (Itskovitz-Eldor et al. 2000). This may indicate 
that the magnitude of the LH surge is in part determined by the 
endocrine status of the patient since high response patients were 
excluded from the current study. In the current study the duration of 
the LH surge appeared to be shorter compared to the natural cycle 
(24 hrs versus 36-48 hours, respectively). This phenomenon might be 
explained by the immediate pituitary desensitization after the initial 
flare effect, since two doses of buserelin 12 h apart did result in 
similar LH profiles (Itskovitz-Eldor et al. 1991). Despite the shorter 
duration compared to physiological conditions, the induced LH surge 
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effectively stimulated final oocyte maturation as reflected by the high 
percentage of metaphase II oocytes (72-85%) as well as good 
fertilization and embryo implantation rates.  
An alternative means of mimiking the mid-cycle gonadotropin 
surge is the administration of a high dose of recombinant LH (Imthurn 
et al. 1996). However, the relatively short half-life of this compound 
(Porchet et al. 1995) suggests that very high or multiple doses should 
be given. A recently published large randomized comparative trial 
showed the complete absence of OHSS in women receiving a single 
dose of recombinant LH in doses up to 30,000 IU (The european 
recombinant human LH study group 1998). Extensive studies in the 
monkey using different doses of LH or hCG suggest that the duration 
of the midcycle LH surge is critical for inducing a normally functioning 
corpus luteum (Zelinski-Wooten et al. 1992; Chandrasekher et al. 
1994). A relatively short LH surge resulted in normal oocyte 
maturation and ovulation, whereas luteal phase length was reduced 
implying that luteal support is required under these conditions. In the 
current study, serum E2 and P levels were comparable for all 
treatment groups up to the day of oocyte retrieval. However, 
thereafter both the E2 and P levels were higher in  hCG treated 
subjects. This difference can be explained by the prolonged half-life of 
hCG as compared to LH, responsible for continued support of the 
corpus luteum. These luteal phase steroid levels far above the 
physiological range may suppress the release of endogenous 
gonadotropins required for corpus luteum support (Gibson et al. 1991) 
and may exhibit a negative impact on endometrial receptivity (Forman 
et al. 1988; Simon et al. 1998). In the current study luteal phase 
supplementation was applied by daily progestin administration. 
Therefore, the dynamics of mid-cycle LH requirements for subsequent 
normal luteal function in the human requires further investigation.  
 The physiological role of the mid-cycle FSH surge that occurs 
in the natural cycle has not been elucidated so far, but recent studies 
suggest that FSH may play a role in the process of nuclear maturation 
by actively promoting resumption of meiosis (Zelinski-Wooten et al. 
1995; Yding Andersen C. et al. 1999). Moreover, studies in the rat 
have demonstrated that a high dose of FSH alone is capable of 
inducing ovulation (Galway et al. 1990). On the other hand, a 
midcycle FSH surge is not mandatory since normal oocyte maturation 
and ovulation occurs after the administration of hCG. The potential 
favorable impact of a GnRH-agonist induced FSH surge is unknown 
at present.  
 In summary, the application of a single dose of GnRH agonist 
was shown to be effective in inducing a gonadotropin surge and 
triggering final oocyte maturation in normal responder patients 
following ovarian hyperstimulation for IVF co-treated with GnRH 
antagonist. Effects on the dynamics of the pituitary – ovarian axis 
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during the luteal phase along with its capacity to prevent OHSS 
requires further evaluation. This more physiological approach to 
inducing oocyte maturation may provide a successful and safer 
alternative for patients undergoing IVF. 
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General Discussion 
 
The introduction of GnRH agonists to IVF was initially viewed as a 
major step towards improving IVF outcome. However, the 
complications arising from the use of these compounds have 
provoked increasing concerns (Edwards et al. 1996; Fauser et al. 
2002a). The ‘long protocol’, characterized by pituitary ‘down-
regulation’ using a GnRH agonist for at least two weeks followed by 
co-administration of daily 150-450 IU FSH, is nowadays the most 
commonly practized strategy of ovarian stimulation for IVF. These 
protocols are complex, expensive, time-consuming and associated 
with a certain degree of risk (Fauser et al. 1999). These risks include 
OHSS, an increased incidence of (higher order) multiple pregnancies 
and (possibly) ovarian cancer (Shoham 1994; Tarlatzis et al. 1995; 
Bristow & Karlan 1996). Cryopreservation of excess embryos followed 
by transfer in a subsequent (unstimulated) cycle is often used as 
justification for profound ovarian stimulation for IVF. However, a large 
proportion of cryopreserved embryos will not survive the thawing 
process and even when the embryos survive the thawing process the 
supplementary benefit to cumulative pregnancy rates is disappointing, 
as shown in this thesis (de Jong et al. 2002). Therefore alternative 
strategies for ovarian stimulation for IVF need to be considered 
(Edwards et al. 1996; Olivennes & Frydman 1998; Bouchard & 
Fauser 2000; Fauser et al. 2002a). 
GnRH antagonist action is characterized by an immediate 
suppression of pituitary gonadotropin release and a rapid recovery of 
normal secretion of endogenous LH and FSH after cessation (Hall 
1993). Their arrival in the clinical scene has not been easy. Due to 
problems with solubility and histamine releasing properties (Kiesel & 
Runnebaum 1992), the development of these compounds has taken a 
few decades. The previously mentioned problems have been dealt 
with by the development of the third generation of GnRH antagonists. 
The potential benefits of these third generation compounds may be 
considered as substantial, as outlined in this thesis. Before 
introducing these GnRH antagonists into general clinical practice a 
mandatory dose-finding study was carried out and described in this 
thesis. The minimal effective dose of the GnRH antagonists ganirelix 
and cetrorelix for suppressing a premature LH rise during ovarian 
stimulation for IVF was established at 0.25 mg per day for both 
compounds (Albano et al. 1997; The ganirelix dose-finding study 
group 1998). The daily dose of the GnRH antagonist had no 
detectable influence on late follicle development during ovarian 
stimulation for IVF. However, in the follicular phase the observed low 
steroid serum concentrations in patients receiving a high daily dose of 
the GnRH antagonist ganirelix (1.0 and 2.0 mg/day) could only be 
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partially attributed to the low LH levels (de Jong et al. 2001a). In the 
group receiving 0.25 mg/day of the GnRH antagonist, similar steroid 
serum concentrations were found when compared to the ‘long 
protocol’ (The european orgalutran study group et al. 2000). The 
subsequent non-inferiorty study outlined in this thesis comparing the 
‘long protocol’ with an ovarian stimulation strategy for IVF with co-
administration of a GnRH antagonist showed no significant 
differences in clinical outcome (The european orgalutran study group 
et al. 2000; Albano et al. 2000; The european and middle east 
orgalutran study group 2001). The incidence of OHSS may be lower 
in the patients receiving a GnRH antagonist compared to the ‘long 
protocol’ (Ludwig et al. 2000; Olivennes et al. 2002). But this could 
not be confirmed in a recent meta-analysis (Al-Inany & Aboulghar 
2002).However, when the chance on severe OHHS is imminent in 
patients undergoing ovarian stimulation for IVF and co-treated with a 
GnRH antagonist, cancellation of the cycle and treatment with a high 
dose GnRH antagonist might be considered (de Jong et al. 1998).  
The clinical introduction of GnRH has made feasible the 
development of new paradigms for ovarian stimulation for IVF 
(Bouchard & Fauser 2000). Due to the competitive-binding properties 
of GnRH antagonists, the pituitary is not ‘down-regulated’, providing 
the opportunity to use a GnRH agonist for inducing an LH and FSH 
surge for induction of the final stages of oocyte maturation, resulting 
in pregnancy and birth (de Jong et al. 2001b). This approach, 
described in this thesis, showed comparable quality and fertilization 
rates of recovered oocytes while luteal phase steroid levels were 
closer to the physiological range when compared to hCG (Fauser et 
al. 2002b). In addition, due to the shorter half-life of native LH when 
compared to hCG, this strategy may contribute to a lower incidence of 
OHSS (Itskovitz-Eldor et al. 2000; Kol & Itskovitz-Eldor 2000).  
Due to the immediate suppressive action of pituitary 
gonadotropin release by GnRH antagonists application of these 
compounds could be started from the mid-follicular phase onwards, 
allowing initiation of a normal menstrual cycle with normal early 
follicular phase recruitment of a cohort of follicles. Extending the ‘FSH 
window’ (Schipper et al. 1998; de Jong et al. 1999a), aiming at less 
preovulatory follicles may further decrease the chance on 
complications. With initiation of ovarian stimulation from the 
midfollicular phase onwards with 150 IU FSH per day a marked 
reduction in amount of gonadotropin used could be established (de 
Jong et al. 2000). Moreover, a normal luteal phase was observed and 
pregnancies occurred in the absence of luteal support in this small 
pilot study. This was in contrast to other observations showing a short 
luteal phase without the provision of luteal support (Albano et al. 
1998; Tavaniotou et al. 2001). 
General discussion 
 
- 127 -   
With respect to current cryopreservation protocols of excess 
embryos a choise needs to be made. Either to modify the 
cryopreservation protocol aiming at higher post thaw survival and 
implantation rates of thawed cryopreserved embryos (Valdez et al. 
1992; Vajta et al. 1998; Arav et al. 2002) or to aim at minimal ovarian 
stimulation for IVF resulting in less excess embryos (Rongieres-
Bertrand et al. 1999; de Jong et al. 2000). For this thesis we choose 
the second option. The final goal is to create single embryo transfer 
as a realistic option. Therefore, selection criteria need to be 
established for assessing embryo quality (Hunault et al. 2002). In 
addition, the prospect of analyzing the single embryo on 
chromosomal competence, i.e. aneuploidy screening by FISH, may 
play a role in designing an effective single embryo transfer IVF 
strategy (Martini et al., ongoing research). The first steps are taken in 
an effort to simplify ovarian stimulation strategies for IVF, aiming at 
less embryos and to reduce the chance on complications (Heinen et 
al., ongoing research) 
Many questions remain to be answered. The cycle day for 
starting ovarian stimulation for IVF is under investigation. All studies 
using a GnRH antagonist for avoiding a premature LH rise, ovarian 
stimulation is initiated on cycle day 3 (Albano et al. 1997; The 
european orgalutran study group et al. 2000; Albano et al. 2000; The 
european and middle east orgalutran study group 2001). In an 
attempt to determine the optimal cycle day for initiation of ovarian 
stimulation initiatives are in progress comparing  ovarian stimulation 
for cycle day 3 vs. cycle day 5 (Hohmann et al. 2002). Secondly, the 
need for luteal support is inconclusive after ovarian stimulation for IVF 
and co-treatment with a GnRH antagonist (Albano et al. 1998; de 
Jong et al. 2000; Tavaniotou et al. 2001). Preliminary data from a 
study comparing recombinant hCG, recombinant LH, and a GnRH 
antagonist for induction of final oocyte maturation after ovarian 
stimulation for IVF and co-treatment with an experimental GnRH 
antagonist (Antide) without the provision of luteal support have been 
presented recently (Beckers et al. 2002). Other initiatives include the 
comparison in terms of health economics and clinical outcome of 3 
cycles profound ovarian stimulation for IVF vs. 4 cycles minimal 
ovarian stimualtion for IVF. Other trials are needed to determine the 
effects of GnRH antagonists on endometrial parameters. For 
simplification of ovarian stimulation for IVF, clinical trials are underway 
using long-acting FSH. By adding the carboxy-terminal peptide (CTP) 
of the hCG β-subunit to the FSH β-subunit (FSH-CTP) the circulating 
half-life up is increased up to 4 days (Lapolt et al. 1992; Fares et al. 
1992) possibly leading to administration regimes of once every 4 days 
and increasing patient’s convenience.  
 In conclusion, the arrival of GnRH antagonists in clinical 
practice offers the opportunity for designing flexible, short, efficient 
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and patient friendly IVF strategies. A reduction in short and long term 
risks of ovarian stimulation for IVF might be possible without seriously 
affecting pregnancy rates, although it has been showed recently that 
pregnancy rates of IVF with application of GnRH antagonists may be 
slightly reduced in comparison with the ‘long protocol’ (Al-Inany & 
Aboulghar 2002). However, since clinicans are in the beginning of 
learning curve using GnRH antagonists, pregnancy rates may 
improve with increasing clinical experience. In addition, the 
development of the ‘long protocol’, currently considered as gold 
standard, took a decade. Moreover,  data derived from the non-
inferiority study of a GnRH antagonist protocol for IVF (Chapter 2.3) 
demonstrated that centres which also participated in the dose-finding 
study (Chapter 2.1), achieved higher or similar pregnancy rates in the 
GnRH antagonist arm compared to GnRH agonist arm. This was in 
contrast to the centres not participating in the dose-finding study 
showing reversed results. Therefore, to explore the challenging 
possibilities GnRH antagonists offer to revolutionize IVF, additional 
studies and gaining clinical experience remain mandatory. 
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Summary 
 
Chapter 1 
 
The use of ovarian stimulation has improved the clinical outcome of 
IVF considerably. However, without the prevention of a possible 
premature LH surge in IVF cycles a significant portion of the cycles 
need to be cancelled. Soon after the elucidation of the chemical 
structure of GnRH, GnRH agonists were developed and used 
(empirically) for prevention of a premature LH rise in IVF cycles. The 
development of GnRH antagonists, available for clinicians, lasted a 
couple of decades. In this chapter, a comparison is made between 
the use of GnRH agonists and GnRH antagonists. In addition, 
potential benefits arising from the use of GnRH antagonists is 
highlighted. 
 
 
Chapter 2 
 
Section 2.1 A multicentre, double-blind, randomized dose-finding 
study of Org 37462 (ganirelix) was conducted in 333 women 
undergoing ovarian stimulation with recombinant follicle stimulating 
hormone (recFSH; Puregon) to establish the minimal effective dose 
preventing premature luteinizing hormone (LH) surges during ovarian 
stimulation. For ovarian stimulation, recFSH was given in a fixed daily 
dose of 150 IU for 5 days from days 2 to 6 of the menstrual cycle. 
From cycle day 7 onward, up to and including the day of human 
chorionic gonadotropin (hCG), Org 37462 (dosages 0.0625, 0.125, 
0.25, 0.5, 1.0 and 2.0 mg/0.5 ml) was administered once daily by s.c. 
injection, and the recFSH dose was adjusted depending on ovarian 
response. The lowest (0.0625 mg) and highest (2.0 mg) dose groups 
were terminated prematurely on the advice of an external 
independent advisory committee. Serum Org 37462 concentrations 
increased in a linear dose-proportional manner, whereas serum LH 
and increases of estradiol fell with increasing Org 37462 dose. During 
Org 37462 treatment, serum LH concentrations >10 IU/L were 
observed in the lowest dose groups with incidences of 16% (0.0625 
mg), 9% (0.125 mg) and 1.4 % (0.25 mg). On the day of hCG, the 
number of follicles >11, >15 and >17 mm were similar in the six dose 
groups, whereas serum estradiol concentrations were highest in the 
0.0625 mg group (1475 pg/mL) and lowest in the 2 mg group (430 
pg/mL). The median daily dose of recFSH was between 150 and 183 
IU and the overall median duration of Org 37462 treatment was ~ 5 
days in the six treatment groups. Overall, Org 37462 treatment 
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appeared to be safe and well tolerated. The mean number of 
recovered oocytes and good-quality embryos was similar in all dose 
groups and ranged from 8.6 to 10.0 and 2.5 to 3.8, respectively. The 
mean number of replaced embryos in the different dose groups 
ranged from 2.3 to 2.7. The implantation rate was highest in the 0.25 
mg group (21.9%) and lowest in the 2 mg group (1.5%). The early 
miscarriage rates (first 6 weeks after embryo transfer) were 11.9 and 
13% in the 1 and 2 mg group respectively, whereas in the other dose 
groups this incidence was 0% (0.0625 mg) up to a maximum of 3.7% 
(0.5 mg). The vital pregnancy rate (with heart activity) at 5-6 weeks 
after embryo transfer was highest in the 0.25 mg group, i.e. 36.8% 
per attempt and 40.3% per transfer, and resulted in an ongoing 
pregnancy rate 12-16 weeks after embryo transfer of 33.8% per 
attempt and 37.1% per transfer. In conclusion, a daily dose of 0.25 
mg Org 37462 prevented LH surges during ovarian stimulation and 
resulted in a good clinical outcome. 
 
Section 2.2 This randomized controlled multicentre trial was initiated 
to investigate relations between dose of gonadotropin releasing 
hormone (GnRH) antagonist and follicular phase characteristics. A 
total of 311 patients with an indication for IVF were analyzed. Ovarian 
stimulation for in vitro fertilzation (IVF) with recombinant follicle 
stimulating hormone (recFSH) was initiated starting on cycle day 2. 
From cycle day 7 onwards they were co-treated with 0.0625, 0.125, 
0.25, 0.5, 1.0, or 2.0 mg/day of the GnRH antagonist ganirelix. The 
number of follicles, total follicular surface area, gonadotropin, and 
steroid serum concentrations were measured.  In all patients, similar 
follicular growth was observed comparing all treatment groups. FSH 
levels increased during the follicular phase. Late follicular phase 
luteinizing (LH), androstenedione (AD) and estradiol (E2) levels 
showed a GnRH antagonist dose related decrease (P < 0.05). Late 
follicular phase E2 levels correlated with total follicular surface area, 
AD, LH and FSH (all P < 0.001). Increasing GnRH antagonist doses 
exhibit additional suppressive action on E2 levels. Based on these 
findings it was concluded that follicular growth was unaffected by the 
dose of GnRH antagonist. A rise in follicular phase FSH serum 
concentrations during the follicular phase, largely related to 
exogenous FSH, enabled ongoing follicular growth in all treatment 
groups. Increasing GnRH antagonist doses resulted in lower late 
follicular phase E2, AD, and LH levels. The effect of GnRH antagonist 
on late follicular phase E2 levels could not be exclusively attributed to 
LH. 
 
Section 2.3 A multicentre, open-label, randomized study of the 
gonadotropin-releasing hormone (GnRH) antagonist ganirelix 
(Orgalutran/Antagon) was performed in women undergoing ovarian 
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stimulation with recombinant FSH (recFSH;Puregon). The study was 
designed as a non-inferiority study using a ‘long protocol’ of buserelin 
(intranasal) and recFSH as a reference treatment. A total of 730 
subjects was randomized in a treatment ratio of 2:1 
(ganirelix:buserelin) using an interactive voice response system which 
stratified for age, type of subfertility and planned fertilization 
procedure [IVF or intracytoplasmic sperm injection (ICSI)]. The 
median duration of GnRH analogue treatment was 5 days in the 
ganirelix group and 26 days in the buserelin group, whereas the 
median total recFSH dose was 1500 IU and 1800 IU respectively. In 
addition, in the ganirelix group the mean duration of stimulation was 1 
day shorter. During ganirelix treatment the incidence of LH rises (LH > 
10 IU/L) was 2.8% versus 1.3% during recFSH stimulation in the 
buserelin group. On the day of triggering ovulation by human 
chorionic gonadotropin (hCG), the mean number of follicles > 11 mm 
diameter was 10.7 and 11.8, and the median serum estradiol 
concentrations were 1190 pg/mL and 1700 pg/mL in the ganirelix and 
buserelin groups respectively. The mean number of oocytes per 
retrieval was 9.1 and 10.4 respectively, whereas the mean number of 
good quality embryos was 3.3 and 3.5 respectively. The fertilization 
rate was equal in both groups (62.1% ), and the same mean number 
of embryos (2.2) was replaced. The mean implantation rates were 
15.7% and 21.8%, and the ongoing pregnancy rates per attempt were 
20.3% and 25.7% in the ganirelix and buserelin groups respectively. 
Evaluation of aIl safety data indicated that the ganirelix regimen was 
safe and weIl tolerated. The overaIl incidence of ovarian 
hyperstimulation syndrome was 2.4% in the ganirelix group and 5.9% 
in the reference group. The results of this study support a safe, short 
and convenient treatment regimen of ganirelix, resulting in a good 
clinical outcome for patients undergoing ovarian stimulation for IVF or 
ICSI. 
 
Section 2.4 This case report describes the first attempt to treat 
imminent ovarian hyperstimulation syndrome (OHSS) by using a 
gonadotropin releasing hormone (GnRH) antagonist. A 33 year old, 
normo-ovulatory woman undergoing in-vitro fertilization received daily 
subcutaneous injections of 150 IU of recombinant follicle-stimulating 
hormone (recFSH) from cycle day 2, together with GnRH antagonist 
(ganirelix) 0.125 mg from cycle day 7 onwards. On cycle day 10 the 
patient was found to have a serum estradiol concentration of 16 500 
pmol/L and, on ultrasound examination, four preovulatory (>16 mm) 
and nine intermediate sized (10–16 mm) follicles. RecFSH injections 
were discontinued, human chorionic gonadotropin (hCG) withheld, 
whereas the ganirelix dose was increased to 2 mg/d. This regimen led 
to a rapid decrease in serum estradiol concentrations and the 
decrease in ovarian size on ultrasound. Since GnRH antagonists are 
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clinically available for in vitro fertilization programmes this suggested 
regimen might have a role in preventing severe OHSS. 
 
 
Chapter 3 
 
Section 3.1 This observational longitudinal study was carried out to 
calculate the added benefit of a cryopreservation program to the 
cumulative ongoing pregnancy rate over a maximum of three 
consecutive IVF cycles. One thousand two hundred and fifty one 
couples with an indication for IVF who began their first treatment 
between January 1995 and December 1999 were evaluated. A 
maximum of three cycles per couple, including subsequent cycles in 
which cryopreserved of supranumerical embryos were thawed, were 
analyzed. Pregnancies arising from the cryopreservation cycle were 
considered augment the cumulative pregnancy rate among patients 
who did not achieve an ongoing pregnancy from the fresh embryos 
transfer cycle. The ‘projected cryoaugmented pregnancy rates’, which 
assume that pregnancy rates of patients with unthawed 
cryopreserved embryos are comparable to those who had an embryo 
transfer of thawed cryopreserved embryos, were calculated. Clinical 
outcome in terms of ongoing pregnancy rates was analyzed by 
Markov chain analysis to estimate the added value of the 
cryopreservation program. A total of 2367 IVF stimulation cycles and 
329 cycles in which cryopreserved embryos were thawed for transfer 
were initiated. The cumulative ongoing pregnancy rate following 3 
successive started fresh IVF cycles was 42.5%. When pregnancies 
arising from the transfer of thawed cryopreserved embryos were 
included the cumulative ongoing pregnancy rate increased to 43.8%. 
When the data was extrapolated to include pregnancies which could 
be expect to result from as yet unthawed embryos, a further increase 
was observed to 44.8%. When analyzed in these terms the 
supplementary benefit of cryopreserving supranumerical embryos 
appears limited. It is be proposed that a reduction in embryos 
available for cryopreservation which may result from milder ovarian 
stimulation protocols will have little negative impact on cumulative 
ongoing pregnancy rates. 
 
Section 3.2 Based on the previous section it may be concluded that 
the true added value of the cryopreservation program for excess 
embryos is limited. The possibility of cryopreserving excess embryos 
as a justification for aiming at a maximum number of oocytes during 
ovarian stimulation for IVF is poorly justified. Therefore it is legitimate 
to design ovarian stimulation for IVF protocols aiming at less follicles, 
with an opportunity to reduce the chance on complications. This 
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section deals with mild ovarian stimulation for IVF. A minimal 
intervention in the mid follicular phase of the normal menstrual cycle 
could result in less follicles and thus less oocytes without endangering 
to chance to conceive.  
 
Section 3.3 This pilot study was performed to study if a minimal 
interference in the process of single dominant follicle selection may 
serve as the basis for a simplified ovarian stimulation regimen for IVF. 
The normal menstrual cycle served as reference. Total number of 
dominant follicles on the day of hCG, and endocrine cycle 
characteristics were primary outcome measurements. Fifteen normo-
ovulatory patients with a regular indication for IVF underwent ovarian 
stimulation for IVF with 100 or 150 IU per day  recombinant FSH 
starting on cycle day 5. From cycle day 8 or later patients were co-
treated with 0.25 mg/d GnRH antagonist. No luteal support was 
provided. Multiple follicle development occurred in 5 out of 8 patients 
in the 100 IU group and in all 7 women in the 150 IU group. Follicular 
phase luteal phase length were normal compared with the normal 
menstrual cycle, but the endocrine profile was abnormal. Pregnancies 
were obtained. In conclusion, treatment with a fixed daily dose of 150 
IU recombinant FSH starting in the mid-follicular phase resulted in 
ongoing growth of a restricted number of dominant follicles and 
oocytes retrieved, adequate to lead to embryo transfer. A marked 
reduction in the total amount of gonadotropins administered 
compared to standard treatment can be achieved. Withholding luteal 
support does not exclude pregnancies. 
 
 
Chapter 4 
 
Section 4.1 This case report describes to our knowledge the first 
pregnancy and birth after induction of final oocyte maturation with a 
GnRH agonist in a woman undergoing ovarian hyperstimulation for 
IVF while co-treated with the GnRH antagonist Orgalutran. A 28-year 
old, normo-ovulatory woman undergoing in-vitro fertilization received 
daily subcutaneous injections of 150 IU of recombinant follicle-
stimulating hormone (recFSH) from cycle day 2, and GnRH 
antagonist (Orgalutran) 0.25 mg from cycle day 7 onwards. On cycle 
day 11 the patient showed 12 and 3 follicles > 11 and > 17 mm in 
diameter on ultrasound, respectively. RecFSH injections were 
discontinued and 0.5 mg leuprorelin was administered for final oocyte 
maturation. On the day of oocyte pick-up 12 oocytes were retrieved, 
11 metaphase II oocytes and 1 germinal vesicle. On day 5 after 
oocyte pick-up, 2 blastocysts were transferred and 3 cryopreserved. A 
viable intra-uterine twin pregnancy was observed on ultrasound 6 
Alternative approaches to ovarian stimulation for in vitro fertilization 
 
- 164 - 
weeks after embryo transfer, which spontaneously reduced to a 
singleton pregnancy. At 40 weeks amenorrhoea the patient delivered 
a healthy daughter. In conclusion, triggering final stages of oocyte 
maturation with a GnRH agonist may offer an effective and safe 
option for patients undergoing ovarian stimulation for IVF, using a 
GnRH antagonist for the prevention of a premature LH surge.  
 
Section 4.2 In a randomized multi-center study, the efficacy of two 
different gonadotropin-releasing hormone (GnRH) agonists was 
compared with human chorionic gonadotropin (hCG) for triggering 
final stages of oocyte maturation after ovarian hyperstimulation for in 
vitro fertilization (IVF). Ovarian stimulation was conducted by 
recombinant follicle stimulating hormone (RecFSH) (Puregon) and the 
GnRH antagonist ganirelix (Orgalutran) was co-administered for the 
prevention of a premature luteinizing hormone (LH) rise. Luteal 
support was provided by daily progestin administration. Frequent 
blood sampling was performed at midcycle in the first 47 eligible 
subjects included in the current study which were randomized for a 
single dose of either 0.2 mg triptorelin (n=17), 0.5 mg leuprorelin 
(n=15) or 10,000 IU hCG (n=15). Serum concentrations of LH, follicle-
stimulating hormone (FSH), estradiol (E2) and progesterone (P) were 
assessed at variable intervals. LH peaked at 4 hours after both 
triptorelin and leuprorelin administration with median LH levels of 130 
IU/L and 107 IU/L (P < 0.001), respectively. LH levels returned to 
baseline after 24 hrs. Subjects receiving hCG showed peak levels of 
240 IU/L hCG 24 hrs after administration. A rise in FSH to 19 IU/L (P 
< 0.001) was noted in both GnRH agonist groups 8 hrs after injection. 
Within 24 hrs the AUC for LH and FSH was significantly higher (P < 
0.001) in both GnRH agonist groups compared to hCG. E2 and P 
levels were similar for all groups up to the day of oocyte retrieval. 
Luteal phase AUC’s for P and E2 were significantly elevated (P < 
0.001) in the hCG group. The mean (+ SD) number of oocytes 
retrieved was 9.8 ± 5.4, 8.7 ± 4.5 and 8.3 ± 3.3, the percentage of 
metaphase II oocytes was 72%, 85% and 86%, and fertilization rates 
were 61, 62, and 56% in the triptorelin, leuprorelin and hCG group 
respectively (P = NS for all three comparisons).  These findings 
support the effective induction of final oocyte maturation in both 
GnRH agonist groups. In summary, after treatment with the GnRH 
antagonist ganirelix for the prevention of premature LH surges, 
triggering of final stages of oocyte maturation can be induced 
effectively by a single bolus injection of GnRH agonist as 
demonstrated by the induced endogenous LH and FSH surge and the 
quality and fertilization rate of recovered oocytes. Moreover, corpus 
luteum formation is induced by GnRH agonists with luteal phase 
steroid levels closer to the physiological range compared to hCG. 
This more physiological approach for inducing oocyte maturation may 
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represent a successful, and safer alternative for IVF patients 
undergoing ovarian hyperstimulation. 
 
 
Chapter 5 
 
This chapter summarises the conclusions which could be drawn form 
the work presented in the current thesis. Realizing that clinical 
experience with the application of GnRH antagonists is fairly limited, 
new paths should be explored to enhance the potentials of this 
application. Therefore, directions for future research are presented.
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Samenvatting (Dutch) 
 
Hoofdstuk 1 
 
De klinische uitkomsten van de IVF behandeling zijn door het gebruik 
van hyperstimulantia voor het ovarium aanzienlijk verbeterd. Echter 
zonder het gebruik van middelen, welke een voortijdige eisprong 
verhinderen, zou een significant deel van de pogingen tot IVF 
gestaakt dienen te worden. Spoedig na de opheldering van de 
chemische structuur van GnRH werden GnRH agonisten ontwikkeld 
en later ook (empirisch) gebruikt in de kliniek voor het verhinderen 
van een voortijdige LH piek tijdens een IVF behandeling. De 
ontwikkeling van GnRH antagonisten, welke bruikbaar bleken in de 
kliniek, duurde echter nog enige decennia. Een vergelijking tussen 
het gebruik van GnRH agonisten en antagonisten wordt in dit 
hoofdstuk gemaakt, tevens worden de potentiële voordelen van het 
gebruik van GnRH antagonisten tijdens een IVF behandeling 
aangehaald. 
 
 
Hoofdstuk 2 
 
Paragraaf 2.1 Een dubbel blind gerandomiseerd multi-centrisch 
onderzoek werd uitgevoerd voor het vinden van de minimale 
effectieve dosering van Org 37462 (GnRH antagonist, ganirelix) voor 
het verhinderen van een premature LH piek. Bij 333 vrouwen werd 
ovariële hyperstimulatie bewerkstelligd middels recFSH en de GnRH 
antagonist ganirelix werd gebruikt voor het verhinderen van een 
voortijdige LH piek. RecFSH werd toegediend voor ovariële 
hyperstimulatie in een gefixeerde dosering van 150 IU/dag gedurende 
5 dagen (vanaf cyclus dag 2 tot en met 6). Vanaf cyclus dag 7 en 
verder (tot en met de dag dat hCG werd toegediend) werd een GnRH 
antagonist (dosering 0.0625, 0.125, 0.25, 0.5, 1.0 en 2.0) dagelijks 
s.c. geïnjecteerd, terwijl de dosering recFSH werd aangepast aan de 
ovariële reactie. De toepassing van de laagste (0.0625 mg) en 
hoogste (2.0 mg) dosering GnRH antagonist werd voortijdig gestaakt 
op het advies van een extern onafhankelijk advies commissie. De 
serum concentratie van GnRH antagonist nam lineair toe terwijl de 
serum concentratie van LH en oestradiol afnam bij het gebruik van 
hogere doseringen GnRH antagonist. Serum LH concentraties van > 
10 IU/L werden waargenomen tijdens het gebruik van relatief lage 
doseringen met incidenties van 16% (0.0625 mg), 9% (0.125 mg), en 
1.4% (0.25 mg). Op de dag van hCG toediening waren het aantal 
follikels >11, >15 en >17 mm vergelijkbaar in de zes 
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behandelgroepen, terwijl de serum oestradiol concentraties het 
hoogst was in de groep van 0.0625 mg  en het laagst in de groep van 
2.0 mg GnRH antagonist (1475 en 430 pg/mL, respectievelijk). De 
mediaan van de dagelijkse dosering recFSH lag tussen de 150 en 
183 IU en de mediaan van de duur met de GnRH antagonist was ~ 5 
dagen in alle 6 de onderzoeks groepen. In het algemeen bleek de 
GnRH antagonist behandeling veilig en werd goed verdragen. In de 
zes behandelgroepen was het gemiddelde aantal eicellen dat 
gewonnen werd en het aantal embryo’s van goede kwaliteit dat 
gekweekt kon worden vergelijkbaar (variërend van 8.6 tot 10.0 en 2.5 
tot 3.6, respectievelijk). Voor de behandelgroepen lag het gemiddelde 
aantal embryo’s dat teruggeplaatst werd tussen de 2.3 en 2.7. Het 
implantatie percentage was het hoogst in de 0.25 mg GnRH 
antagonist behandelgroep (21.9%), het laagst in de 2 mg 
behandelgroep (1.5%). Het percentage vroege spontane abortussen 
(binnen 6 weken na embryo transfer) was 11.9 en 13% in de 1.0 en 
2.0 mg groep respectievelijk. Ter vergelijking, in de andere groepen 
varieerde dit percentage van 0% (0.0625 mg) tot maximaal 3.7% (0.5 
mg). Het percentage echografische vitale zwangerschappen 
(hartactie 5-6 weken na embryo terugplaatsing) was het hoogst in de 
0.25 mg groep (36.8% per poging en 40.3% per terugplaatsing), 
resulterend in het doorgaande zwangerschapspercentage (12-16 
weken na terugplaatsing) van 33.8% per poging en 37.1% per 
terugplaatsing. Concluderend, de dagelijkse dosering van 0.25 mg 
Org 37462 GnRH antagonist voorkomt een LH piek tijdens ovariële 
hyperstimulatie en resulteert in een goede klinische uitkomst. 
 
Paragraaf 2.2 Deze gerandomiseerde gecontroleerde multi-centrische 
studie werd uitgevoerd om relaties tussen de dosis GnRH antagonist 
en karakteristieken van de folliculaire fase van de cyclus te 
bestuderen. Een totaal aantal van 311 patiënten werd geanalyseerd. 
Begonnen werd met ovariële hyperstimulatie met recFSH ten 
behoeve van IVF vanaf cyclus dag 2. Hiernaast kregen de 
deelnemers vanaf cyclus dag 7 een dagelijkse gift GnRH antagonist 
in de dosering 0.0625, 0.125, 0.25, 0.5, 1.0 of 2.0 mg. Het aantal 
follikels, de totale folliculaire oppervlakte, gonadotrofine en steroïd 
concentraties werden gemeten. Voor alle patiënten werd een 
vergelijkbare groei van follikels waargenomen voor alle 
behandelgroepen. FSH serum concentraties namen toe gedurende 
de folliculaire fase. Serum concentraties van LH, AD en E2 vertoonde 
een GnRH dosis gerelateerde afname in de late folliculaire fase (P < 
0.05). E2 concentraties correleerden met de totale folliculaire 
oppervlakte, AD, LH en FSH (allen P < 0.001). Hogere GnRH 
antagonist doseringen hadden een additioneel onderdrukkend effect 
op E2 concentraties. Geconcludeerd wordt, op basis van deze 
bevindingen, dat groei van follikels niet door de dosering GnRH 
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antagonist te beïnvloeden is. De toename van FSH serum 
concentraties, hoofdzakelijk bepaald door het exogene FSH, maakt 
groei van follikels mogelijk in alle behandel groepen. Hogere 
doseringen van GnRH antagonisten hebben een lagere serum 
concentratie van E2, AD en LH tot gevolg. Het effect van de GnRH 
antagonist op E2 serum concentraties in de laat folliculaire fase berust 
derhalve niet uitsluitend LH serum concentraties. 
 
Paragraaf 2.3 Dit ‘open label’ gerandomiseerd multi-centrisch 
onderzoek met de GnRH antagonist ganirelix werd uitgevoerd bij 
vrouwen die ovariële hyperstimulatie met recFSH ondergingen. Het 
onderzoek was als een ‘non-inferiority’ studie opgezet waarbij het 
‘lange protocol’ (busereline en recFSH) als referentie diende. Een 
totaal aantal van 730 patiënten werd gerandomiseerd in een ratio van 
2:1 (ganirelix:busereline) waarbij gebruik gemaakt werd van een 
interactief telefoon systeem waarbij gestratificeerd werd voor leeftijd, 
oorzaak van subfertiliteit en voorgenomen fertilisatie procedure (IVF 
of ICSI). Bij de duur van de GnRH analoog behandeling was de 
mediaan 5 dagen in de ganirelix groep en 26 dagen in de busereline 
groep, terwijl voor de totaal gebruikte hoeveelheid recFSH de 
mediaan respectievelijk 1500 en 1800 IU was. Ter aanvulling, de 
gemiddelde duur van ovariële hyperstimulatie was 1 dag korter. 
Gedurende de ganirelix behandeling was de incidentie van een LH 
stijging (LH > 10 IU/L) 2.8% tegenover 1.3% in de busereline groep. 
Op de dag dat hCG gegeven werd voor het in gang zetten van de 
ovulatie was het gemiddeld aantal follikels > 11 mm in diameter 10.7 
en 11.8, terwijl de mediane oestradiol serum concentraties 1190 en 
1700 pg/mL bedroeg in respectievelijk de ganirelix en busereline 
groep. Het gemiddeld aantal eicellen gewonnen per punctie was 9.1 
in de ganirelix en 10.4 in de busereline groep, met een gemiddeld 
aantal embryo’s van goede kwaliteit van respectievelijk 3.3 en 3.5. 
Het fertilisatiepercentage was vergelijkbaar in beide groepen (62.1%), 
evenals het gemiddeld aantal embryo’s dat werd teruggeplaatst (2.2). 
Het gemiddeld implantatiepercentage was 15.7 en 21.8%, met het 
doorgaande zwangerschapspercentage van 20.3 en 25.7% in de 
ganirelix en busereline groep respectievelijk. Evaluatie van alle data 
aangaande de veiligheid van ganirelix duidde er op dat ganirelix veilig 
was en goed verdragen werd. De incidentie van het ovarieel 
hyperstimulatie syndroom bedroeg 2.4 % in de ganirelix groep 
tegenover 5.9% in de referentie groep. Uit de resultaten van deze 
studie kan geconcludeerd worden, dat de behandeling met ganirelix 
ter verhindering van een LH piek, een veilige, korte en patiënt 
vriendelijk methode is welke resulteert in een goede klinische 
uitkomst bij patiënten die ovariële hyperstimulatie ondergaan ten 
behoeve van IVF of ICSI. 
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Paragraaf 2.4 Deze casus bespreking beschrijft de eerste poging voor 
het behandelen van een patiënte met een imminent ovarieel 
hyperstimulatie syndroom (OHSS) middels een GnRH antagonist. 
Een 33 jarige normo ovulatoire vrouw onderging een IVF 
behandeling. Ovariële hyperstimulatie werd bewerkstelligd middels 
dagelijkse injecties van 150 IU recFSH vanaf cyclus dag 2. Vanaf de 
7de cyclus dag kreeg ze hiernaast ook dagelijkse injecties van 0.25 
mg GnRH antagonist ganirelix. Op cyclus dag 10 presenteerde de 
patiënte zich met een oestradiol serum concentratie van 16500 
pmol/L en op transvaginale sonografie waren 4 Graafse follikels 
(diameter > 16 mm) en 9 follikels tussen de 10 en 16 mm in diameter 
zichtbaar. De recFSH injecties werden gestopt en de dosis GnRH 
antagonist opgehoogd tot 2.0 mg per dag. Deze behandelwijze leidde 
tot een snelle afname van de oestradiol concentratie en een 
echografisch waarneembare afname van ovarieel volume. Daar 
GnRH antagonisten reeds beschikbaar zijn voor de kliniek zou deze 
manier van behandelen een rol kunnen gaan spelen in de 
behandeling van ernstige vormen van OHSS. 
 
 
Hoofdstuk 3 
 
Paragraaf 3.1 Deze observationele longitudinale studie werd 
uitgevoerd om de toegevoegde waarde van een cryopreservatie 
programma aan het cumulatief doorgaande 
zwangerschapspercentage voor maximaal drie opeenvolgende IVF 
cycli te berekenen. Twaalfhonderdeenenvijftig paren met een indicatie 
voor IVF welke hun eerste behandeling begonnen tussen januari 
1994 en december 1999 werden geëvalueerd. Maximaal drie cycli per 
paar, inclusief de eventueel daarop volgende cycli waarin ingevroren 
embryo’s werden ontdooid om terug te plaatsen, werden 
geanalyseerd. Zwangerschappen voortkomend uit een cyclus waarbij 
ontdooide cryo embryo’s werden teruggeplaatst nadat de voorgaande 
verse cyclus geen zwangerschap opleverde, worden als additionele 
waarde beschouwt. De zogenaamde ‘geprojecteerde’ toegevoegde 
cryo zwangerschapspercentages, waarbij de resultaten van de 
ontdooide cryo embryo’s werden geëxtrapoleerd naar de nog in de 
vriezer aanwezige embryo’s, werden berekend. De klinische uitkomst 
in de vorm van doorgaande zwangerschapspercentages werden 
berekend met behulp van een zogenaamde Markov Chain analyse. 
Een totaal aantal van 2367 IVF stimulatie cycli en 329 cycli, waarbij 
ingevroren embryo’s werden ontdooid voor terugplaatsing, werden 
geïnitieerd. Het cumulatief zwangerschapspercentage volgend uit 3 
gestarte verse IVF stimulatie cycli was 42.5%. Wanneer 
zwangerschappen volgend uit de terugplaatsing van ontdooide 
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embryo’s werden toegevoegd dan steeg het cumulatief 
zwangerschapspercentage tot 43.8%. Inclusief de geëxtrapoleerde 
data van de nog in de vriezer aanwezige embryo’s deed dit 
percentage stijgen tot 44.8%. Concluderend kan gezegd worden dat 
de toegevoegde waarde van het cryopreservatie programma van 
overtollige embryo’s zeer beperkt is. Een eventuele reductie van 
beschikbare embryo’s voor cryopreservatie als resultaat van mildere 
ovariële stimulatie protocollen zal weinig invloed hebben op het 
cumulatief doorgaande zwangerschapspercentage. 
 
Paragraaf 3.2 In de voorafgaande paragraaf werd geconcludeerd dat 
de toegevoegde waarde van het cryopreservatie programma van 
beschikbare overtollige embryo’s zeer beperkt is. De mogelijkheid van 
het invriezen van overtollige embryo’s als rechtvaardiging voor 
maximale ovariële stimulatie is daarom matig onderbouwd. Vanwege 
de hiervoor genoemde redenen is het legitiem om protocollen te 
ontwikkelen voor ovariële hyperstimulatie ten behoeve van IVF 
waarbij gedoeld wordt op minder follikels met daarbij de mogelijkheid 
tot het verlagen van het complicatie risico van de behandeling. Deze 
paragraaf introduceert het begrip van milde ovariële stimulatie ten 
behoeve van IVF. Een minimale interventie tijdens de mid folliculaire 
fase van de spontane menstruele cyclus zou in minder follikels en 
oöcyten kunnen resulteren, zonder de kans op zwangerschap in 
gevaar te brengen. 
 
Paragraaf 3.3 Deze ‘pilot studie’ werd uitgevoerd ten bewijze of een 
minimale interventie gedurende het proces van dominante follikel 
selectie kan dienen als basis voor een eenvoudiger ovarieel stimulatie 
schema ten behoeve van IVF. De normale cyclus diende als 
referentie. Het totaal aantal dominante follikels aanwezig op de dag 
dat hCG werd toegediend en de endocrinologische cyclus 
karakteristieken waren de belangrijkste parameters voor analyse. 
Vijftien normo ovulatoire vrouwen met een indicatie voor IVF 
ondergingen ovariële hyperstimulatie voor IVF behandeling middels 
100 of 150 IU recFSH per dag, beginnend op cyclusdag 5. Vanaf 
cyclusdag 8 of later ontvingen ze hiernaast ook 0.25 mg GnRH 
antagonist per dag. Van luteale ondersteuning werd afgezien. 
Multipele dominante follikels werden waargenomen bij 5 van de 8 
patiënten in de 100 IU groep en bij alle 7 vrouwen in de 150 IU groep. 
De lengte van de folliculaire en luteale fase was overeenkomstig de 
normale menstruele cyclus, echter de endocrinologische 
karakteristieken bleken afwijkend. Zwangerschappen werden gezien. 
Concluderend, behandeling met een gefixeerde dosis van 150 IU 
recFSH beginnend in de mid folliculaire fase van de cyclus 
resulteerde in doorgaande groei van een beperkt aantal dominante 
follikels en gewonnen oöcyten, afdoende voor embryo transfer. Een 
Alternative approaches to ovarian stimulation for in vitro fertilization 
 
- 174 -  
aanzienlijke reductie in gonadotrofinen gebruik was bewerkstelligd. 
Het afzien van luteale ondersteuning sluit zwangerschappen niet uit. 
 
 
Hoofdstuk 4 
 
Paragraaf 4.1 Deze casus beschrijft bij een IVF patiënte, naar onze 
mening voor de eerste keer, zwangerschap en geboorte na het 
induceren van de laatste fase van oöcyt maturatie met een GnRH 
agonist na ovariële hyperstimulatie en GnRH antagonist behandeling 
(ter preventie van een premature LH piek). Een 28 jarige normo 
ovulatoire vrouw onderging IVF. Dagelijks subcutane injecties met 
150 IU recFSH vanaf cyclus dag 2 werden toegediend, met daarbij 
vanaf de 7de cyclus dag, dagelijks 0.25 mg GnRH antagonist. Op 
cyclus dag 11 werden middels echografie 12 en 3 follikels van 
respectievelijk > 11 mm en > 17 mm in diameter waargenomen. De 
recFSH injecties werden gestaakt en 0.5 mg leuproline werd 
toegediend voor de laatste fase van oöcyt maturatie. Op de dag van 
punctie werden 12 oöcyten gewonnen, waarvan 11 in metafase II en 
1 germinal vesicle. Vijf dagen na punctie werden 2 blastocysten 
teruggeplaatst. Aanvankelijk werd een intacte tweeling zwangerschap 
aangetoond, echter deze reduceerde zich spontaan tot een 1-ling 
zwangerschap. Bij een amenorroe duur van 40 weken werd een 
gezonde dochter bij de patiënte geboren. Concluderend, het 
opwekken van de laatste fase van oöcyt maturatie met een GnRH 
agonist kan een veilige optie zijn voor patiënten die ovariële 
hyperstimulatie ondergaan, gecombineerd met een GnRH antagonist 
ter preventie van een premature LH piek. 
 
Paragraaf 4.2 Deze gerandomiseerde multi-centrische studie 
vergelijkt, na ovariële hyperstimulatie voor IVF, de effectiviteit van 
twee verschillende GnRH agonisten met hCG voor het opwekken van 
de laatste fase van oöcyt maturatie. Ovariële hyperstimulatie werd 
bewerkstelligd middels recFSH en de GnRH antagonist Orgalutran 
werd gebruikt voor het verhinderen van een voortijdige LH piek. 
Luteale ondersteuning vond plaats middels dagelijkse progestin 
injecties. Mid cyclisch werd bij de eerste 47 geïncludeerde patiënten 
van deze studie frequent bloed afgenomen. Deze patiënten kregen na 
randomisatie een enkele dosis van 0.2 mg triptoreline (n=17), 0.5 mg 
leuproline (n=15), of 10,000 IU hCG (n=15). Serum LH, FSH, E2 en P 
concentraties werden bepaald op verschillende tijdstippen. Een LH 
piek werd waargenomen 4 uur na zowel de toediening van triptoreline 
als leuproline met mediane LH concentraties van respectievelijk 130 
IU/L en 107 IU/L (P < 0.001). LH waarden daalden naar de basis na 
24 uur. Patiënten die hCG kregen toegediend vertoonden een LH 
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piek 24 uur na toediening. Een toename van FSH tot 19 IU/L (P < 
0.001) werd na 8 uur in beide GnRH antagonist groepen 
waargenomen. Binnen 24 uur was de AUC voor LH en FSH 
significant hoger (P < 0.001) in de beide GnRH antagonist groepen in 
vergelijking tot de hCG groep. E2 en P concentraties waren 
vergelijkbaar in alle groepen tot aan de dag van punctie. De AUC 
voor P en E2 in de luteale fase was significant verhoogd in de hCG 
groep (P < 0.001). Het gemiddelde (+ SD) aantal oöcyten dat 
gewonnen werd was 9.8 + 5.4, 8.7 + 4.5 en 8.3 + 3.3, het percentage 
metafase II oöcyten was 72, 85 en 86%, en fertilisatiepercentages 
waren 61, 62, en 56% in de triptoreline, leuproline en hCG groep 
respectievelijk (P = NS alle drie de vergelijkingen). Deze bevindingen 
ondersteunen een effectieve inductie van de laatste fase van oöcyt 
maturatie in beide GnRH agonist groepen. Concluderend, na 
behandeling met de GnRH antagonist voor de verhindering van een 
premature LH piek kan de laatste fase van oöcyt maturatie effectief 
opgewekt worden middels een enkele bolus injectie met een GnRH 
agonist, aangetoond door zowel de geïnduceerde endogene LH en 
FSH piek als de kwaliteit en het fertilisatiepercentage van de 
gewonnen oöcyten. Er aan toegevoegd, de vorming van het corpus 
luteum, geïnduceerd door GnRH agonisten, gaat gepaard met steroïd 
concentraties in de luteale fase, die dichter in de buurt van de 
fysiologische waarden liggen in vergelijking tot hCG. Deze meer 
fysiologische aanpak voor de inductie van oöcyt maturatie kan een 
succesvol veilig alternatief bieden voor IVF patiënten die ovariële 
hyperstimulatie ondergaan.   
 
 
Hoofdstuk 5 
 
Dit hoofdstuk geeft een opsomming van conclusies welke uit het 
werk, gepresenteerd in dit proefschrift, getrokken kunnen worden. 
Gerealiseerd hebbende dat de klininische ervaring met de toepassing 
van GnRH antagonisten nog beperkt is, zullen nieuwe wegen 
bewandeld moeten worden om deze toepassing te optimaliseren. 
Daarom worden er in dit hoofdstuk mogelijke suggesties voor verder 
onderzoek gegeven.  
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